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Abstract 
 
Malaria continues to be a devastating disease and a major cause of death in sub-Saharan 
Africa. With resistance against most of the available antimalarial drugs, there is a need for 
ongoing research and development of antimalarial agents. Fosmidomycin and its acetyl 
analogue FR900098 have been identified as potent inhibitors of Plasmodium falciparum, the 
causative agent of the most deadly form of malaria. Clinical trials of these agents have 
revealed poor absorption due to their high hydrophilicity. In the present studies the effect of 
halogenation of the acyl chain as well as the biological effect of extending the acyl sidechain 
was explored. This provided the basis on which fosmidomycin  hybrids were designed to 
investigate the feasibility of hybrid extending into NADPH binding pocket. 
 
Synthesis of a series of halogenated FR900098 analogues was carried out in three stages. 
This included i) The introduction of the phosphonate group by reaction with 1,3-
dibromopropane in an Arbuzov reaction, ii) The introduction of a hydroxamate group by 
reaction of the propyl phosphonate by means of a nucleophilic substitution reaction with 
BocNHOBn and iii) The introduction of a halogenated acyl side chain on a protected 
fosmidomycin backbone. The synthesis of fosmidomycin-hybrids for which chloroquine-
fosmidomycin hybrids were used as the prototype, involved convergence of the two 
separately constructed moieties i.e. fosmidomycin and the quinoline moieties in a covalent 
linkage.  The quinoline moiety was easily synthesized from the reaction of 4,7-
dichloroquinoline  with 1,2-diamino ethane. The aminoquinoline so formed resulted in 
chloroquine-fosmidomycin hybrids 3.8 and 3.9 when reacted with halogenated FR900098 
analogues. 
 
Antiplasmodial assays were conducted on the chloroquine-fosmidomycin hybrids and the 
halogenated fosmidomycin derivatives against the chloroquine resistant Gambian FCR-3 
strain of P. falciparum. The most potent iodoacetyl fosmidomycin analogues 2.21 gave an 
IC50 value of 5.54 µM which is eight times more potent than the known antiplasmodial 
FR900098 which gave an IC50 value of 41.67 µM. All the halogenated FR900098 analogues 
showed better antiplasmodial activity than their non-halogenated derivatives. This indicated 
that the presence of halogens in the FR900098 analogues contributes to their biological 
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activity. The acetyl and propyl linked hybrids 3.8 and 3.9 showed potent antiplasmodial 
activity with IC50 values of 0.18 and 0.82 µM respectively. These were by far the most potent 
hybrids synthesized and provided leads for a new class of promising antimalarial agents. 
 
Preliminary E. coli DXR enzyme inhibition assays were carried out on the halogenated 
fosmidomycin analogues. The results showed good inhibition of the enzyme by the 
phosphonic acids of the chloroacetyl and chloropropyl analogues 2.1 and 2.2 respectively. 
Molecular modelling of the compounds on E. coli (PDB code: 2EGH) and P. falciparum 
(PDB code: 3AUA) DXR showed strong binding of the halogenated fosmidomycin analogues 
while the hybrids in the absence of docked NADPH showed minimum binding to the 
enzymes. 
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1. LITERATURE REVIEW AND INTRODUCTION 
In spite of our rapidly advancing  knowledge about malaria, its causative agents, its mode of 
transmittance and the available preventative measures and treatment, it continues to be one of 
the most deadly infectious diseases in Africa. The World Health Organisation (WHO) 
reported 225 million cases of malaria and 781 000 deaths due to malaria in 2009.1 About 91% 
of the mortality was reported in Africa, where expensive treatment cannot be afforded.  
About 30 000 travellers visiting malaria endemic regions from developed countries are 
reported to contract malaria annually. Given the increasing migration of people around the 
world from malaria endemic regions to non-endemic regions and vice versa malaria is fast 
becoming a major threat to humanity.2 Scientists have an obligation to find solutions to the 
world’s malaria problem by finding or developing effective and affordable drugs to combat 
the disease. 
 
1.1 BRIEF OVERVIEW ON MALARIA ETIOLOGY AND TRANSMISSION OF 
THE CAUSATIVE AGENT 
1.1.1 Causative organism and vector of malaria 
Malaria symptoms have been recorded as far back as 2700 BC. However, it was not until 
1889 that Alphonse Laveran discovered that malaria is caused by protozoa. Its transmission 
vector from human to human was later discovered in 1898 by Ronald Ross to be the female 
Anopheles mosquito.1 Malaria is an infectious disease caused by species of the protozoan 
genus known as Plasmodium. Plasmodium belong to the apicomplexan strain and have a self-
replicating plastid-like organelle known as the apicoplast, which is considered to have 
resulted from endosymbiosis of unicellular green algae in their evolution.3 Five species are 
known to affect human beings and they include Plasmodium falciparum, Plasmodium ovale, 
Plasmodium malariae, Plasmodium knowlesi4 and Plasmodium vivax. P. falciparum has been 
the cause of a large number of deaths, particularly in Africa.5  
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1.1.2 Life cycle of the plasmodium parasite 
The life cycle of the plasmodium parasite begins when a female Anopheles mosquito bites 
and ingests blood from an infected host. The plasmodium gametocytes in the ingested blood 
reproduce sexually over 1 – 2 weeks in the gut of the mosquito (Figure 1.1) and are then 
introduced in the form of sporozoites when the mosquito bites another person. The 
sporozoites migrate into the hepatocytes where they multiply asexually.6 The sporozoites 
enter the red blood cells as merozoites and continue to reproduce for another 1-3 days before 
rupturing the red blood cells for release at 48 hours interval.5 Gametocytes form at the same 
time and are ingested by mosquitoes which starts the life cycle again.6 
 
 
Figure 1.1. The life cycle of Plasmodium parasite7 
 
1.1.3 Signs and symptoms of malaria 
Although the severity of the disease caused by the five species of Plasmodium varies, they 
exhibit the same symptoms. The symptoms typically include: anaemia, splenomegally, 
jaundice, hepatomegally, and malaria paroxysm. The paroxysm corresponds with the 
rupturing of the red blood cells every 48 hours except for P. malariae which occurs every 72 
Chloroquine 
Mefloquine 
Pyrimethamine 
Quinine  
Sulphadoxine 
Pyrimethamine 
Primaquine 
 
Primaquine 
Primaquine 
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hours.8 Initially, the paroxysm is characterized by chills, rapid pulse, headache and nausea. 
These are then followed by profuse sweating and fever.6 
 
1.2 CHEMO-THERAPEUTIC AGENTS USED FOR PREVENTION AND 
TREATMENT OF MALARIA 
The life cycle of malaria parasites involves many stages. Thus far, no single drug has been 
able to eradicate all stages of the parasite in the human host. As such the antimalarial drugs 
are sometimes classified based on their antimalarial activity or the stages that they inhibit.5, 9 
These biological categories include: 
1. Sporozoiticides: This group of drugs eradicates the sporozoites as soon as they 
enter the blood stream after a mosquito bite. This prevents the parasite from 
infecting the liver cells. Primaquine is known to have sporozoiticides activity. 
2. Tissue schizonticides: These are drugs that destroy the exoerythrocytic liver-tissue 
stage of the parasite and thus prevent the parasites from entering the erythrocytes. 
This type of drugs is used as prophylaxis and one such example is pyrimethamine. 
Some tissue schizonticides are used to prevent relapse of P. ovale and P. vivax 
malaria e.g. primaquine.  
3. Blood schizonticides: These drugs destroy the erythrocytic stage of the parasite 
which is responsible for the manifestation of malaria symptoms. This is the easiest 
phase to attack the parasite as the drugs are delivered directly into the blood 
stream. Many of the known antimalarial drugs are active at this stage and some 
examples include chloroquine, sulphadoxine and mefloquine. 
4. Gametocides: This group of drugs destroy the sexual form of the parasite. This 
prevents transmission of parasite to the Anopheles mosquito and thus stops the 
lifecycle of the parasite. An example of a drug with gametocidal activity on four 
of the Plasmodia species that affects human is primaquine. No study has yet 
reported a full parasitological response of P. knowlesi to antimalarial drugs in 
human given its recent discovery to affect human.10 
 
For the Plasmodium parasite to survive it obtains essential amino acids by digesting 
haemoglobin of the host red blood cells. This results in the production of haematin which is a 
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complex of ferriprotoporphyrin IX (Fe(III)PPIX) and is toxic to the parasite. The parasite 
then detoxifies haematin by converting it through biocrystallization to insoluble non-toxic 
haemozoin.5 
 
On the basis of chemical or structural classification, the available chemotherapeutics for the 
prophylaxis and treatment of malaria can be categorized into three major groups. These 
include the aminoquinolines, antifolates and artemisinin derivatives. These groups of 
compounds have different targets and modes of action and as such are often used in 
combination as recommended by WHO. The aminoquinolines dates as far back as the 17th 
century with the use of quinine (Figure 1.2; 1.1) while the antifolates have a fairly recent 
history (1950s). Although Artemisia annua, the plant from which artemisinin is derived, has 
been used by the Chinese for treatment of fever and other ailments for over two thousand 
years, the active compound was only isolated in 1972.11 The evolution and mechanism of 
action of the different classes are discussed below.  
 
1.2.1 The Aminoquinolines 
This class of compounds are characterized by the presence of a quinoline nucleus in their 
chemical structure. Quinine (1.1) was first isolated from the bark of the cinchona tree in 1834 
by Pelletier, a French chemist.12 It is often extracted along with three other alkaloids: 
quinidine (1.2), cinchonine (1.3) and cinchonidine (1.4). Cinchonine (1.3) and cinchonidine 
(1.4) are optical isomers of each other lacking the methoxy group of quinine (1.1) while 
quinidine (1.2) is an optical isomer of quinine.  Quinidine (1.2) has better antimalarial 
properties than quinine but unfortunately it is also highly cardiotoxic. The structure of 
quinine can be described as having three parts: the quinoline or 6-methoxyquinoline 
component, the quinuclidine component and the hydroxylated methylene group connecting 
the two rings (Figure 1.2). Different modifications to quinine failed to yield any compound 
with superior antimalarial activity and thus quinine was the sole drug used in the treatment of 
malaria for many years until after World War I. Quinine (1.1) acts as a blood schizonticide 
and also possesses some gametocidal activity against P. vivax and P. malariae. It is reserved 
for use in severe falciparum malaria especially in areas with known chloroquine resistance.  
Adverse effects to quinine include hypoglycaemia at therapeutic doses as well as a condition 
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known as cinchonism.13 Cinchonism can develop from an overdose and sometimes standard 
doses of quinine. Mild cinchonism is characterized by a group of symptoms which include 
headache, blurred vision, vomiting, dizziness and confusion while severe symptoms include 
blindness, deafness, renal failure and death due to cardiotoxicity.  
 
 
Figure 1.2. Alkaloids from the bark of the Cinchona tree 
 
Both World War I and II played a significant role in the discovery and development of 
synthetic antimalarial agents. The shortage of quinine during World War I is believed to be 
the catalysing factor in the research to synthesize quinine (1.1) and the development of 
alternative agents to it. About 60 years before World War I, in an attempt to synthesize 
quinine, Perkin synthesized a dye that was later called Perkin’s mauve.14 Perkin’s mauve 
encouraged research into using aniline derivatives as precursors in dye synthesis which then 
led to the synthesis of methylene blue (1.5). Koch and Ehrlich found that the dye stains cells 
selectively. They also noticed that methylene blue (1.5) could affect physiological functions 
of the cell, such as motility in the protozoa. This, in 1891, brought Guitmann and Ehrlich to 
the realization that they could use the dye as a chemotherapeutic agent to selectively target 
parasite cells in host tissues. They investigated its effect on two patients and successfully 
treated the patients for malaria with methylene blue.14  Research on methylene blue was 
abandoned for 30 years due to its side effect of staining the subject’s tissues and skin.  
 
Erlich’s student, Roehl, who at the time was working at I.G. Farben industries, continued to 
study the dye and developed a method for testing these compounds in canaries. Roehl 
modified the methyl side group of methylene blue (1.5) by incorporating basic aliphatic side 
chains.14 The modifications significantly enhanced the antiplasmodial activity of the 
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compound but the compounds retain the properties of the dye that colours the patient’s 
tissues. Schulemann from Elberfeld laboratories of Bayer which formed part of I.G. Farben 
industries in Germany applied the knowledge from this study and reasoned that the 
antimalarial activity of the quinoline nucleus of quinine (1.1) could be increased with this 
new basic side chain. This line of reasoning resulted in the synthesis of an 8-aminoquinoline, 
pamaquine (1.6, plasmoquine) in 1924 as the first synthetic antimalarial agent (Scheme1.1).15  
 
 
Scheme 1.1. Evolution of pamaquine (1.6) from methylene blue (1.5) 
 
Pamaquine (1.6) had the advantage of being able to destroy plasmodium gametocytes and 
preventing relapse in vivax malaria. The 8-aminoquinolines were re-evaluated during and 
after World War II and this led to the synthesis of a series of derivatives from which 
primaquine (1.7) emerged as the most active and least toxic agent in 1946.16 It differs from 
pamaquine (1.6) in that it lacks the diethyl groups from the side chains (Figure 1.3).16, 17 
Primaquine (1.7) is a tissue schizonticide used for the treatment of P. vivax and P. ovale 
infections and has virtually no effect on the blood stages of the parasite. Although the 
mechanism of action remains unclear, primaquine (1.7) is known to generate reactive oxygen 
species that results in the formation of superoxides and hydroxyl radicals which in turn 
destroy the parasite. As a side effect it causes haemolytic anaemia and is thus contraindicated 
in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.18 G6PD is an 
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enzyme important in red blood cell metabolism and often results in haemolytic anaemia in 
patients who are deficient especially during an infection.  
 
A promising new development in the class of 8-aminoquinoline is tafenoquine (1.8), also 
known as WR238605, which is currently in phase IIb/III clinical trials for prevention and 
treatment of malaria. Tafenoquine (1.8) is a 5-phenoxy derivative of primaquine (1.7) 
developed by the Walter Reed Army Institute of Research (WRAIR) in the USA in an effort 
to find an alternative to primaquine which would be safer, longer acting and with a broader 
spectrum of activity.19 Although its mode of action is unknown, it has been shown to have 
activity against the blood stages of malaria,18, 20 has a longer half-life than primaquine and 
appears to be a good candidate for falciparum prophylaxis.21 It also shows less toxicity as 
compared to primaquine22 but retains the haemolytic property of the parent drug and thus is 
also not recommended for use in G6PD deficient patients. 
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Figure 1.3. Structures of antimalaril aminoquinolines 
 
After the discovery of pamaquine (1.6), a commercial research programme dedicated to 
discovering antimalarial drugs at Elberfeld laboratories was set up where researchers 
discovered mecaprine (1.9, quinacrine) in 1932. The compound evolved from the 
replacement of the quinoline ring of pamaquine with an acridine ring, introducing a chlorine 
atom and moving the side chain opposite to the ring nitrogen as it is in the quinine structure 
(Figure 1.3).23 Mepacrine unfortunately was only fairly active as a cure or prophylaxis for 
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malaria while exhibiting toxicity over long-term administration and thus prompting the 
search for better antimalarial agents to continue. In an effort to better understand the structure 
activity relationship and improve its antimalarial activity, mepacrine was modified such that 
the methoxy-bearing ring was removed. This gave rise to chloroquine (1.10, resorchin) in 
1934,23 a representative of the 4-aminoquinolines. Chloroquine despite its good antimalarial 
activity was perceived to be too toxic and was abandoned. Its derivative sontoquine (1.11) 
which seemed less toxic was synthesized in 1936. Interest in chloroquine was rekindled in 
1946 when allied scientists from the USA, Britain and Australia while working together 
obtained data from clinical studies conducted on sontoquine by a French physician. The US 
clinical trials showed that chloroquine was far superior to mepacrine.24 Chloroquine became 
one of the most popular antimalarials known and was the drug of choice in many countries 
for the treatment of malaria. 
 
Replacement of the alkylamino side chain of chloroquine (1.10) with an anilino group 
resulted in the development of amodiaquine (1.12) in 1950. Amodiaquine is a more active 
antimalarial drug than chloroquine but it is rapidly metabolized into its less active desethyl 
derivative.25 It was used for treatment and prophylaxis of malaria but was stopped in the 
1970s due to high toxicity which included hepatitis and agranulocytosis. Studies have 
however shown that these severe side effects are absent when used in doses required for 
malaria treatment.26 Although the drug is still widely available in Africa its use remained 
discontinued in the USA. 
 
The 4-aminoquinolines which include chloroquine (1.10), hydroxychloroquine (1.13) and 
amodiaquine (1.12) act as blood schizonticides.1, 5 They are weak bases that accumulate in 
the red blood cells where they are able to attack parasites at the multiplying stage. Unlike the 
8-aminoquinolines with unknown mode of action, 4-aminoquinolines are generally accepted 
to bind to haematin and as a result prevent the conversion of haematin to haemozoin. 
Haematin then accumulate in the digestive vacuole of the parasite where it destroys it.27 4-
Aminoquinolines have a unique affinity for haematin that is higher than that of 8-
aminoquinoline. The 7-chloro substituent of chloroquine is important to prevent the 
conversion of the toxic haematin to haemozoin and although it is necessary the chlorine 
substituent to be present it is not sufficient for a strong antiplasmodial activity.28 
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Other antimalarial agents that can be classified with the aminoquinolines include mefloquine 
(1.14), halofantrine (1.15) and lumefantrine (1.16). Although halofantrine and lumefantrine 
do not have the quinoline nucleus, they are structurally related to quinine. Mefloquine (WR 
142490) and halofantrine were also discovered by WRAIR in the antimalarial drug 
development programme to address the problem of chloroquine resistant P. falciparum that 
was killing many of the American soldiers during the Vietnam War. During the programme 
WRAIR screened over 200 000 compounds coming up with mefloquine and halofantrine. 
Mefloquine was approved for marketing by the United States Food and Drug Administration 
(FDA) in 1989 while halofantrine was approved in 1992.29 
 
The introduction of a 2-CF3 group into the quinine (1.1) skeleton prevents metabolic 2’-
hydroxylation and eventual deactivation of the drug.  This gave rise to antimalarials such as 
mefloquine (1.14) which is a highly active blood schizonticide with a very long half-life (2 – 
4 weeks). It is particularly effective against chloroquine-resistant strains of the plasmodium 
parasite but  has a range of side effects that consists of neuropsychiatric, gastrointestinal and 
cardiovascular effects.5 Resistance is easily developed to mefloquine due to its prolonged 
half-life and because of its relationship to quinine, cross-resistance between the two drugs 
have also been reported. Its use is therefore restricted to prophylaxis and to treatment of 
strains that are resistant to chloroquine or pyrimethamine and even then it is combined with 
another antimalarial drug to prevent development of resistance.  
 
Halofantrine (1.15) is produced and used as a racemic mixture since the two enantiomers 
appear to have no significant difference in activity. It is a blood schizonticide active against 
chloroquine sensitive and chloroquine resistant strains of P. falciparum. Metabolic N-
dealkylation of halofantrine produces an active metabolite, N-desbutylhalofantrine, which 
contributes to its overall antimalarial activity. Despite its high activity, it induces arrhythmias 
and is associated with prolonged depolarization and repolarization of the heart (QT intervals) 
which can lead to sudden death. High production cost,  variable bioavailability and.30 cross-
resistance with mefloquine also limits its use. 
 
The exact mechanism of action of quinine (1.1), mefloquine (1.14) and halofantrine (1.15) 
(classified as arylamino alcohols) against malaria is still unclear, it has been argued that 
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arylamino alcohols interfere with the dimerization of toxic haematin to haemozoin in a 
manner different to the mechanism of action of 4-aminoquinolines. In addition to interfering 
with the dimerization of haematin, quinine and mefloquine binds to phospholipids and inhibit 
the fusion of haemoglobin-laden vesicles to the digestive vacuole in the endolysosomal 
system. This is done either by directly impairing membrane function or by inhibiting calcium 
release from acidic stores. The arylamino alcohols also inhibit membrane recycling and as a 
result causes the death of the parasite.31 
 
Lumefantrine (1.16) is a 2,4,7,9-substituted fluorene with schizonticidal activity. It is not 
used in monotherapy because it is slow acting. It is often used in combination with artemether 
(1.32) (co-artemether) to combine the rapid activity of the artemisinin derivative with 
lumefantrine’s high cure rate. Although lumefantrine is structurally related to halofantrine it 
appears to have less cardiotoxic side effects than halofantrine.21 Desbutyl-lumefantrine, is an 
active metabolite and has higher antimalarial activity and also shows synergistic effects with 
artemisinin.32 
 
There is an on-going interest in the use of organometallic compounds in chemotherapy of 
diseases such as the use of platinum complexes for cancer treatment.33 Biot et al. (1997) 
explored the incorporation of the organometallic ferrocenyl unit into the chloroquine 
molecule. It was postulated that addition of iron or a ferrocenyl  group to the chloroquine 
molecule would abolish chloroquine resistance in chloroquine resistant P. falciparum since 
the parasite has a high affinity for iron. Several ferrocene-chloroquine compounds were 
synthesized with the ferrocenyl group covalently incorporated into the side chain of 
chloroquine.34 
 
Ferroquine (Figure 1.3, 1.17) emerged as the most active of the ferroquine-chloroquine series 
with better activity than chloroquine against both chloroquine sensitive and chloroquine 
resistant strains of P. falciparum.35 Although the ferrocene group on its own does not possess 
antiplasmodial activity, it enhances the antiplasmodial property of chloroquine when 
enclosed inside the chloroquine structure and reverses chloroquine resistance by an unknown 
mechanism. Based on the similarities in their chemical structure ferroquine is postulated to  
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also bind to haematin to prevent haemozoin formation. Ferroquine is currently in phase IIb 
clinical trials under development as a promising antimalarial drug candidate.36 
 
1.2.2 Folate antagonists 
Research into new antimalarial agents resurged during World War II due to a lack of access 
to quinine (1.1). Drug development focused on pyrimidine derivatives as inhibitors of DNA 
synthesis.37 This later led to the synthesis of proguanil (Figure 1.4, 1.18) albeit with the 
replacement of the pyrimidine ring with a biguanide chain. Proguanil was found to be even 
more effective than mepacrine (1.9) and quinine (1.1) against avian malaria and it is able to 
cure relapse cases of P. vivax malaria. Proguanil is in fact a prodrug which is metabolized 
into the active metabolite, cycloguanil (1.19). Synthesis of proguanil analogues was 
encouraged by the observed activity of proguanil (1.18). It was found that chlorination of the 
phenyl ring and lengthening of the linker between the phenyl ring and the diaminopyrimidine 
ring of proguanil increases the potency of the drug. It is from this discovery that 
chlorproguanil (1.20) and clociguanil (1.21) emerged. Like proguanil, chlorproguanil is also a 
prodrug that is metabolized to the active metabolite chlorcycloguanil (1.27).37 
 
Continuing with the pyrimidine work, Hitchings et al.38 carried out tests on several 
substituted diaminopyrimidines with the aim to find an antagonist against the nucleic acids of 
fast-growing cells such as bacteria, protozoa and neoplasm. Since these parasites divide more 
rapidly than host cells an antagonist would affect the parasite more on the basis of differential 
growth rate.38 Falco et al.39 then observed that the structure of the diaminopyrimidines is 
similar to proguanil (1.18) which is a folic acid antagonist. He therefore hypothesized that 
2,4-diaminopyrimidines would have antimalarial properties. Screening of this group of 
compounds led to the discovery of pyrimethamine (1.22) which closely resembles the active 
metabolite of proguanil and is 200 times more active than the latter in P. berghei.23 
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Figure 1.4. Folate inhibitors 
 
Another class of antifolate drugs used in the treatment of malaria is the sulpha drugs. 
Dapsone (1.23) was first produced by Fromm and Wittmann in 1908 in an attempt to 
synthesize azo (-N=N-) dyes.40 Its antimicrobial and antiplasmodial properties were however 
only discovered in the 1930s when research into sulpha drugs had surged due to the activity 
observed for Prontosil® (Figure 1.4, 1.24). Prontosil®, also discovered in the 1930s, is a 
sulpha prodrug which is only activated biologically when metabolized to its active 
metabolite, sulphanilamide.  
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Proguanil (1.18), pyrimethamine (1.22) and the sulpha drugs (Figure 1.4) all inhibit 
plasmodia growth by interfering with folate biosynthesis in the malaria parasite. Folate is an 
important component in almost all living organisms. It is necessary for the biosynthesis of 
amino acids and DNA replication.41 While humans cannot biosynthesize folate and rely on 
dietary intake, most bacteria and some protozoa such as P. falciparum are able to produce 
their own folate. P. falciparum can synthesize folate de novo and still make use of folate 
salvaged from the host cell.41 
 
Two enzymes from the Plasmodium folate pathway have been the target of most antifolate 
drugs for malarial treatment. These enzymes are dihydrofolate reductase (DHFR) and 
dihydropteroate synthase (DHPS). DHFR has a homologue in humans with some differences 
while DHPS has no human homologue, making it a good target for antimalarial compounds. 
DPHS catalyses the condensation of 7,8-dihydro-6-hydroxymethylpterin pyrophosphate with 
p-aminobenzoic acid to form 7,8-dihydropteroate (Scheme 1). The dihydropteroate is later in 
the pathway converted to dihydrofolate which is reduced by DHFR in an NADPH-dependent 
reaction to tetrahydrofolate. The tetrahydrofolate are then converted into tetrahydrofolate 
cofactors which are necessary for nucleic and amino acids biosynthesis.42 
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Scheme 1.2 Summarized pathway of folate biosynthesis and its inhibitors in P. falciparum 
 
Antifolate drugs inhibit folate synthesis by blocking the enzymes of this pathway and as a 
result disrupt DNA replication in the parasite. These drugs are blood schizonticides although 
wide spread resistance has reduced their use. Sulpha-based drugs such as sulphadoxine (1.25) 
are structural inhibitors of DHPS. They inhibit the enzyme by competing with its substrate, p-
aminobenzoic acid, for binding.20 
 
Proguanil (1.18), chlorproguanil (1.20), Pyrimethamine (1.22) and trimethoprim (1.26) and 
are active against PfDHFR.42 and inhibit both the de novo synthesis of folates and the salvage 
of exogenous folate derivatives.41 Combinations of DHFR inhibitors with DHPS inhibitors 
have synergistic effects. where one drug potentiates the effect of the other. An example of 
this is the combination of sulphadoxine with pyrimethamine (Fansidar®).  
 
p-Aminobenzoic acid + 7,8-Dihydro-6-hydroxymethylpterin 
Sulpha 
drugs:Sulphado
xine 
Dapsone 
DPHS 
7,8-Dihydropteroate 
Dihydrofolate 
Tetrahydrofolate 
Pyrimethamine 
Trimetoprim 
Chlorproguanil DHP
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1.2.3 Artemisinin derivatives 
The discovery of artemisinin emerged from “project 523” designed by Chinese researchers in 
1967 to develop antimalarial therapies. A compound named Arteannuin B (Figure 1.5, 1.29, 
qinghaosu II) was first isolated in 1972 from Artemisia annua, however this did not give the 
expected antimalarial effect and thus the search for the active compound in the plant 
continued. The crystalline form of  artemisinin (1.30) was later isolated in 1973 from A 
annua which had been in use for over 2000 years in traditional Chinese medicine for the 
treatment of chills and fever.   
 
Artemisinin (1.30) is a 1,2,4-trioxane, sesquiterpene lactone and its total synthesis was first 
reported in 1983.43 Since then several groups have reported its synthesis and attempts have 
been made to genetically modify plant and microbes to produce the compound.44, 45 Despite 
all these the main supply of the artemisinin still remains the plant A. annua. Even though its 
mode of action is still under debate, it is generally believed that the iron from haem attacks 
and breaks the endoperoxide linkage of the compound resulting in the formation of oxygen 
free radicals. The free radicals are then rearranged to carbon free radicals which alkylate and 
destroy the parasite proteins and eventually lead to the parasite’s death.46 
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Figure 1.5. Artemisinin and its derivatives 
 
Artemisinin derivatives are amongst the most potent antimalarial agents and are active 
against sexual and asexual stages of chloroquine sensitive and resistant strains of P. 
falciparum. The parent drug and its derivatives inhibit the trophozoite stage of the 
Plasmodium lifecycle, preventing the progression of the disease and making them the fastest 
acting antimalarial agents available. They also have gametocidal action thus preventing 
transmission of resistant strains. 
 
Unfortunately the use of artemisinin has its limitations. It has poor oil and water solubility, a 
short plasma half-life of 3-5 hours and a high rate of recrudescence.47 These preclude its use 
as monotherapy or prophylaxis. In order to improve its pharmacokinetic properties, 
derivatives of artemisinin were sought. Artemisinin is easily reduced to dihydroartemisinin 
(DHA, Figure 1.5, 1.31) using sodium borohydride.47 In an effort to increase artemisinin’s oil 
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and water solubility, ether and ester derivatives of the compound were prepared from DHA. 
These first generation analogues included artemether (1.32) and arteether (1.33) which are oil 
soluble ether derivatives of artemisinin used for intramuscular administration. Artesunate 
(1.34) is a water soluble hemisuccinate ester of artemisinin used for intravenous treatment. 
These analogues are metabolized into the active metabolite DHA which still exhibit short 
plasma half-life and as a result the high rate of recrudescence persists.47 In order to prevent 
recrudescence, the WHO has recommended that artemisinin derivatives be used with longer 
acting antimalarials as first line treatment for uncomplicated malaria. As such there are 
artemisinin combination therapies (ACTs) such as artesunate-mefloquine, artemether-
lumefantrine (coartem®), artesunate-amodiaquine and DHA-piperaquine combinations.  
 
Due to their fast rate of reducing parasitemia, it is envisaged that it will be difficult for the 
parasite to develop resistance to this class of drugs. However, low Plasmodium susceptibility 
to artesunate has been reported in some patients in Western Cambodia where artemisinin 
monotherapy is often used.48 This raises concern about the development of resistance to 
artemisinin in the near future. 
 
A comparison of the effect of artesunate (1.34) and quinine (1.1) on patients infected with the 
malaria parasite did not show any significant difference between the two drugs. Quinine 
however exhibited  hypoglycaemia side effect when used as monotherapy.49 A combination 
of these two drugs shows synergism in their antimalarial activity and  prompted the synthesis 
of a quinine-artemisinin hybrid (1.35) which has since been shown to exert superior 
antimalarial activity to either of the two drugs alone or a 1:1 combination of the two.  This 
hybrid also has a potent activity against 3D7 chloroquine resistant P. falciparum.50 
 
Second generation artemisinin derivatives have been developed with the aim to increase the 
half-life and bioavailability of this group of compounds.47, 51 This has resulted in some very 
potent derivatives such as 1.36 with excellent in vitro antimalarial activity and 1.37 which is 
15 times more potent than artemisinin (1.30).52 Medicine for Malaria Ventures (MMV), a 
non-profit organization focussed on developing antimalarial agents, has teamed up with 
various research groups to completely fully synthesize artemisinin derivatives that are active, 
have long half-lives, are safe and can be produced on a large scale. In this venture, 
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Vennerstrom and co-workers have designed and are developing completely synthetic ozonide 
antimalarial agents based on the 1,2,4-trioxolane moiety which is related to the artemisinin 
endoperoxide pharmacophore.53 One such agent that has been selected for drug development 
is OZ277 (Figure 1.6, 1.38), a secondary ozonide with a 5-membered 1,2,4-trioxolane ring. 
OZ277 is currently in phase III clinical trials and has been shown to have a rapid onset of 
action, is active against all asexual erythrocytic stages of P. falciparum but has low in vivo 
half-life of approximately two hours.53 Although the exact mechanism of action of these 
peroxide agents is not clear, the ozonides are believed to act the same way as artemisinin and 
requires functional groups that are reactive with Fe(II) for antiplasmodial activity.  
 
Figure 1.6. Structures of ozonides OZ277 (1.38) and OZ439 (1.39) 
 
The same group has developed the next-generation ozonides with increased in vivo half-life.54 
This was achieved by replacing the cis-8’-alkyl group of the first generation ozonides such as 
in OZ277 (1.38) with cis-8’-phenyl group. The next-generation ozonides with the cis-8’-
phenyl substituents were more than 50-fold more stable to Fe(II)-mediated degradation as 
compared to the first-generation ozonides. Nonetheless the next-generation ozonides reacts 
rapidly with haem to an extent that is comparable to the first-generation ozonides i.e. they are 
stable enough not to undergo haem-mediated degradation in blood yet react sufficiently with 
haem (Fe(II)-reactivity) to kill Plasmodium parasites.  A candidate that has emerged superior 
from the next-generation ozonides and is currently in phase IIa clinical trials is OZ439 
(Figure 1.7, 1.39).54 OZ439 has in vitro activity against P. falciparum and exhibit in vivo 
activity against P. berghei. It has a long half-life of more than 20 hours after oral 
administration to rats as compared to 0.5 hours for DHA (1.31) and one hour for OZ277. This 
is however still low as compared to mefloquine for example with half-life of two to four 
weeks and thus would still require combination with longer-acting antimalarial drugs to 
prevent rapid development of resistance.  
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1.3 PROBLEMS ASSOCIATED WITH KNOWN MALARIA TREATMENT: 
RESISTANCE 
Treatment of malaria, especially in sub-Saharan countries where the disease is prevalent is 
inundated with many problems.55 These include, access to treatment, safety of available 
treatment, tolerability, adherence and effectiveness of the treatment. Many of the countries 
where malaria is endemic are developing countries where many cannot afford $1 per 
treatment. The fact that malaria mostly affects these economically poor countries has not 
encouraged investment in the development of new antimalarial drugs.  
 
The biggest problem by far in the treatment of malaria, is resistance. P. falciparum has shown 
resistance to virtually all known classes of antimalarial drugs on the market.56 The 
development of widespread resistance to chloroquine, sulphadoxine and pyrimethamine 
individually and in combination has complicated the management of malaria. The WHO 
responded by recommending that combination therapies be used to reduce the rate at which 
resistance develops. The drugs are combined such that they have independent modes of 
action and different targets. Examples of these are non-artemisinin based combination such as 
Sulphadoxine-pyrimethamine + mefloquine and artemisinin-based combination such as 
artemether-lumefantrine. While these combinations have proved effective they are about 10 
times more expensive than monotherapy treatment. In some cases resistance has developed to 
some combinations. This includes sulphadoxine-pyrimethamine + chloroquine in areas where 
P. falciparum resistance to chloroquine is high.55 
 
1.3.1 Chloroquine resistance mechanism 
Chloroquine (1.10) has been in use since the 1950s and was the first line treatment in many 
malaria endemic countries. Even now with widespread resistance, chloroquine (1.10) remains 
the treatment of choice in many economically poor countries because it is cheap. The 
mechanism of chloroquine resistance has been under investigation since the discovery that 
that the resistance can be reversed. 
 
The mechanism of resistance of P. falciparum to chloroquine is still under investigation but it 
has been shown to be due to mutations in the chloroquine resistance transporter (PfCRT) 
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protein.57 This protein transporter, found in the digestive vacuole of the parasite actively 
transports protonated chloroquine out of the digestive vacuole in exchange for proton. 
Although this happens in both chloroquine sensitive (CQS) and chloroquine resistant (CQR) 
strains of P. falciparum, it occurs at a much faster rate in the CQR parasites. The active 
transport of chloroquine out of the digestive vacuole of the CQR parasite is associated with 
substitution of positively charged lysine (K) at position 76 of the PfCRT polypeptide chain 
with uncharged threonine (T) i.e. K76T substitution.58 The wild type PfCRT with its charged 
lysine creates an electrostatic environment which prevents access of charged chloroquine to 
PfCRT. Once mutated, the uncharged threonine makes PfCRT more accessible to the charged 
chloroquine which is then transported out of the digestive vacuole.58, 59 Since resistance to 
chloroquine is due to its diminished accumulation within the digestive vacuole as opposed to 
chloroquine interaction with haematin, increase in the concentration of chloroquine within the 
vacuole should reverse the resistance. 
 
Verapamil, a calcium channel blocker has been shown to reverse chloroquine resistance.60 
Verapamil is postulated to bind to the carrier protein and prevent the conformational change 
that allows the interconversion of the carrier from one state to another. Verapamil replaces 
the positively charged lysine which is absent in mutated parasite at position 76.58 This 
restores the electrostatic charge of the protein and prevents charged chloroquine from binding 
to PfCRT and thus cannot be transported out of the digestive vacuole. 
 
1.3.2 Antifolate resistance 
P. falciparum resistance to folate inhibitors are due to single point mutations in the genes 
coding for the DHFR and DHPS enzymes. Resistance to pyrimethamine has been found to be 
due to accumulation of mutations on the dhfr domain of P. falciparum dihydrofolate 
reductase-thymidylate synthase (DHFR-TS). DHFR-TS of the parasite have 608 amino acids 
with the first 231 comprising of DHFR domain. Mutations at this domain on codons 51 
(N51I), 59 (C59R) and 108 (S108N) lead to pyrimethamine resistance. S108N has been 
found to be a necessary first mutation in DHFR for resistance to any DHFR inhibitors to 
occur. It has also been established that the greater the number of mutations the greater the 
degree of resistance.42 
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WR99210 (Figure 1.7, 1.40) is an active metabolite of PS-15 (1.41) that binds to and inhibit 
DHFR. WR99210 has the closest flexibility to DHFR substrate, dihydrofolate61 and this is 
possibly why it is a very potent inhibitor and has low susceptibility to point mutations in 
DHFR. There is a possibility that mutations that are strong enough to disrupt the binding of 
WR99210 will also disrupt dihydrofolate from binding.42 
 
Figure 1.7. Chemical structures of WR99210 (1.40) and PS-15 (1.41) 
 
Resistance to sulpha drugs occur also as a result of point mutations on DHPS and like DHFR, 
the more mutations on DPHS the greater the resistance to the sulpha drugs. Single mutations 
to A437G, K540E or S436A induce some degree of resistance. These mutations along with 
other multiple mutations are required for higher degrees of resistance to the sulpha drugs. The 
double mutant A437G/K540E is prevalent in Africa and when found with a triple mutant 
form of DHFR (N51I/C59R/S108N) results in a parasite that is highly resistant to 
sulphadoxine-pyrimethamine combination.62 
 
The world currently relies heavily on artemisinin and its derivatives for the treatment of 
malaria. Though in vitro resistance has been reported63 there has not been an unquestionable 
in vivo resistance to artemisinin. However, judging from the trend observed thus far, 
especially in western Cambodia where emergence of resistance to different antimalarials is 
not new and where there appears to be low susceptibility to artesunate, the plasmodium 
parasite might soon acquire resistance to artemisinin. This would be disastrous seeing that 
artemisinin class of drugs is currently one of the most effective treatment against the disease.  
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1.4 TARGETS FOR ANTIMALARIAL DRUGS 
There has been cross resistance between many antimalarial drugs making it necessary to find 
new drugs and targets. These targets should preferably be specific to the parasite or with 
enough differences from homologous targets in the host in order that drug development could 
be directed toward more selective compounds for the parasite. The current approach to 
development of new antimalarial chemotherapy generally include: i) optimization of existing 
antimalarial agents e.g. combination therapies, ii) development of analogues of existing 
drugs, iii) use of compounds developed against other diseases, iv) development of drug 
resistance reversals, v) natural products and vi) development of active compounds against 
new targets.64 The completion of P. falciparum genome sequencing has created a better 
understanding of the parasite biology, thus aiding the search for new drug targets.   Table 1.1 
shows some of these targets and their inhibitors.  
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Table 1.1. Identified targets for antimalarial agents64-66 
Target Location P/way or Process Target Enzyme Inhibitor 
Parasite membrane Phospholipid synthesis Choline transporter G-25 
 
Membrane transport Unique channels Dinucleoside dimmers 
 
   
Apicoplast DNA synthesis DNA gyrase Quinolones 
 
Transcription RNA polymerase Rifampicin 
 
Protein synthesis Apicoplast ribosome Doxycycline 
 
Type II fatty acid 
synthesis 
FabH 
FabI 
Thiolactomycin 
Triclosan 
 
Isoprenoid synthesis DXR Fosmidomycin 
 
Protein farnesylation Farnesyl transferase Peptidomimetics 
 
   
Mitochondrion  Electron transport 
Cytochrome 
oxidoreductase 
Atovaquone 
 
   
Cytosol Folate metabolism DHFR 
Pyrimethamine, proguanil, 
cycloproguanil 
 
 DHPS Sulphadoxine, dapsone 
 
Glycolysis Lactate dehydrogenase Gossypol derivatives 
 
Pyrimidine metabolism Thymidylate synthase 5-fluoroorotate 
 
 OPRT 
5-substituted orotate 
analogues 
 
Shikimate pathway EPSP synthase Glyphosate 
 
Purine metabolism HGPRT Immucillin-H 
 
Calcium catabolism SERCA Artemisinin 
 
   
Digestive vacuole Haem polymerization Haematin Quinolines 
 
Hb degradation Plasmepsins, falcipains  Leupeptin, pepstatin 
 
Reactive species 
generation 
Unknown Artemisinin 
 
   
Nucleus 
Cyclin-dependent 
protein kinases 
pfnek-1, pfcrk-1, pfmrk 
Isoquinolone 
sulphonamides, oxindole 
derivatives 
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1.5 THE APICOPLAST AS A DRUG TARGET FOR ANTIMALARIAL DRUG 
DEVELOPMENT 
Plastids are organelles believed to originate from endosymbiotic bacteria or cyanobacteria. 
The endosymbiotic relationship is thought to have resulted from the engulfment of the 
cyanobacteria by a eukaryotic cell. The undigested bacterium then remained preserved as a 
plastid in the eukaryotic host cell. As such the plastids are semi-autonomous and serve as a 
site for many metabolic processes that the host cell has come to depend upon.67 An example 
of such a plastid is the chloroplast found in plants and some algae. Chloroplast serves a 
number of functions in these organisms the most significant of which is photosynthesis.  
 
An important non-photosynthetic plastid found in apicomplexan parasites is the apicoplast. 
Apicoplast originated as a result of a secondary endosymbiosis of a red-alga which already 
contained a plastid.68 The apocoplast in P. falciparum (Figure 1.8) is believed to perform a 
number of housekeeping functions necessary for the survival of the parasite. While these 
functions have not been conclusively defined, the apicoplast is thought to be the site of fatty 
acid synthesis, is implicated in haem and amino acid synthesis and has been proven to be the 
site of non-mevalonate isoprenoid biosynthesis in the parasite.  
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Figure 1.8. Cellular structure of P. falciparum trophozoite showing the apicoplast69 
 
Due to their prokaryotic origin from the primary endosymbiosis, the metabolic processes that 
take place in the apicoplast are significantly different to that of their eukaryotic host and can 
thus be selectively targeted for drug development. Being semi-autonomous the apicoplast 
replicates its own DNA, transcribe and translate its RNA into proteins. Coupled with fatty 
acid and isoprenoid biosynthesis,67 the apicoplast has been deemed indispensible to the 
malarial parasite.68 Identifying the functions of the apicoplast has prompted drug 
development research to inhibit the P. falciparum growth by inhibiting the processes that take 
place in the organelle. 
 
1.5.1 DNA replication, transcription and translation 
Based on their prokaryotic origin, antibiotics have been found to effectively inhibit 
plasmodial growth. To this end ciprofloxacin has been shown to directly inhibit apicoplast 
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DNA replication in P. falciparum.70 Rifampicin inhibits bacterial RNA polymerase, 
preventing transcription in bacteria. This explanation is used to rationalise  its antiplasmodial 
activity, although direct evidence of this has not been observed in the apicoplast.68 Several 
antibiotics have been suggested to inhibit plasmodial growth through inhibition of protein 
translation in the parasite at the apicoplast level. These antibiotics include thiostrepton, 
micrococcin, clindamycin, doxycycline, tetracycline and amythiamycin.67 
 
1.5.2 Fatty acid biosynthesis 
Biosynthesis of fatty acid in humans is catalyzed by a multifunctional protein classified as a 
type I fatty acid synthase. Until recently, it was believed that plasmodium species are unable 
to produce their own fatty acids but rely on the host cell for their needs. Plants, bacteria and 
plasmodium biosynthesize their fatty acids in a pathway that requires separate enzymes at 
different stages, known as type II synthases. Some of the type II synthases include acyl 
carrier proteins (ACP) FabB, FabH, FabZ and FabI which take part in a series of 
condensation and dehydration reactions. Identification of genes that codes for these ACP in 
association with the apicoplast of P. falciparum confirms the occurrence of a type II fatty 
acid biosynthetic pathway in the parasite. This provides new targets to which new 
antiplasmodial drugs can be developed.71 Triclosan, a known antibacterial, has been shown to 
inhibit the growth of P. falciparum. It binds and inhibits the enoyl-ACP reductase (FabI), the 
enzyme that elongates the fatty acids at the rate-limiting final step of the synthesis.72 
 
1.5.3 Isoprenoid biosynthesis 
Isoprenoid biosynthesis is one of the functions observed in the apicoplast of P. falciparum. 
This process is inhibited by fosmidomycin, an antibiotic which binds to 1-deoxy-D-xylulose 
5-phosphate reductoisomerase (DXR), one of the enzymes of the isoprenoid synthetic 
pathway.73 Yeh et al.74 recently discovered that fosmidomycin inhibition can be rescued by 
externally supplying isopentenyl pyrophosphate (IPP) to the parasite. Parasite survival was 
also observed in those plasmodial cells which had lost their apicoplast when externally 
supplemented with IPP during the blood stage growth of P. falciparum. This indicated that 
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isoprenoid biosynthesis is the only essential function of the plasmodial apicoplast at the blood 
stage, validating this pathway as a target for development of antimalarial drugs.  
 
1.6 TARGETING THE MEVALONATE-INDEPENDENT PATHWAY 
1.6.1 The mevalonate and mevalonate-independent pathways 
For many years, the mevalonate pathway was believed to be the only route for the 
biosynthesis of isoprene units. Isoprene units include the 5-carbon isomers isopentenyl 
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) which are added head-to-
tail in different chain lengths to make different isoprenoids. Isoprenoids are a very diverse 
family of natural compounds comprising over 35 000 compounds such as steroids, bile salts 
and carotenoids that play important roles in all organisms. They are involved in signal 
transduction, membrane structure, electron transport and growth regulations.75 The 
mevalonate pathway involves the condensation of three molecules of acetyl-coenzyme A 
(acetyl-CoA) to give 3-hydroxy-3-methylglutaryl CoA (HMG-CoA). HMG-CoA is reduced 
to mevalonic acid (MVA) by HMG-CoA reductase and subsequent phosphorylation of the 
MVA by kinases result in mevalonate-5-diphosphate. Mevalonate diphosphate decarboxylase 
in a decarboxylation reaction converts mevalonate-5-diphosphate to IPP. DMAPP is then 
formed from the action of IPP isomerase on IPP (Scheme 1.3). 
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Scheme 1.3. The Mevalonate and Non-mevalonate pathways of terpenoid synthesis 
 
In the early 1990s, Rohmer et al. (1993) discovered an alternative pathway to the synthesis of 
isoprene units in bacteria.76 This mevalonate-independent pathway (also known as non-
mevalonate pathway, DOXP pathway or MEP pathway) has since been identified in green 
algae, higher plants77 and in the apicoplast of P. falciparum.73 The pathway consists of seven 
steps that begin with the condensation of glyceraldehyde-3-phosphate and pyruvate by 1-
deoxy-D-xylulose 5-phosphate (DOXP) synthase (DXS) to form DOXP. The second step 
constitutes the first step that is specific to this pathway and involves the intramolecular 
rearrangement and reduction of DOXP in an NADPH dependent reaction to form 2-C-
methyl-D-erythritol (MEP) by DOXP reductoisomerase (DXR or IspC). 4-Diphosphocytidyl-
2-C-methyl-D-erythritol (CDP-ME) synthase (IspD) cytidilates MEP to CDP-ME releasing 
pyrophosphate in the process. In an ATP dependent reaction, the 2-hydroxy group on CDP-
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ME is phosphorylated by CDP-ME kinase (CMK or IspE) to form CDP-ME-2-phosphate. 2-
C-methyl-D-erythritol-2,4-cyclodiphosphate (MECDP) synthase (IspF) cyclises CDP-ME-2-
phosphate to MECDP. Ring opening reduction of MECDP by 1-hydroxy-2-methyl-2-buten-
4-yl diphosphate (HMBPP) synthase (GcpE or IspG) gives rise to HMBPP. In the final step 
HMBPP is again reduced followed by removal of a hydroxyl group to form a mixture of IPP 
and DMAPP in a reaction catalysed by IPP/DMAPP synthase (LytB or IspH).78 
 
1.6.2 DXR as a validated target 
The formation of DOXP, catalysed by DXS in the first step of the mevalonate-independent 
pathway, is also involved in thiamine and pyridoxol biosynthesis in Escherichia coli.79 This 
makes the second step i.e. the DXR catalyzed conversion of DOXP to MEP the first 
committed step of the mevalonate-independent pathway. The fact that the pathway and its 
enzymes are absent in humans make them even more desirable as drug targets. Each enzyme 
of the pathway is thus a potential target for the development of antibacterial, herbicidal and 
antiplasmodial agents.  
 
Soon after the discovery of the non-mevalonate pathway, the antibacterial fosmidomycin 
(1.46) was identified as an inhibitor of the pathway, specifically inhibiting the DXR 
enzyme.80 The phase II clinical trial of fosmidomycin in combination with clindamycin 
revealed a good tolerability and safety profile for the drug.81 Fosmidomycin has been shown 
to inhibit recombinant DXR from E. coli,80 P. falciparum73 and M. tuberculosis82 in in vitro 
assays. Yet, compounds downstream from the DXR reaction in the pathway, most notably 
MEP, have also been detected after fosmidomycin treatment in three studies.83-85 This is 
unexpected since the pathway should end when DXR is inhibited by fosmidomycin. This 
raised questions as to whether fosmidomycin inhibits DXR or another enzyme in the 
plasmodium parasite to give its antimalarial effect, and if it does, is DXR really necessary for 
parasite survival? In an attempt to find answers to these questions, a study was conducted 
with parasites from which the dxr gene had been removed. The study showed no parasite 
growth when the dxr gene is absent, confirming that DXR is essential for P. falciparum 
growth.86 This nevertheless still did not explain the presence of MEP after addition of 
fosmidomycin to the DXR assays. 
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It is important to functionally validate potential therapeutic targets. Although fosmidomycin 
inhibits recombinant PfDXR, in vitro, and has antiplasmodial and antimalarial activity, in 
vivo, it is still not a proof that fosmidomycin binds only to DXR, in vivo. Zhang et al.87 found 
that fosmidomycin exclusively blocks an enzyme/s of the DOXP pathway. This was shown 
by the rescuing of fosmidomycin-mediated growth inhibition when the growth medium was 
supplemented with isoprenol. Had fosmidomycin been attacking any other function outside 
the DOXP pathway, addition of the isoprenol should not rescue the growth inhibition. 
Enzymes of this pathway were thus validated as targets for drug development. In the same 
study, the intermediate 2-C-methylerythrose 4-phosphate formed during the conversion of 
DOXP to MEP was found to increase upon fosmidomycin addition which means that 
fosmidomycin probably blocks the conversion of the intermediate to MEP. All the other 
metabolites isolated downstream of MEP decreases. Metabolic profiling of the 
fosmidomycin-treated Plasmodium thus identifies IspD as the second target in the parasite. 
There was weak inhibition of purified IspD when treated with fosmidomycin suggesting that 
inhibition of this pathway by fosmidomycin might be more complicated than initially 
anticipated. Computational docking of IspD with fosmidomycin and 2-C-methylerythrose 4-
phosphate showed that the intermediate binds better to the enzyme than fosmidomycin. 
Zhang and co-workers speculated that it is the accumulated intermediate upon treatment with 
fosmidomycin that binds to and inhibit IspD as opposed to fosmidomycin itself binding to the 
enzyme.87 This explains why MEP was present even after addition of fosmidomycin to the 
assay. Given that DXR inhibition by fosmidomycin led to all the effect that was observed and 
which inhibited the parasite growth, DXR was as a result functionally validated as target for 
antiplasmodial agents. 
 
1.6.3 General features and characteristics of the DXR enzyme 
DXR is a homodimer (Figure 1.9 A) in which each monomer is divided into 3 subunits that 
form a V-shape. While the crystal structure of P. falciparum DXR (PfDXR) has only recently 
been reported,88E. coli DXR (EcDXR) has been extensively studied.89-94 Each monomer of 
EcDXR has a molecular mass of 43.5 kDa and consists of 398 residues. The monomer is 
divided into (i) the N- or amino-terminal dinucleotide binding domain which forms one arm 
of the V-shape, (ii) the carboxyl-terminal which forms the other arm of the “V” and (iii) the 
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connecting domain which links the N- and the C-terminals (Figure 1.9 B). The N-terminal is 
made up of residues 1-150 and is the site of NADPH binding which is necessary for the 
activity of the enzyme. The carboxyl-terminal is a four-helix bundle comprising of residues 
312-398 and is reported to play a structural role in supporting the catalytic domain. The 
connecting domain houses the catalytic site of the enzyme where substrate, metal ion and 
inhibitors bind and is involved in the dimerization of the enzyme.89, 90 The connective domain 
comprises of residues 160 – 270 and also integrates residues 206 – 216 which make up the 
flexible “lid” that closes over the active site upon substrate or inhibitor binding to shield the 
active site from solvent. 
 
Figure 1.9. Crystal structure of EcDXR90 
Ribbon representation of DXR dimer (A) and monomer (B) showing the three domains: amino-terminal (blue), 
connective domain (red) and carboxyl terminal (green) modelled with NADPH (yellow) and showing the flexible 
loop (ochre) 
 
1.6.4 The 1-deoxy-D-xylulose 5-phosphate reductoisomerase catalyzed reaction 
It was established over the years that the transformation of DOXP (Scheme 1.4, 1.42) to MEP 
(1.44) happens in two steps, a rearrangement step followed by a NADPH and divalent metal 
ion-dependent reduction step. NADPH is required for the initial rearrangement of DOXP to 
2-C-methylerythrose-4-phosphate intermediate (1.43) but no reduction occurs until the next 
stage when the intermediate is converted to MEP (Scheme 1.4).95 
 
B 
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Scheme 1.4. DXR catalyzed conversion of DOXP to MEP95, 96 
 
Two mechanisms were proposed for the rearrangement of DOXP to 2-C-methylerythrose-4-
phosphate, the α-ketol rearrangement and the retroaldol-aldol rearrangement. The α-ketol 
rearrangement involves the deprotonation of the C-3 hydroxyl followed by C-4 shift to C-2 to 
give the 2-C-methylerythrose-4-phosphate intermediate (Scheme 1.5 A, 1.43). 
 
 
Scheme 1.5. The α-ketol rearrangement (A) and retroaldol-aldol rearrangement (B) 
mechanism96 
 
The retroaldol-aldol reaction involves the breakage of the C3-C4 bond, followed by an aldol 
condensation of the two segments with a resulting shift of C-4 to C-2 (Scheme 1.5 B). 
Determining the correct mechanism for the conversion of DOXP to MEP has been an 
ongoing project for researchers. Munos et al.97 and Wong and Cox96  found more evidence 
favouring the retroaldol-aldol mechanism. The two groups incorporated 2H selectively at C-3 
and C-4, synthesizing 3-2H DOXP and 4-2H DOXP, respectively. A competitive secondary 
kinetic isotope effect (KIE) study of the DXR reaction was then carried out separately with 
both deuterated substrates. KIE can be used to observe hybridization changes of a carbon 
atom. The study was used to distinguish between the α-ketol and retroaldol-aldol mechanisms 
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by observing the re-hybridization pattern of the substrates to 2-C-methylerythrose-4-
phosphate. Hybridization changes would be expected at C-2 and C-3 and no change at C-4 if 
the α-ketol reaction occurred i.e. KIE will be expected for the 3-2H DOXP and no KIE for the 
4-2H DOXP. The studies reported sp3 to sp2 hybridization for both 3-2H DOXP and 4-2H 
DOXP and re-hybridization back to sp3 for 4-2H substrate. This is consistent with the 
retroaldol-aldol mechanism and confirms the presence of this mechanism in the DOXP 
pathway.96, 97 The rearrangement step was confirmed to be the rate-limiting step of the 
reaction.98 
 
The stereochemistry of the reduction step of the DXR reaction was established based on the 
delivery of pro-S hydride from NADPH to the re face of the intermediate aldehyde. This 
earned DXR a class B dehydrogenase classification.99 
 
1.6.5 FR-900098 and fosmidomycin as inhibitors of DXR 
FR900098 (Figure 1.10, 1.45) was originally isolated from Streptomyces rubellomurinus sp. 
nov ATCC31215100 and later synthesized.101 Fosmidomycin (1.46) was also isolated from S. 
lavendulae and exhibited superior antimicrobial activity to FR900098.102 The activity of 
fosmidomycin was narrowed down to inhibition of isoprenoid biosynthesis in those 
organisms that produce isoprene units exclusively via the DOXP pathway. This was 
identified by fosmidomycin’s inhibition of menaquinone and carotenoid biosynthesis in 
Micrococcus luteus.103 
 
Figure 1.10. Structures of FR900098 (1.45) and fosmidomycin (1.46)  
 
Fosmidomycin (1.46) and its derivative FR900098 (1.45) are structurally simple compounds 
consisting of phosphonic acid and a retro-hydroxamate groups which are necessary for their 
Chapter 1  Literature review 
 
 Page | 36 
 
inhibitory activity. Fosmidomycin  was found to be a specific inhibitor of DXR preventing 
conversion of DOXP to MEP (1.44).80 Jomaa and co-workers73 identified the DOXP (1.42) 
pathway in P. falciparum and found that both fosmidomycin and FR900098 inhibit the 
pathway. Interestingly, FR-900098 showed better antiplasmodial activity than fosmidomycin 
both in vivo and in vitro.  
 
1.6.6 Binding of substrate and inhibitors to DXR enzyme 
The first piece of evidence that the inhibitor (fosmidomycin, 1.46), binds in a similar mode as 
the substrate (DOXP) to DXR was the molecular docking of the crystal structure complex of 
EcDXR with fosmidomycin and Mn2+ (pdb code: 1ONP).91 This was only later confirmed 
when the ternary complex structure of EcDXR with the substrate was solved by Sweeney et 
al.89 The binding of substrate or inhibitor to the enzyme in the presence of NADPH induces a 
considerable conformational change. This flexibility of DXR is important for substrate 
binding and catalysis and also results in the formation of a catalytic pocket over which the 
flexible ‘lid’ closes. The catalytic pocket or the substrate binding cavity so formed is divided 
into three regions: i) the positively charged pocket into which the phosphonate end of the 
inhibitor binds, ii) the hydrophobic region which accommodates the propyl backbone and iii) 
the amphipatic region where the hydroxamate binds.89 The phosphate moiety of DOXP forms 
a network of hydrogen bonds with Ser186, Asn227, Lys228 and His209. The C-2 carbonyl 
also forms hydrogen bonds with Glu152 and Ser151, C-3 hydroxyl with Lys125 and Glu231 
and C-4 hydroxyl group with Glu152, Asn227 and Lys228. Similarly, the phosphonate 
moiety of fosmidomycin forms hydrogen bonds with Ser186, Ser222, Asn227 and Lys228 
while the N-formyl-N-hydroxyl group of the hydroxamate component forms an octahedral 
coordination with a divalent metal ion as well as the carbonic acids Asp150, Glu152 and 
Glu231 and one water molecule.91, 94 
 
The binding site of fosmidomycin in PfDXR as resolved by Umeda et al.88 also consists of 
three regions which include a binding pocket for the phosphonate, a hydrophobic patch for 
the propyl backbone and a binding pocket for the hydroxamate group. The phosphonate 
binding pocket houses residues Ser270, Asn311, His293 and two water molecules to which 
the phosphonate forms tight hydrogen bonds. The coordination of the hydroxamate group of 
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fosmidomycin with Mg2+ to residues Asp231, Glu233 and Glu315 is such that it forms a 
distorted trigonal bipyramidal geometry where the two oxygen atoms of the inhibitor adopt a 
cis-arrangement.88 FR900098 (1.45) interact with the DXR enzyme in a similar mode to 
fosmidomycin (1.46). Its methyl group has a Van der Waals interaction with the indole group 
of Trp296 and is suggested to be the reason for its higher antiplasmodial activity as compared 
to fosmidomycin. It is also possible that the interaction is needed for the cis arrangement of 
the two hydroxamate oxygen atoms such that there are six atoms in the same plane (Figure 
1.11), allowing for the binding of the metal ion at the active site. The complex of FR900098 
when compared with fosmidomycin showed an induced fit movement of the active site 
residues of the PfDXR to accommodate the methyl group of the compound. 
 
Figure 1.11. Metal coordination of FR900098 (1.45) with PfDXR88 
 
1.6.7 The pharmacokinetics and toxicological properties of fosmidomycin 
The oral absorption of fosmidomycin (1.46) is about 30%. At 0.25 h after dosing a healthy 
volunteer’s serum concentration was 157 µg/ml for an intravenous (i.v.) dose of 
fosmidomycin at 30 mg/kg, 12.3 µg/ml for an intramuscular (i.m.) dose of 7.5 mg/kg and 
2.45 µg/ml for a 500 mg oral dose.104 In rats, fosmidomycin (1.46) is rapidly distributed into 
tissues with high concentrations in kidney, liver and bones. The serum level after i.v. 
injection fitted a 3-compartment open model with first order kinetics.105 Fosmidomycin is not 
metabolized, it is excreted unchanged in urine. Urine recovery of the drug over 24 hours after 
dosing was 85% of the i.v. dose, 66% of the i.m. dose and 26% of the oral dose. 
Fosmidomycin has a half-life of 1.8 hours after i.v. dose and shows no accumulation in the 
serum or urine after repeated oral or parenteral dosing.20, 104 
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Fosmidomycin is well tolerated even when given in repeated doses of 8 g/day i.v for seven 
days, 4 g/day i.m for five days and 4 g/day orally for 7 days. No abnormalities or changes 
were observed in physical, haematological, biochemical or urine examination.106 In some 
cases at the highest dose level, nausea, vomiting and loose stools were observed.20 
 
1.7 FOSMIDOMYCIN AND FR900098 AS LEAD COMPOUNDS IN DRUG 
DESIGN 
1.7.1 Structure activity relationship of fosmidomycin and FR900098 
 
 
 
Fosmidomycin (1.46) and FR900098 (1.45) interact at the active site of the DXR enzyme 
with the phosphonate group, the 3-carbon backbone and the hydroxamate group of the 
compounds (Figure 1.12). The phosphonate moiety forms tight hydrogen bonds with the 
active site of the enzyme at the phosphonate binding pocket. The hydroxamate group of the 
lead compounds is essential for the binding of the inhibitors to the divalent metal ion found at 
the active site of the enzyme. 
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Figure 1.12. Hydrogen bond interaction of Fosmidomycin (1.46, pink) with DXR active 
site89 
 
The latest study of PfDXR in complex with inhibitors88 revealed that a cis arrangement of the 
two oxygen atoms of the hydroxamate moiety is necessary for the metal chelation. It has been 
suggested that any functional group with cis arrangement of two oxygen atom might also 
exhibit comparable metal coordination. The 3-carbon spacer in these lead compounds appears 
to be optimum for the hydrophobic binding of the backbone to the hydrophobic pocket of the 
enzyme at the active site. Compounds with shorter spacers would be unable to occupy both 
the phosphonate and the hydroxamate binding site and longer spacers would not be able to 
efficiently bind to the site. 
 
The problems associated with fosmidomycin pharmacokinetics i.e. low oral absorption, short 
plasma half-life, high rate of recrudescence and the need for a long duration of treatment 
when used as mono-therapy have prompted research into developing compounds with better 
pharmacokinetic profiles. Several analogues of fosmidomycin (1.46) have been synthesized, 
focusing on different parts of the compound.104, 107-109 
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1.7.2 Phosphonate esters of fosmidomycin and FR900098 
Given that the oral bioavailability of fosmidomycin is only 30% due to its high polarity and 
the ease of ionization of the phosphonate group at physiological pH,105 masking this property 
of the phosphonate group was expected to improve bioavailability. Ester prodrugs of 
fosmidomycin and FR900098 were synthesized to mask the polar properties and improve the 
oral bioavailability of the drugs. The esters are expected to be more lipophilic and therefore 
cross the membranes through diffusion after which esterases will cleave off the ester group 
and release the active drug.110 Substituted and un-substituted diaryl esters of FR900098 such 
as 1.47 and 1.48 (Figure 1.13) were synthesized and although these compounds showed 
improved oral activity in infected mice,109 there were concerns about the toxicity of the 
envisaged phenol derivative that will be generated upon cleavage of the esters.  
 
Figure 1.13. Diaryl and acyloxylalkyl esters of FR900098 
 
Masking the phosphonate group to form acyloxyalkyl esters resulted in prodrugs with 
significantly higher antiplasmodial activity than FR900098 (1.45). Ortmann and co-
workers108 synthesized series a of acyloxyalkyl esters (Figure 1.13) of which the 
pivaloyloxymethyl ester 1.49 emerges with better activity than the parent drug in reducing 
paracetaemia in untreated control mice. Acetyloxyethyl 1.50 and propionyloxyethyl 1.51 as 
well as compounds 1.52 and 1.53 also showed higher activity than FR900098. Double ester 
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prodrug 1.50 showed the best antiplasmodial activity in vivo which was 2-fold that of 
FR900098 against P. vinckei and 5-fold more active against P. falciparum in vitro. These 
compounds showed no effect on recombinant E. coli DXR, confirming that the 
antiplasmodial activity of the compounds is due to the release of free FR900098 in the 
parasite. The masking of the phosphonate moiety thus increases the oral bioavailability of 
FR900098 and also increases the intrinsic activity of the drug probably due to the increased 
concentration of the drug at the active site.110 The half-life of the compounds will probably 
remain the same as that of FR900098 since the active drug is still the same. 
 
1.7.3 Isosteric replacement of the phosphonate group 
The replacement of the phosphonate group of fosmidomycin (1.46) or FR900098 (1.45) with 
carboxylate (1.54) or sulphonamide (Figure 1.14, 1.55) groups resulted in drastically reduced 
activity against Synechocystis sp. PCC6803 DXR. This was ascribed to the presence of two 
ionizable groups on the phosphonate, one ionizable groups on the carboxylate and 
sulphamate which is neutral depending on the pH.111 Another explanation could be the 
structural difference where the phosphonate has a pyramidal structure and the carboxylate a 
planar structure.88 The non-N-methylated retro-hydroxamate analogues 1.56 and 1.57 with 
carboxylate and sulphonate groups instead of phosphonate group showed 4000 – 6000-fold 
reduced activity against E. coli DXR than 1.58 with the phosphonate group. The N-
methylated derivatives were generally more active than the non-N-methylated analogues, but 
ultimately the phosphonated analogues were more active than the carboxylate or sulphonate 
analogues such as 1.59 and 1.60 which were 500 – 1000 folds less active than the 
phosphonated analogue 1.61 (Table 1.2). Unfortunately the activity of these compounds 
against P. falciparum DXR was not tested for better comparison of their antiplasmodial 
potential. 
 
Figure 1.14. Analogues with modified phosphonate groups 
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Table 1.2. Analogues with reverse hydroxamate and modified phosphonate groups 
 
Compound X R N E. coli DXR: IC50 (µM) 
1.56 COOH H 2 720 
1.57 SO3H H 2 1000 
1.58 PO(OH)2 H 2 0.17 
1.59 COOH Me 2 25 
1.60 SO3H Me 2 48 
1.61 PO(OH)2 Me 2 0.049 
FR900098 (1.45)    0.032 
 
 
1.7.4 Modifications of the hydroxamate group 
The N-formyl/N-acetyl and N-hydroxyl groups of fosmidomycin and FR900098 are important 
for the inhibitory effect of these compounds. These groups ensure the anchorage of the 
inhibitors through metal chelation to the divalent ion at the site of action. Replacement of the 
N-hydroxyl with a N-methyl group resulted in very weak inhibitors of Synechocystis sp. 
PCC6803 DXR.111 Reverse hydroxamate analogues 1.62 and 1.63 (Figure 1.15) have been 
synthesized111, 112 and both show some activity against E. coli DXR,112 since they are still 
able to chelate metals.  The features of the analogues are the same as those of the parent 
drugs but arranged differently. This rearrangement however results in lower antimicrobial 
activity than fosmidomycin. Interestingly, 1.63 remains active against fosmidomycin resistant 
E. coli strains. Courtois et al.113 synthesized and investigated the inhibition of fosmidomycin 
analogues containing benzoxazolone or oxazolopyridinone moieties against ajmalicine 
production in Catharanthus roseus plant cell culture. Inhibition of ajmalicine production was 
used as a marker for monoterpenoid indole alkaloids inhibition. Surprisingly, the series gave 
rise to four diethyl esters that inhibited ajmalicine accumulation. Two of these esters 1.64 and 
1.65 lost their inhibitory effect when converted to their corresponding phosphonic acid 1.66 
and 1.67 respectively (Figure 1.13). More diethyl esters of fosmidomycin-oxazolopyridinones 
derivatives were later synthesized by Mincheva et al.114 and compounds 1.68 and 1.69 
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respectively inhibited alkaloid production by 91% and 87% as compared with 69% inhibition 
exhibited by fosmidomycin in Catharantus roseus cells. 
 
 
Figure 1.15. Fosmidomycin analogues with hydroxamate modifications 
 
Replacement of the formyl residue of fosmidomycin with spacious acyl residues resulted in 
analogues which were active against recombinant E. coli DXR in the micromolar range. The 
most active analogue of the synthesized series, 1.70 (Figure 1.15) was significantly less 
active (IC50 5.4 µM) than fosmidomycin (IC50 0.035 µM).115  
 
1.7.5 Modifications of the propyl chain backbone 
Decreasing the length of the propyl carbon chain separating the phosphonate and the 
hydroxamate groups of fosmidomycin or FR90098 has been shown to diminish the 
antimicrobial effect of these compounds.116Although antimicrobial or antiplasmodial effects 
of a lengthened carbon spacer analogue of the compounds have not been reported, retro-
hydroxamate analogues of FR900098 and fosmidomycin have been tested (compound 1.62 
and 1.63, section. 1.7.4). Reversing the arrangement of the hydroxamate group of 
fosmidomycin and FR900098 increases the carbon spacer between the phosphonate and the 
hydroxamate. While these compounds remain potent against E. coli, their activity is reduced.  
Shortening the length of the compounds or decreasing the number of methylene as in 
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compounds 1.71 and 1.72 (Table 1.3) severely decreases the affinity of the compounds for E. 
coli DXR (IC50 1000 and 77 µM, respectively) as compared to 1.62 and 1.63 (IC50 1 and 0.5 
µM, respectively). This is possibly because the compounds were too short to occupy the 
space between the phosphonate and hydroxamate binding sites on the enzyme. Conversely, 
lengthening the compounds as in 1.73 and 1.74 with an additional methylene group gave 
better activity (0.27 and 0.11 µM, respectively) albeit less than the activity of 1.62 and 
1.63.117 
 
Table 1.3. Analogues with varying chain length between the hydroxamate and the 
phosphonate groups117 
 
 
Compound R N E. coli DXR 
IC50 (µM) 
1.71 H 1 1000 
1.72 Me 1 19 
1.73 H 3 0.27 
1.74 Me 3 0.11 
FR900098 (1.45) 
 
 0.032 
 
Introducing electronegative atoms to the carbon backbone of fosmidomycin and FR900098 
has given rise to some potent antiplasmodial compounds. The β-oxaisosteres of 
fosmidomycin and FR90009, compounds 1.75 and 1.76 (Figure 1.16) showed high growth 
inhibition against the P. falciparum 3D7 strain with 1.76 being more active than both 
fosmidomycin and FR90098. The retro-hydroxamate β-oxaisostere 1.77 was even more 
potent against the parasite than 1.76. Although the antiplasmodial activity of γ-oxa retro 
hydroxamate compounds 1.78 and 1.79 were not reported, the activity against E. coli DXR 
were much less than the parent drugs and their β-oxa analogues.104 
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Figure 1.16. β-Iso-oxasteres of fosmidomycin and FR900098 
 
Fosmidomycin analogues with α-aryl substitution have generally shown improved 
antiplasmodial activity compared to fosmidomycin (compounds 1.80– 1.86, Table 1.4).107 Of 
the series reported, the most active of the compounds are those with halogens substituents on 
the α-aryl group. The most potent, halogen substituted analogue of the series, 1.80, showed a 
higher activity against P. falciparum Dd2 and 3D7 strains with IC50 values of 0.028 and 0.090 
µM compared to FR900098 with 0.18 and 0.32 µM, respectively.  
 
Table 1.4. Substituted α-aryl analogues of fosmidomycin (1.46) and FR900098 (1.45)107  
 
 
Compound R R1 R2 Dd2: IC50 (µM) 3D7: IC50 (µM) 
1.80 H Cl Cl 0.028 0.090 
1.81 Me Cl Cl 0.090 0.25 
1.82 Me H H 0.35 0.55 
1.83 Me Me H 0.22 0.95 
1.84 H OMe H 0.20 0.36 
1.85 Me OMe H 0.27 0.85 
1.86 Me Cl H 0.095 0.35 
FR900098 (1.45) CH3 - - 0.18 0.32 
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1.8 AIM, RATIONALE AND OBJECTIVES 
With the high number of annual mortalities due to malaria and the failing battle against 
resistance, it is imperative that research towards the development of new antimalarial 
compounds continue. Fosmidomycin and its derivatives have advantages such as target 
selectivity and activity against both CQS and CQR strains of P. falciparum. This offers a 
basis on which further development can be carried out to improve on the activity and the 
disadvantages of the compounds as antiplasmodial or antimalarial agents. Thus, the aim of 
this project was to design and synthesize new fosmidomycin analogues with potential 
antiplasmodial activity.  More specifically, we wished to address two specific research 
questions.  Firstly, we wished to explore the effect of halogenation in the acyl chain on the 
biological activity of FR900098 analogues.  Secondly, we wanted to explore the feasibility of 
extending the acyl chain of FR90098 into the NADPH binding site and still producing DXR 
inhibition. The latter provide the added advantage of opening up possibilities of 
fosmidomycin-hybrid design (Scheme 1.6). 
 
Therefore the specific objectives of this project were: 
1. To synthesise a series of halogenated fosmidomycin analogues of varying chain 
length.   
2. To synthesise analogues of FR900098 by extending the acyl side chain into the 
NADPH binding pocket (using chloroquine-fosmidomycin as a model compound) 
3. To assess the antiplasmodial and DXR inhibitory activity of synthesized compounds 
4. To explore the binding interactions of the synthesized compounds using molecular 
docking studies  
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Scheme 1.6. Summary scheme of the aims of the research. 
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2. DESIGN AND SYNTHESIS OF HALOGENATED FOSMIDOMYCIN 
ANALOGUES 
 
2.1 INTRODUCTION 
Several analogues of fosmidomycin (1.46) and FR900098 (1.45) have been synthesized in an 
effort to either improve the oral bioavailability or increase the potency of the drugs as 
antiplasmodial or antibacterial agents (Chapter 1).107, 118-120  Three main strategies have been 
utilized to improve the activity of these compounds. These include (i) esterification of the 
phosphonate group, (ii) extending the acyl side chain and (iii) introducing an aromatic ring 
alpha to the phosphonate group. In this chapter we explore the effect of halogenation as well 
as lengthening of the acyl side chain on the activity of fosmidomycin analogs. This was 
inspired by the promising antiplasmodial activity of fosmidomycin intermediates produced in 
the process of synthesizing the chloroquine- and pyrazinoic acid-fosmidomycin hybrids 
discussed in chapter 3. 
 
2.1.1 Rationale for the synthesis of halogenated fosmidomycin analogues 
The synthesis of halogenated analogues and their antiplasmodial activity carried out in this 
study was supported firstly by the findings that analogues of fosmidomycin and FR900098 
containing halogen substituents have in many cases shown better activity against DXR than 
the analogues without the halogens.107, 121 Silber and co-workers have also predicted, using 
adaptation of fields for molecular comparison  (AFMoC),  that compounds with halogens are 
more active against DXR than fosmidomycin or FR900098,122 thus making this aspect worth 
investigating. Another rationale behind the study was that fosmidomycin and FR900098 are 
highly hydrophilic and thus have low oral bioavailability or absorption into the parasite. 
Halogens are known to increase lipophilicity with the exception of fluorine which can either 
increase or decrease the lipophilicity of compounds.123 Increasing the length of the acyl side 
chain is also expected to increase lipophilicity of the compounds. We therefore reasoned that 
the halogenated FR900098 analogues proposed in this study would increase both the activity 
and the lipophilicity of the compounds and therefore make it easier for the compounds to pass 
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through the membranes of the parasites. The calculated LogP (cLogP) of the chlorinated 
FR900098 analogues 2.1 in comparison with FR900098 and fosmidomycin (Table 2.1) 
clearly shows the effect of the addition of a chlorine substituent on the lipophilicity of the 
compounds. The lipophilicity increased from -1.600 for FR900098 to -1.035 for the 
chlorinated analogue 2.1. Increasing the acyl chain length also showed significant increase in 
the LogP and hence lipophilicity of the compounds as is observed for compounds 2.2 and 2.3 
at -0.764 and -0.494, respectively. 
 
Table 2.1. cLogP of fosmidomycin, FR900098 and the proposed chlorinated analogues 
Compound  Structure cLogP* 
Fosmidomycin (1.46) 
 
-1.578 
FR900098 (1.45) 
 
-1.600 
2.1 
N
OH
P
O
OH
OH
O
Cl
 
-1.035 
2.2 
 
-0.764 
2.3 
 
-0.494 
*Calculated on molinspiration (http://www.molinspiration.com/cgi-bin/properties) 
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2.1.1 Synthetic approaches to fosmidomycin and related compounds 
The synthesis of fosmidomycin analogues can be divided into three main stages which 
include: (i) introduction of the phosphonate moiety into a three carbon backbone, (ii) 
introduction of the hydroxylamine moiety and (iii) N-acylation of the latter. 
 
Introduction of the phosphonate group 
Introduction of the phosphonate group, or C-P bond formation, is an essential key step in the 
synthesis of the fosmidomycin analogues as this group is essential for tight binding to the 
DXR active site. The most common synthetic methods used to introduce the phosphonate 
moiety in fosmidomycin analogues are the Michaelis-Arbuzov reaction (also known as the 
Arbuzov reaction) and the Michaelis-Becker reaction. The reaction was originally discovered 
by Michaelis124 and later explored by Arbuzov.125, 126 The Arbuzov reaction involves heating 
a trialkylphosphite with an alkyl halide at a temperature of between 120oC and 160oC to form 
a dialkyl phosphonate ester (Scheme 2.1). The reaction proceeds through nucleophilic attack 
on the alkyl halide by the lone pair electrons of the phosphorus atom to form a phosphonium 
intermediate. A second nucleophilic attack by the halide anion on the phosphonium 
intermediate gives the dialkylphosphonate ester and a new alkyl halide (Scheme 2.1 A). This 
method has been successfully employed in the synthesis of phosphonated N-
heteroarylcarboxamides118 and diaryl ester prodrugs of FR900098.109 
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Scheme 2.1. TheMichaelis-Arbuzov reaction127  
A scheme showing alkylation of the phosphonate through a nucleophilic reaction with an alkyl halide (A) and 
with an activated alkene (B)  
 
Fosmidomycin (1.46) and FR00098 (1.45) were first synthesized in 1980 using the 
Michaelis-Becker reaction to introduce the phosphonate moiety of the compounds.101 The 
reaction occurs through a nucleophilic attack of the mesomeric anions of the salt on the alkyl 
halide to give a dialkyl phosphonate ester.127 Another method that has been used to 
phosphorylate fosmidomycin analogues is the addition of an alkyl phosphonate to an 
activated double bond.107 This involves the addition of a nucleophilic phosphorus such as 
trialkyl phosphite to an alkene or alkyne that is substituted with an acceptor such as an α,β-
unsaturated aldehyde or ketone in order to obtain the dialkyl phosphonic ester (Scheme 2.1 
B). 
 
A method that makes use of cesium carbonate (Cs2CO3) was recently described by Cohen et 
al.128 The reaction involves the use of Cs2CO3 as a base and tetrabutylammonium iodide 
(TBAI) as a phase transfer catalyst in the formation of the C-P bond. The high efficiency of 
the reaction has been attributed to the Cs effect. The Cs ion has a very large ionic radius and 
low charge density. It also has a low degree of solvation and ion pairing as compared to other 
alkali salts.129 In an aprotic solvent such as DMF with high dielectric constant, Cs is “naked” 
and this property makes it highly reactive. The mild reaction described by Cohen progress at 
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room temperature, where Cs2CO3 together with the phase transfer catalyst are added to the 
dialkyl phosphite followed by the alkyl halide to give phosphonate esters in good yields.  
 
Scheme 2.2 shows a summary of the methods that have been employed in the introduction of 
the phosphonate moiety to fosmidomycin analogues as described above.  
 
 
Scheme 2.2. Schematic review of phosphonate introduction in the synthesis of fosmidomycin 
analogues. 
a20
, 101, 109, 118; b 128; c107  
 
The synthesis of halogenated fosmidomycin analogues as described in this chapter employed 
two of the methods discussed above, the Arbuzov reaction and the Cs2CO3 reaction. This was 
based on ease of the reactions and the availability of the starting materials.  
 
 
Introduction of the hydroxylamine group 
 
Introduction of the hydroxylamine group into the fosmidomycin analogues have mostly been 
through similar approaches but using different sources of hydroxylamine reagents. This 
includes masked amines such as BocNHOBn,120, 130 BocNHOBoc,109 TsNHOBn20, 111, 131 in a 
base catalyzed reaction with an alkyl halide (Scheme 2.3). The base deprotonates the amine, 
allowing it to initiate a nucleophilic attack on the alkyl halide. Other methods of 
incorporating hydroxylamine have involved the conversion of an aldehyde by treatment with 
O-protected hydroxylamine to yield an oxime which is then reduced with sodium 
cyanoborohydride.107, 132, 133 In another approach by Schlüter et al,134 dioxolane was used as 
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the starting material, which gave the O-protected hydroxylamine after acid hydrolysis 
followed by oxime formation and subsequent reduction by sodium cyanoborohydride in an 
acidic medium.  
 
Where R = Phosphonate or phosphate ester 
R’ = Boc; Ts; H 
 R”= Bn; Boc 
Scheme 2.3. Schematic review of hydroxylamine introduction to fosmidomycin analogues 
a20
, 111, 131; b134; c120, 130; d109; e107, 132, 133 
 
The retrohydroxamate functionality is introduced into fosmidomycin analogues by acylation 
with an appropriate acid chloride. Different halogenated acyl chlorides were used in the 
synthesis of the halogenated fosmidomycin analogues discussed in this chapter. The reaction 
generally involves the treatment of the O-protected amine with the required acyl chloride to 
obtain the desired retrohydroxamate compound.   
 
Both the N-oxime and the phosphonic acid moieties of fosmidomycin and its analogues are 
sensitive to harsh reaction conditions and is therefore protected during the course of the 
synthesis. As such these groups are mostly incorporated in their protected form. The final 
stage of a series of reactions involving these protected forms of N-oximes or phosphonates is 
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therefore the removal of these protective groups. Typically, the N-oxime is protected by a 
benzyl group and will usually be removed or hydrolyzed by hydrogenation using a suitable 
catalyst such as Pd/C or Pd(OH)2/C. In some instances a Boc group is used and is easily 
removed by treatment with TFA.  
  
The phosphonate is also sometimes protected with a benzyl or phenol group. However the 
most common protective group for the phosphonates of fosmidomycin analogues is the ethyl 
ester and sometimes the methyl ester. The esters are generally easily hydrolyzed to free 
phosphonic acid by transesterification with TMSBr (trimethylsilyl bromide) or TMSI 
(trimethylsilyl iodide) and subsequent hydrolysis with H2O. In some instances the TMSX are 
not effective and harsher conditions have to be employed. This could involve refluxing the 
esters under very acidic conditions which in turn could be incompatible with other sensitive 
groups in the compound. 
 
2.1.2 Synthetic objectives 
The initial motivation for this study came from the observed antiplasmodial activity of 
selected halogenated fosmidomycin analogues or the reactive α-bromoketone intermediates in 
the process of synthesizing chloroquine-fosmidomycin hybrids (Chapter 3). While many 
investigations around fosmidomycin have been directed at improving the activity of the drug, 
most have focussed on increasing the lipophilicity of the compound. These have mainly been 
achieved through substitution at the α-carbon and by synthesizing phosphonate esters, 
respectively. Few studies have attempted improving these properties from the hydroxamate 
end of the compound. In view of the fact that several derivatives with one or more chlorine 
atoms at the α-position have consistently proved to be more active than their non-halogenated 
analogues107, 121 , this study focused on modifications to FR900098 by incorporating halogens 
at the side chain.    
 
Having established that extending the hydroxamate side chain of fosmidomycin by 5 to 19 
carbons significantly decreases the activity of the compound,115 this project also focused on 
synthesizing compounds with a side chain of two to four carbons with a terminal chlorine 
  Chapter 2          Design and synthesis of halogenated fosmidomycin analogues 
____________________________________________________________________________________________________ 
 
 Page | 56 
 
atom. This is expected to increase the lipophilicity of the compounds and thus increase its 
absorption. 
 
Therefore, the aim of this part of the study was to synthesize halogenated analogues of 
FR900098 (1.45) and extended chlorinated acyl chain derivatives of FR900098 with potential 
activity against P. falciparum. As such the specific objective of this chapter was to describe 
the synthesis of halogenated derivatives of FR900098. This research will contribute to 
determining if the fosmidomycin side chain can be extended beyond the acetyl side chain 
(FR900098) without decreasing its activity and also if halogens at the side chains will have 
any effect on the activity of the compounds. 
 
2.2 RESULTS AND DISCUSSION 
2.2.1 Synthetic strategy 
Ultimately, the phosphonic acids of the halogenated derivatives were required in order to 
compare their antiplasmodial activity and DXR inhibition activity with the parent drug 
FR900098. To this end, a retrosynthetic route showing the development of the analogues 
from 1,3-dibromopropane (2.6) to the free phosphonic acids was generated as shown in 
Scheme 3.4. This was a combination of the approaches used by Kurz and co-workers120 as 
well as Reichenberg and co-workers109 to synthesize ester protected prodrugs of 
fosmidomycin (1.46) and FR900098 (1.45). The reaction begins by the introduction of the 
protected phosphonate group on to 1,3-dibromopropane (2.6) by an Arbuzov reaction. This is 
followed by incorporation of the protected amine to give the fosmidomycin backbone. Partial 
deprotection of the amine followed by acylation of the backbone with different chloroacyl 
chlorides should yield the desired extended chlorinated acyl side chain analogues. The final 
stage involves the deprotection of the hydroxamate and phosphonate groups to release the 
free phosphonic acids. 
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Scheme 2.4. Retrosynthetic route toward halogenated fosmidomycin analogues 
 
2.2.2 Synthesis of the fosmidomycin backbone (2.4) 
As established previously, it is important to conserve the fosmidomycin backbone structure, 
which includes the phosphonate moiety, the hydroxamate moiety and the propyl linker 
between the two functional groups. Since the modifications envisaged in this project were to 
occur at the side chain, synthesis of the fosmidomycin backbone (2.4) was carried out before 
modifications to the side chain. This has the advantage of being able to synthesize large 
quantities of 2.4 from which all the other analogues could be derived.  
 
Scheme 2.5 shows the synthesis of the fosmidomycin backbone (2.4) which began with the 
Arbuzov reaction of triethylphosphite (P(OEt)3) with 2.6 to afford the bromophosphonate 2.5 
in 54% yield. The hydroxamate component of the analogues was then introduced by reacting 
2.5 with tert-butyl benzyloxycarbamate(BnONHBoc) in the presence of NaH. Using a 
method adapted from Gebhardt and coworker,135 the reaction was initially carried out in dry 
DMF at room temperature. This however only gave a 25% yield of the desired protected 
FR900098 backbone 2.7. As this compound was to serve as the basis for the synthesis of 
most of the FR900098 analogues intended, optimizing the yield of this reaction was desired. 
Changing the reaction solvent to freshly distilled THF ensured a 100% yield (Scheme 2.5). 
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Scheme 2.5. Synthesis of protected hydroxyamino-propylphosphonate backbone (2.4) of 
FR900098 analogues 
 
Selective deprotection of the hydroxamate moiety by the removal of the Boc group was 
achieved by stirring 2.7 in equivalent volumes of TFA and CH2Cl2 at room temperature 
overnight to yield 2.4 in 93%. This compound  thus served as a precursor from which the 
analogues discussed in this thesis were synthesized. 
 
The 1H and 13C NMR spectra of fosmidomycin analogues in CDCl3 and D2O are 
characterized by broad signals and complex splitting patterns.  A combination of one- and 
two-dimensional NMR techniques is therefore required to confirm and assign the spectra of 
all synthesized compounds. For this reason, it might be useful to briefly discuss the 
spectroscopic characteristics of compound 2.4, which is the simplest analogue in this series.  
This would then facilitate discussion of some of the more complex analogues.  
 
The 1H NMR spectrum of 2.4 (Figure 2.1) in combination with its1H-1H COSY NMR 
spectrum (Figure 2.2) allowed the identification of three isolated spin systems.  The three 
carbon fosmidomycin backbone is represented by 1H NMR signals at δ 2.92 (2H, t, J = 6.0 
Hz, H-3) and two overlapping methylenes at δ1.72 (4H, m, H-1 and H2).  Signals at δ 4.0 
(4H, m, H-1’) and δ 1.27 (6H, t, J = 7.0 Hz, H-2’) can be assigned to the ethyl protecting 
group on the phosphonate ester while the benzyloxy-protecting group is represented by 
signals at δ 7.26 (5H, m, Ar) and 4.64 (2H, s, H-1”).  
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Figure 2.1 1H NMR spectrum of 2.4 (CDCl3, 400 MHz) 
 
Figure 2.2 1H – 1H COSY NMR spectrum of 2.4 (CDCl3, 400 MHz) 
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The assignment of the carbons was also done by analysing both one and two dimensional 
NMR spectra (HSQC and HMBC).  The carbons (Figure 2.3) of the fosmidomycin backbone 
appear at δ 52.0 (d, 3JC,P = 16.6 Hz, C-3), 23.1 (d, 1JC,P = 142.1 Hz, C-1) and 20.4 (d, 2JC,P = 
4.9 Hz, C-2) while the ethyl protecting group exhibit carbon signals at δ 61.5 (d, 2JC,P = 6.5 
Hz, C-1’) and 16.4 (d, 3JC,P = 6.0 Hz, C-2’).  The benzyloxy-protecting group shows signals 
at δ 76.3 (C-1”), 137.7 (C-2”), 128.4 (C-4” and C-6”), 128.3 (C-3” and C-7”) and 127.8 (C-
5”). The 13C NMR spectra described throughout this study were proton decoupled but the 
effect of phosphorus coupling could be observed. Coupling to phosphorus could be observed 
for one to three bonds between the phosphorus and the C- nuclei but any coupling greater 
than three bonds was not observed. The 13C NMR spectrum of 2.4 (Figure 2.3) showed 
doublets of the methylene and methyl carbons of the ethyl esters δ 61.5 (d, C-2’, 2JC-P = 6.5 
Hz) and 16.4 (d, C-1’, 3JC-P = 6.0 Hz) respectively. These chemical shifts and coupling 
constants are typical of diethyl alkyl phosphonate esters.118 Another observation typical of the 
diethyl alkyl phosphonate is the large coupling constant of one bond coupling of carbon to 
phosphorus (1JC-P), which was 142.1 Hz for the shift at δ 23.1 (C-1) of 2.4. 2JC-P and 3JC-P 
coupling are significantly smaller than 1JC-P coupling in these types of compounds. This was 
observed for compound 2.4 which had a 2JC-Pconstant of 4.9 Hz for the chemical shift at δ 
20.5 (d; C-2) and a 3JC-P constant of 16.6 Hz  for the doublet at δ 52.0 (d; C-3) as compared to 
1JC-P of 142.1 Hz for C-1 at δ 23.1. 2JC-P is influenced by the hybridized state of the C-2 and 
would increase from a sp3 carbon to a sp2 carbon. 3JC-P of phosphorus to C-3 coupling follows 
the Karplus relationship which is dependent on the dihedral angle between the affected 
nuclei.136, 137 Since the backbone 2.4 is mostly conserved in fosmidomycin analogues and the 
halogenated FR900098 analogues synthesized in the present study, NMR properties of 2.4 
was expected and found to carry through in 13C NMR spectra of the compounds. 

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Figure 2.3. 13C NMR spectrum of 2.4 (CDCl3, 100 MHz) 
 
2.2.3 Synthesis of fosmidomycin analogues with chlorinated acyl side chains 
Following the successful synthesis of the partially deprotected hydroxyamino 
propylphosphonate (2.4) we now turned our attention to the preparation of various 
chlorinated fosmidomycin/FR900098 analogues with two, three and four carbon side chains, 
2.8, 2.9 and 2.11 respectively (Table 2.2). The compounds were synthesized to investigate the 
effect of increased lipophilicity by short side chains and the presence of the chlorine atom on 
antiplasmodial activity. The non-halogenated analogues 2.10 and 2.12 were also synthesized 
in order to compare and determine if the presence of the chlorine atom, the extended side 
chain or a combination of both have any effect on the antiplasmodial activity of the 
compounds. 
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Table 2.2. Synthesis of chlorinated acetyl, propionyl and butyryl analogues of fosmidomycin 
 
Acyl chloride R Time (hr) Product Yield (%) 
Chloroacetyl chloride 
3-chloropropionyl chloride 
 
4-Chlorobutyryl chloride 
Acetyl Chloride 
-CH2Cl 
-CH2CH2Cl 
-CH=CH2 
CH2CH2CH2Cl 
-CH3 
2.5 
2.5 
 
3.5 
2.5 
2.8 
2.9 
2.10 
2.11 
2.12 
60 
33 
11  
53 
89 
 
Synthesis of the chlorinated analogues of fosmidomycin commenced with acylation of 2.4 
with an appropriate acyl chloride using triethylamine as base to give the acetyl, chloroacetyl, 
chloropropionyl and chlorobutyryl derivatives (Table 2.2; 2.8 – 2.12).  Not, surprisingly, the 
reaction of with chloropropionyl chloride also gave the derivative 2.10.  This occurred via 
base-catalyzed elimination of HCl due to the increased acidity of the α-protons (Scheme 2.6). 
This was an advantage as the derivative was also required for comparison of the effect of the 
chlorine atom on the activity of the compounds on the DXR enzyme and plasmodium growth. 
Loss of the terminal chlorine was not observed with the chloroacetyl and chlorobutyryl 
derivatives.  
 
 
Scheme 2.6. Proposed mechanism of chloride elimination to form 2.10 
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2.2.4 Structural assignment of chlorinated acyl fosmidomycin analogues 
As expected the NMR spectra of the precursor 2.4 and analogues 2.8 – 2.12 were very similar 
to each other. The major difference being the number of signals observed for the hydroxamic 
acid side chains. The structures of the analogues were confirmed by extensive one and two 
dimensional NMR experiments.  Here we will focus our attention on compound 2.11 and will 
then highlight key spectroscopic features of the other synthesized compounds.   
 
HRESI-MS provided a molecular ion peak at m/z 406.1544 which is consistent with a 
molecular formula of C18H29ClNO5P [M + H]+ for compound 2.11.  The 1H NMR spectrum 
of 2.11 (Figure 2.4) showed a number of complex, overlapping signals. Two key spin systems 
were identified from the 1H NMR and 1H-1H COSY (Figure 2.5) spectra of 2.11, and were 
confirmed by analysis of 13C (Figure 2.6), HSQC and HMBC NMR data.  These consisted of 
the fosmidomycin propyl backbone at δ 1.69 (2H, m, H-1), 1.92 (2H, m, H-2) and 3.68 (2H; 
t; 6.5 Hz; H-3) and the chloroacyl side chain at 2.55 (2H; t; 6.8 Hz; H-5), 2.02 (2H; m; H-6) 
and 3.55 (2H; t; 5.9 Hz; H-7).  In addition, 1H NMR signals corresponding to the 
phosphonate ester protecting group were observed at δ1.27 (6H; t; 6.9 Hz; H-2’) and 4.04 
(4H; m; H-1’) while signals at δ7.35 (5H; s; H-2” – H-7”) were assigned to the benzyl 
protecting group of the hydroxylamine.   
 
The 13C NMR spectrum showed the characteristic phosphorus-carbon splitting as observed 
for the fosmidomycin backbone 2.4. The ethyl ester doublets were observed at δ 61.5 (d, 6.0 
Hz, C-1’) and 16.3 (d, 6.0Hz, C-2’). The propyl carbons were observed at δ 45.8 (s, C-3), 
23.0 (d, 142.0 Hz, C-1) and 20.2 (d, 5.0 Hz, C-2) while the aromatic carbons of the benzyl 
protecting group resonated between 134.1 – 128.7 ppm. The deshielded signal at 173.6 was 
assigned to the carbonyl carbon C-4 and the chemical shifts at 45.5 (s, C-7), 29.2 (s, C-5) and 
27.1 (s, C-6) accounted for the remaining carbons of the butyryl side chain of compound 
2.11. 
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Figure 2.4. 1H NMR spectrum of 2.11 (CDCl3, 400 MHz) 
 
Figure 2.5. 1H – 1H COSY NMR spectrum of 2.11 (CDCl3, 400 MHz) 
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Figure 2.6. 13C NMR spectrum of 2.11 (CDCl3, 100 MHz) 
 
All other spectroscopic data confirmed the structure of 2.11 as diethyl 3-(N-(benzyloxy)-4-
chlorobutanamido)propylphosphonate. 
 
The molecular formula C16H25ClNO5P [M + H]+was deduced from the ESI-MS analysis of 
chloroacetyl analogue 2.8 which gave the molecular ion at m/z 378.1226. It  showed very 
similar 1D NMR spectra to that of the chlorobutyryl analogue 2.11. Where compound 2.11 
showed three methylene signals, compound 2.8 showed only one chloromethylene proton 
shift at δ 4.10 (s, H-5) which showed an HSQC correlation to the carbon signal at 40.99 (s, C-
5). The proton also showed an HMBC correlation to the carbonyl carbon at δ 168.0 (s, C-4). 
This data together with all other spectroscopic data obtained for 2.8 established it as diethyl 
3-(N-(benzyloxy)-2-chloroacetamido)propylphosphonate. 
 
The chloropropyl analogue 2.9 also displayed similar NMR spectra to 2.11. The two 
methylene protons of the acyl side chain were observed at δ 2.83 (t, 6.6 Hz, H-5) and 3.74 (s, 
H-6) which overlaps with H-3 triplet also at 3.74 ppm. The corresponding carbons were 
observed at δ 35.4 (s, C-5) and 39.3 (s, C-6), respectively. The ESI-MS of compound 2.9 
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gave molecular ion peak at m/z 392.1394 which correlates with the molecular formula 
C17H27ClNO5P [M + H]+. All other spectroscopic data further confirm 2.9 as diethyl 3-(N-
(benzyloxy)-3-chloropropanamido)propylphosphonate. 
 
Compound 2.12 is the protected analogue of FR900098. It also exhibits similar spectroscopic 
backbone data to 2.8, 2.9 and 2.11. However, where all the other analogues had methylene 
groups at the acyl side chain, 2.12 has only one isolated methyl group which is observed at δ 
2.04 (s, H-5) in the 1H NMR spectrum and δ 20.3 (s, C-5) in the 13C NMR spectrum. The 
NMR data corresponds with the literature data reported for the compound diethyl 3-(N-
(benzyloxy)acetamido)propylphosphonate.108 
  As was observed with the chlorinated analogues, the 1H NMR spectrum of the acrylate-
fosmidomycin derivative 2.10 (Figure 2.7) showed the presence of fosmidomycin backbone 
methylene protons at δ 1.75 (H-1), 1.95 (H-2) and 3.76 (H-3). The methyl triplet and 
methylene multiplets of the ethyl ester were also observed at δ 1.28 and 4.06 respectively. 
The interesting part of the 1H NMR spectrum showing differences to the chlorinated 
analogues were the two doublets observed at δ 5.71 (1H; J = 10.4 Hz; H-6A) and 6.39 (1H; J 
= 17.1 Hz; H-6B) and a double doublet observed at δ 6.71 (1H; J = 10.4, 17.1 Hz). The fact 
that both doublets showed HSQC correlations to the same carbon at δ 129.3 (C-6) and are 
both coupled to the methine double doublet showed that each proton of the methylene groups 
are enantiotropic. This is characteristic of a monosubstituted alkene. The ESI-MS of 
compound 2.10 showed its molecular ion at m/z 356.1621 which is consistent with the 
molecular formula C17H26NO5P [M + H]+ and along with UV and IR confirmed compound 
2.10 as diethyl 3-(N-(benzyloxy)acrylamido)propylphosphonate. 
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Figure 2.7. 1H NMR spectrum of 2.10 
 
2.2.5 Antiplasmodial activity of the extended chlorinated acyl side chain analogues 
The main aim of this part of the study was to obtain potential antiplasmodial compounds 
from the lead compounds fosmidomycin (1.46) and FR900098 (1.45). As a result the 
synthetic progress of the research was guided by antiplasmodial assays. Given that a series of 
extended chlorinated acyl side chain analogues of FR900098 had been synthesized, 
compounds 2.8 – 2.12 were tested for antiplasmodial activity to guide the project forward. 
 
This initial in vitro antiplasmodial test of the analogues was conducted on a chloroquine 
sensitive D10 strain of P. falciparum. The test was carried out on continuous in vitro cultures 
of asexual erythrocyte stages of the parasite which were maintained using a modified method 
of Trager and Jensen.138 Table 2.3 shows the results obtained from the antiplasmodial assay. 
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Table 2.3. Antiplasmodial activity of compounds 2.8 – 2.12 
 
Compound R R1 R2 D10:IC50 (µM) 
FR900098 (1.45) -CH3 H H 43.4 
2.8 -CH2Cl Et Bn 7.5 
2.9 -CH2CH2Cl Et Bn > 100 
2.10 -CH=CH2 Et Bn 47.5* 
2.11 -CH2CH2CH2Cl Et Bn > 100 
2.12 -CH3 Et Bn > 100 
chloroquine    0.07 
*Estimated from percentage parasite survival 
 
The antiplasmodial assay revealed the chloroacetyl analogue 2.8 to be the most active of the 
synthesized series (IC50 = 7.5 µM), even more active than FR900098 (IC50 =43.4 µM) used as 
the positive control. To a lesser extent 2.10 also showed some activity (IC50 = 47.5 µM) while 
2.9 and 2.11 – 2.12 were considered inactive (IC50 > 100 µM). From these results it was clear 
that the presence of a chlorine atom was responsible for the activity of 2.8 since the acetyl 
analogue, 2.12, was not active. This gave rise to questions regarding the binding site of these 
protected analogues of FR900098. The possibility exists that the medium in which the 
plasmodium parasite was cultured, which included human blood, might contain esterases 
which could hydrolyse the compounds prior to uptake by the parasite. This is not expected to 
show superior activity over FR900098 (1.45) since it would still be difficult for the resulting 
phosphonic acid to be absorbed through the membranes of the parasite. Should the protected 
compounds however be absorbed into the parasite, it was expected that non-specific esterases 
would hydrolyse the compounds to release the free phosphonic acid to bind to the target 
enzyme DXR. This means that 2.12 should be hydrolyzed to FR900098 (1.45) and should 
thus be active against the parasite. As this was not the case the next question arose as to 
whether the compounds got to the site of action without being deprotected and the chlorine 
atom is solely responsible for the activity observed for 2.8. Alternatively, 2.8 might have a 
different target other than DXR. In order to answer these questions, synthesis and testing of 
unprotected halogenated FR900098 was thus required. 
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The loss of activity observed with 2.9 as compared to 2.8 and the inactivity of 2.11 shows 
that increasing the length of the acyl side chain decreases the antiplasmodial activity of the 
compounds. Due to the lack of the terminal chlorine atom in 2.10, its antiplasmodial activity 
was expected to be even less than that of 2.9 but was not the case. This is attributed to the 
terminal double bond of the compound which could be attacked by a nucleophile or which 
could alkylate DXR or another target in the plasmodium parasite. 
 
2.2.6 Synthesis of bromo- and iodo analogues of FR900098 
The promising antiplasmodial activity demonstrated by 2.8 established that the presence of 
chlorine group on the acyl side chain was important in improving antiplasmodial activity. 
This guided the synthesis of the FR900098 analogues into the next stage which was to 
investigate the effect of other halogens other than chlorine on antiplasmodial activity. To this 
end, compounds 2.15 – 2.17 were synthesized (Figure 2.8). 
 
 
Figure 2.8. Target bromo- and iodo-analogues of FR900098 
 
The brominated analogue 2.17 was synthesized using the same procedure used to synthesize 
the chlorinated analogues and acylating hydroxaminopropyl phosphonate (2.4) with 
bromoacetyl chloride (Scheme 2.7 A). Column chromatography of the crude product gave 
2.17 in 87% yield. Due to unavailability of iodoacetyl chloride the same procedure could not 
be used to synthesize the iodide analogue. In a Finkelstein reaction, 2.8 was stirred with NaI 
at room temperature overnight to obtain the iodinated 2.15 in 79% yield without requiring 
further purification (Scheme 2.7 B). Finkelstein reaction of 2.9 to 2.16 required more 
aggressive conditions. Stirring of 2.9 with NaI in acetone for 24 hours gave no product.  
However, heating the reaction mixture at reflux for four hours followed by stirring at room 
temperature for three days gave 2.16 in 54% yield after purification (Scheme 2.7 C). 
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Scheme 2.7. Synthesis of bromo- and iodo-FR900098 analogues 
 
The NMR spectra of 2.15 – 2.17 shared the same characteristics as described for the 
chlorinated fosmidomycin analogues 2.8 – 2.12. Compounds 2.15 and 2.17 gave NMR 
spectra which were similar to that of 2.8, the major difference observed being the upfield 
shift of the halomethylene group at the side chain for each compound. Where the 1H NMR 
spectrum of 2.8 showed the chlorinated methylene protons (H-5) at δ 4.10, the iodinated 
(2.16) and brominated (2.17) derivatives were less deshielded at δ 3.73 and 3.87, respectively 
(Table 2.4). The 13C NMR spectra particularly highlighted the difference in the chemical shift 
of the iodomethylene carbon of 2.15 at a characteristic δ -5.11 (C-5) as compared to 40.99 
and 41.02 for 2.8 and 2.17, respectively (Table 2.4).  
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Table 2.4. Comparison of 1H (400MHz) and 13C NMR (100 MHz) dataof compounds  2.8, 2.15 and 2.17 in CDCl3 
 
 2.8 (X = Cl) 2.15 (X = I) 2.17 (X = Br) 
Position δ 1H (#; mult; JHZ) δ 13C (#; mult; JC-P) δ 1H (#; mult; JHZ) δ 13C (#; mult; JC-P) δ 1H (#; mult; JHZ) δ 13C (#; mult; JC-P) 
2’
 
1.29 (6H; t; 7.1) 16.4 (2 x CH3; 5.9) 1.28 (6H; t; 7.0) 16.4 (2 x CH3; d; 6.0) 1.29 (6H; t; 7.0) 16.4 (2 x CH3; d; 6.0) 
1’
 
4.07 (4H; m) * 61.7 (2 x CH2; 6.5) 4.06 (4H; m) 61.6 (2 x CH2; d; 7.0) 4.07 (4H; m) 61.6 (2 x CH2; d; 7.0) 
1
 
1.72 (2H; m) 22.9 (CH2; d; 142.8) 1.75 (2H; m) 22.8 (CH2; d; 142) 1.73 (2H; m) 22.8 (CH2; d; 142) 
2
 
1.95 (2H; m) 20.1 (CH2; d; 4.7) 1.94 (2H; m) 19.7 (CH2; d; 4.0) 1.94 (2H; m) 20.0 (CH2; d; 5.0) 
3
 
3.75 (2H; t; 6.9) 46.1 (CH2; s) 3.72 (2H; t; 6.7) # 45.8 (CH2; s) 3.75 (2H; t; 6.0) 45.9 (CH2; s) 
4 - 168.0 (C=O; s) - 169.8 (C=O; s) - 168.1 (C=O; br s) 
5 4.10 (2H; s) * 40.99 (CH2; s) 3.73 (2H; s) # -5.1 (CH2; s) 3.87 (2H; s) 41.02 (CH2; s) 
1”
 
4.86 (2H; s) 76.7 (CH2; s) 4.92 (2H; s) 76.3 (CH2; s) 4.90 (2H; s) 76.6 (CH2;s) 
2”-7” (Ar-H) 7.38 (5H; s)  7.38 (5H; s)  7.38 (5H, s)  
2”  133.7 (C; s),   133.9 (C; s)   133.7 (C; s) 
4” and 6”  129.3 (2 x CH)*  129.2 (2 x CH; s)  129.3(2 x CH; s) 
5”  129.3 (CH; s)*  129.2 (CH; s)  129.3(CH; s) 
3” and 7”  128.9 (2 x CH; s)  128.8 (2 x CH; s)  128.8 (2 x CH; s) 
*/#
overlapping chemical shifts 
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2.2.7 Debenzylation of halogenated FR900098 analogues 
Based on the initial antiplasmodial results of compounds 2.8 – 2.12 (Table 2.3), it was 
necessary to synthesize the deprotected derivatives of the halogenated analogues. This would 
help to determine the effect of the protective groups on the absorption of the compounds and 
hence their antiplasmodial effect. The removal of benzyl and ester protective groups was 
carried out in stages such that the benzyl groups were hydrolysed first to release the free 
hydroxamic acid esters. These compounds were tested for antiplasmodial activity to 
determine the effect of the benzyl group since the esters have been shown to promote 
absorption of this group of compounds. 
 
Debenzylation of compounds is often successfully achieved by hydrogenolysis. This reaction 
was initially explored for the synthesis of the halogenated hydroxamic acids 2.18 – 2.24 
(Figure 2.9). 
 
Figure 2.9. Targeted debenzylated halogenated-FR900098 analogues 
 
Compound 2.18 was obtained by hydrogenation of 2.12 in methanol, using Pd/C as a catalyst 
(Scheme 2.8 A). The same procedure when carried out on 2.8 however resulted in 
debenzylation as well as dechlorination of the compound to 2.18 (Scheme 2.8 B). Changing 
Pd/C to Pearlman’s catalyst (Pd(OH)2/C) rendered the reaction more benign and was used to 
successfully debenzylate 2.8 – 2.11 to give 2.19 and 2.22 – 2.24 respectively without loss of 
the chloride atom. Attempts to debenzylate 2.15 and 2.17 with Pearlman’s catalyst resulted in 
the loss of iodine and bromine atoms respectively from the starting compounds. While there 
was the possibility of debenzylating the halogenated analogues under harsh conditions, for 
example acid hydrolysis, it was thought that the compounds would be more liable to 
degradation. For this reason Finkelstein reaction was adopted to substitute chlorine for the 
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desired halogen after debenzylation of 2.19. Stirring 2.19 with NaI in acetone for two days at 
room temperature gave 100% conversion to 2.21 (Scheme 2.8 C). Finkelstein reaction with 
LiBr proved more difficult as only 50% conversion was achieved after three days of stirring 
at room temperature. LiBr salt, 2.19 and the brominated product 2.20 are soluble in aqueous 
solvents, which made separation of the product difficult. The progress of the reaction was 
monitored with TLC and 1H NMR. When no further progress was observed after three days, 
the reaction was halted and worked up by concentrating it under reduced pressure, 
redissolving it in EtOAc and washing with brine. The crude product obtained was again 
treated with fresh LiBr and stirred for three days. The reaction with work up was repeated 
three times at the end of which most of the 2.19 had been converted to 2.20. 
 
Scheme 2.8. Debenzylation of halogenated FR900098 analogues 
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2.2.8 Antiplasmodial activity of protected halogenated acetyl analogues and 
debenzylated analogues of FR900098 
The antiplasmodial activity of the deprotected halogenated fosmidomycin analogues was 
carried out on the CQR Gambian FCR-3 Strain of P. falciparum.I The culture of plasmodium 
was maintained by the method described by Trager and Jenson138 and modified by Van Zyl 
and Viljoen.139 Antiplasmodial activity was assessed using the [3H]-hypoxanthine method 
against one cycle of plasmodial growth (48 hours). The tests were conducted in triplicate and 
the IC50 of the compounds were calculated based on the in vitro uptake of [3H]-hypoxanthine. 
Table 2.5 shows the antiplasmodial activity of the debenzylated analogues of FR900098 in 
comparison with bis(pivaloyloxymethyl) ester prodrugs of fosmidomycin (2.25) and 
FR900098 (2.26). 
 
  
                                                 
IDue to an outbreak of a significant contamination of cultures the antiplasmodial assays could not be done in the 
same lab where CQS P. falciparum strain was initially used. 
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Table 2.5. Antiplasmodial activity of protected and partially protected halogenated 
FR900098 analogues 
 
 
 
R R1 R2 FCR-3: 
IC50 (µM) 
SD 
(µM) 
D10:IC50 
(µM) 
FR900098 (1.45) -CH3 H H 41.67 7.24 > 43.4 
2.8 -CH2Cl Et Bn 9.06 0.38 7.5 
2.12 -CH3 Et Bn >100 29.84 >100 
2.15 -CH2I Et Bn 8.08 0.91 - 
2.16 -CH2CH2I Et Bn > 100 13.32 - 
2.17 -CH2Br Et Bn 11.11 2.43 - 
2.18 -CH3 Et H > 100 20.58  
2.19 -CH2Cl Et H 18.06 4.04 > 100 
2.20 -CH2Br Et H 9.44 2.00 - 
2.21 -CH2I Et H 5.54 0.72 - 
2.22 -CH2CH2Cl Et H > 100 7.78 - 
2.23 -CH2CH3 Et H > 100 27.76 - 
2.24 -CH2CH2CH2Cl Et H > 100 9.21 - 
2.25134 -H C(CH3)3-C(O)-O-CH2 H 2.1# - - 
2.26134 -CH3 C(CH3)3-C(O)-O-CH2 H 0.4# - - 
Chloroquine (1.10)    0.07   
# Tested on P. falciparum 3D7 strain 
 
For comparison between CQS D10 strain used earlier in the study and the CQR FCR-3 strain, 
compound 2.8 was again tested on FCR-3. The different strains of P. falciparum responded to 
the halogenated FR900098 analogue equally as there was no major difference in the activity 
of 2.8 on CQS D10 with IC50 = 7.5 µM and CQR FCR-3 with IC50 = 9.06 µM (Table 2.5). As 
fosmidomycin and its analogues have a different target to CQ this result was not surprising.  
 
From the initial antiplasmodial activity of the protected chlorinated FR900098 analogue 2.8 
compared with the unchlorinated 2.12 it was concluded that introduction of chlorine to the 
compound improved its activity. This trend was also observed with the debenzylated 
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FR900098 analogue 2.18 which showed no activity on FCR-3 (IC50 > 100 µM) while 
analogues 2.19 – 2.21 showed good activity with IC50 values of 18.06, 9.44 and 5.54 µM 
respectively. The benzyl-protected and unprotected acetyl halogenated FR900098 analogues 
2.8, 2.15, 2.17 and 2.19 – 2.21 were all more active against the parasite than FR900098 
(1.45), indicating that the increased lipophilicity helps improve the activity of the compounds 
possibly by improving their absorption into the plasmodium.  An alternative explanation may 
be that the haloacetyl analogues react non-selectively with various biological targets and may 
not affect DXR at all.  This can only be confirmed by assessing the cytotoxicity of these 
compounds and evaluating their activity against DXR.   
 
The halogenated analogues with propyl and butyryl side chain did not affect the survival of 
the plasmodium parasite, demonstrating that acetyl side chain is optimum for antiplasmodial 
activity and any increase in length will decrease or result in loss of activity.   
 
It remains unclear if the halogenated analogues are de-esterified in the plasmodium before 
reaching the site of action on DXR. The debenzylated acetyl derivative 2.18 was inactive as 
was the fully protected acetyl analogue 2.12, both of which were expected to have been 
hydrolyzed to FR900098 within the parasite. The effect of the protective group at the site of 
action would only be clarified by testing the compounds directly on DXR enzyme (chapter 
4). Umeda et al. 88 discovered that the phosphonate binding pocket of P. falciparum DXR has 
space for small functional groups on the phosphonate end. This could mean that the ethyl 
ester protection on the phosphonate is able to fit into the active site such that the analogues 
are still able to inhibit the enzyme. 
 
The presence of the benzyl group on the halogenated analogues has no significant effect on 
the antiplasmodial activity of the compounds. This was clearly demonstrated by the most 
active iodoacetyl derivative 2.21 with no benzyl group and an IC50 value of 5.54 µM as 
compared to its benzylated iodoacetyl analogue 2.15 with IC50 value of 8.08 µM. The 
analogues also compared well with the bis(pivaloyloxymethyl) ester prodrug of 
fosmidomycin (2.25, IC50 = 2.1 µM) though significantly less active than the  FR900098 ester 
prodrug (2.26) with an IC50 of 0.4 µM.134A combination of the halogenated analogue with a 
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bis(pivaloyloxymethyl) ester as opposed to diethyl ester might be worth exploring in order to 
improve the antiplasmodial activity of the compounds.  
 
2.2.9 Attempted deprotection of the phosphonate ester group 
Once the benzyl group had been removed from the halogenated FR900098 analogues, the 
next stage was to hydrolyze the phosphonate esters into free phosphonic acids. Hydrolysis of 
fosmidomycin phosphonate esters analogues in many literature procedures have often been 
achieved by transesterification with TMSBr or TMSI. This mild reaction was attempted on 
the synthesized halogenated compounds and this proved to be a challenge. 
 
 Following a modified microwave method described by Kumar and co-worker140 the 
debenzylated acetyl analogue 2.18 dissolved in dry CH3CN was treated with TMSBr for 10 
minutes in a microwave powered at 50 W and 40oC temperature. The resulting product 
showed degradation of the starting material. Attempting the reaction on the chloroacetyl 
derivative 2.19 also resulted in degradation while no reaction occurred with the protected 
propyl analogues 2.9 and 2.10 (Scheme 2.9 A). In order to validate the method, the same 
procedure was carried out on diethyl 3-bromopropylphosphonate and it successfully gave the 
required pure white crystals of 2.27 (Scheme 2.9 B). This showed that although the reaction 
could be adopted for hydrolysis of phosphonate esters, it is not compatible with the 
synthesized halogenated fosmidomycin analogues. 
 
After the unsuccessful attempt to hydrolyse the phosphonate ester using the microwave, the 
more conventional method of stirring the ester with TMSBr in a dry solvent was employed. 
The acetyl hydroxamic acid derivative 2.18 was treated with 5 molar equivalents of TMSBr 
at 0oC. The temperature was allowed to rise to room temperature and stirred for four days. 
After working up the reaction FR900098 was obtained as a pure compound (Scheme 2.9 C). 
Unfortunately, attempts to hydrolyse the esters of fully protected 2.9 and 2.10 and the 
partially deprotected 2.19 – 2.21 using the same method resulted in degradation of the 
starting esters and none of the desired phosphonic acids. Consequently, the more reactive 
TMSI was used in place of TMSBr, stirring the reaction for two hours at room temperature. 
The 1H NMR spectrum of the crude product did not show the usual ethyl shift. As promising 
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as the product was, all attempts to purify it using a C-18 Sep-Pak cartridge and reversed 
phase HPLC was unsuccessful.  
 
Scheme 2.9. Attempted ester hydrolysis of halogenated FR900098 analogues 
 
An attempt to synthesize the phosphonic acid analogues without protecting the phosphonate 
throughout the synthetic steps was also unsuccessful. Acid hydrolysis of 2.4 prior to the 
reaction with acyl chloride was attempted. 1H NMR spectroscopy again revealed degradation 
of the starting 2.4 (Scheme 2.10). All these failed attempts necessitated looking for 
alternative methods to obtain the free phosphonic acid analogues. 
 
 
Scheme 2.10. Attempted ester hydrolysis of 2.4 
  Chapter 2                   Design and synthesis of halogenated fosmidomycin analogues 
___________________________________________________________________________ 
 Page | 79 
 
2.2.10 Synthesis of benzyl-protected analogues of FR900098 
All attempts to hydrolyze the diethyl phosphonate ester analogues described in the previous 
section were unsuccessful hence a protective group that is easy to remove was required. Since 
it was possible to remove the benzyl group from the hydroxamate end it was reasoned that 
protecting the phosphonate with the same group might be easier to remove and this can be 
done at the same time as the removal of the protection from the O-protected hydroxylamine. 
This meant that the whole series of reactions previously described for the diethyl ester 
phosphonate would be carried out on the benzyl-protected phosphonate i.e. the de novo 
synthesis of the compounds was required. Attempts to substitute the ethyl group of 2.4 with a 
benzyl group by treatment of the ester with TMSBr followed by COCl2, pyridine and BuOH 
(Scheme 2.11) gave rise to a crude product with an inconclusive 1H NMR spectrum. It was 
difficult to determine if the desired substitution had taken place and if it had, it was clear 
from the NMR spectrum that it would require optimizing the reaction to obtain enough of the 
product to proceed with the remaining steps of the reaction. The effort to introduce dibenzyl 
phosphite onto 1,3-dibromopropane (2.6) in the presence of NaH as a base was also to no 
avail as no reaction occurred between the two compounds. 
 
 
Scheme 2.11. Attempted substitution of ethyl with benzyl protective group 
 
Following on from this, 1,3-dibromopropane (2.6) was reacted with dibenzylphosphite (2.30, 
(BnO)2P(O)H) using the method described by Cohen et al.128 Cs2CO3 and tetramethyl 
ammonium iodide (CH3)4NI) were added to a solution of (BnO)2P(O)H in anhydrous DMF. 
The suspension was stirred for an hour before introducing 1,3-dibromopropane (2.6) and 
thereafter stirred for 64 hours at room temperature (Scheme 2.12). Working up the reaction 
by extraction into EtOAc and purification by column chromatography afforded the benzyl-
protected bromopropylphosphonate 2.31 in 63% yield. The hydroxamic moiety was 
introduced by reaction with BocNHOBn. Unlike the reaction of BocNHOBn with 
bromophosphonate 2.5 which gave 100% yield of the protected fosmidomycin backbone 2.7, 
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BocNHOBn reacted with benzyl protected 2.31 to give the benzyl protected fosmidomycin 
backbone 2.32 in 56% yield (Scheme 2.12). Treatment of 2.32 with 1:1 (v/v) ratio of TFA 
and CH2Cl2 resulted in 15% yield of the partially deprotected backbone 2.33. The low yield 
was unexpected as the same reaction on 2.7 had afforded 2.4 in 93% yield. The conditions of 
the reaction were thus modified such that TFA was only 50 molar equivalent of the starting 
material (2.32) and CH2Cl2 was twice the volume of TFA. The reaction temperature was 
reduced to 0oC and stirred for 45 minutes141 to yield a satisfying 97% product of 2.33 
requiring no further purification. Treatment of 2.33 with appropriate acyl chlorides generated 
a series of benzyl-protected protected FR900098 analogues. Hydrogenolysis of these 
analogues using Pd(OH)2/C as catalyst gave the desired phosphonic acids in quantitative 
yields (Scheme 2.12). 
 
i. DMF; Cs2CO3; (CH3)4NI; rt 1 hr
ii. 2.6; 64 hrP
H
O
BnO OBn PBr
OBn
O
OBn
THF; BocNHOBn;
NaH; rt; o/n
PN
OBn
O
OBn
Boc
OBn
2.30 2.31 2.32
TFA; CH2Cl2;
0OC; 45 min
PHN
OBn
O
OBn
OBn i. Et3N; CH2Cl2; rt; 1.5 hr
ii. Acylchloride; 2.5 hr
PN
OBn
O
OBn
OBn
O
R
2.34 R = CH2Cl
2.35 R = CH2CH2Cl
2.36 R = CH2=CH2
2.37 R = CH2CH2CH2Cl
Pd(OH)2/C; H2;
MeOH; rt; 1.5 hr
PN
OH
O
OH
OH
O
R
2.1 R = CH2Cl
2.2 R = CH2CH2Cl
2.38 R = CH2CH3
2.3 R = CH2CH2CH2Cl
2.33
63% 56%
97%
 
Scheme 2.12. Synthesis of chlorinated phosphonic acid analogues of FR900098 
 
Finkelstein reaction of 2.34 with NaI gave 2.39 but hydrogenation of this compound led to 
loss of iodine (Scheme 2.13). Attempts to substitute the chlorine atom of 2.1 with iodine were 
unsuccessful as the phosphonic acid was insoluble in the reaction solvent, acetone. 
Compound 2.1 was soluble in H2O and MeOH both of which cannot be used for the 
Finkelstein reaction due to the solubility of NaI and the expected NaCl salt in these solvent. 
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Finkelstein reaction is a reversible reaction and thus its strength relies on the relative 
solubility of the salts in the reaction solvent. NaI is soluble in acetone while NaCl is insoluble 
and will precipitate out of the solution once formed, this drives the reaction forward. In water 
or MeOH, all the salt as well as the compounds are soluble and the chances of forming 
equilibrium between the chloride and iodine analogues of FR900098 is very high. Separation 
and purification of these salt and highly polar compounds will be almost impossible.    
 
 
Scheme 2.13. Attempted synthesis of iodinated analogue 2.40 
 
2.2.11 Analysis of degradation product of 2.3 
An observation was made during an attempt to obtain 2D NMR data for 2.3, which showed 
that the compound was degrading in D2O as early as nine hours after synthesis. This 
prevented 13C NMR and 2D NMR data of pure 2.3 from being obtained as the compound was 
degrading during the course of acquiring the spectra. The progress of the degradation was 
monitored by 1H NMR and by day 25 no further degradation was observed (Figure 2.10), 
although some of the original 2.3 was still present.  
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Figure 2.10. 1H NMR spectrum (D2O; 600 MHz) of the degradation mixture of 2.3 after 25 
days 
The cleanliness of the 1H NMR spectrum after degradation and the better resolution of the 
chemical shifts as compared to the spectrum of 2.3 (Figure 2.10) which showed broad 
chemical shifts were intriguing. It suggested a systematic degradation or conversion of the 
original compound to form a more stable water soluble product. Analysis of the NMR spectra 
showed diminishing methylene shifts at δ 3.70 and 3.75 in the 1H NMR spectrum of 2.3 
giving rise to the new peaks at δ 4.48 and 3.42 (Figure 2.11) respectively in the degradation 
mixture.  
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Figure 2.11. Comparison of 1H NMR spectra of pure 2.3 (D2O; 600 MHz) and the 
degradation mixture after 25 days in D2O 
 
The new methylene triplet at δ 3.42 (H-3) showed a 1H-1H COSY NMR correlation to the 
multiplet at δ 2.05 (H-2) which in turn showed another correlation to 1.86 (H-1). This is the 
same pattern observed for the methylene protons of the propyl linker between the 
hydroxamate and the phosphonate of all the synthesized FR900098 analogues, confirming 
that this part of the molecule is present and intact. The triplet at δ 4.48 (2H; J = 7.2 Hz) 
showed a COSY relationship to the multiplet at δ 2.36 (2H; H-6) which in turn also showed a 
correlation to the triplet at δ 2.61 (2H; J = 8.23 Hz). All of these shifts integrated to two 
protons each. The correlation of δ 2.32, 2.61 and 4.48 to the carbonyl carbon at δ 183.2 
indicated their positions as the side chain to the retrohydroxamate group. The fact that the 
methylene triplet at δ 3.70 of the 2.3 was deshielded to 4.48 in the degradation product 
suggests a more electronegative atom than chlorine was now attached to the carbon carrying 
the protons at δ 70.7. This analysis corresponded with the expected result of the product 
which would form when the lone pair of electrons of the N-oxime oxygen attacks the 
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chlorinated carbon of the side chain of 2.3. This would result in the removal of the chlorine as 
a good leaving group and intramolecular cyclization of the side chain to afford 2.41 (Scheme 
2.14). The structure could not be confirmed however, because samples could not be separated 
and pure samples were not obtained for further analysis.  
 
Scheme 2.14. Proposed mechanism of intramolecular cyclization of 2.3 to 2.41 
 
2.2.12 Antiplasmodial activity of deprotected Fosmidomycin analogues 
The antiplasmodial assay of the phosphonic acid analogues of FR900098 2.1 – 2.3 and 2.38 
was carried out on the CQR FCR-3 strain of P. falciparum. As expected, none of the 
phosphonic acids (Table 2.6) was as active as their ester analogues (Table 3.5). This 
confirmed that the increased lipophilicity of the ester compounds enhanced their absorption 
into the parasite and as a result more concentration of the drugs was delivered to the site of 
action. It was however not anticipated that FR900098 would show better activity (IC50 = 
41.67 µM) against the plasmodium than the chlorinated 2.1 (IC50 = 64.07 µM) considering 
that the protected chlorinated analogue 2.8 and the debenzylated chlorinated analogue 2.19 
showed better activity than the unchlorinated protected analogues of FR900098 2.12 and 2.18 
respectively (Table 2.5).What was important however was that while the hydroxamic acid of 
FR900098 (2.18) was inactive, the hydroxamic acid of 321 (2.19) was active even more so 
than FR900098 and as such is a promising antimalarial agent. 
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Table 2.6. Antiplasmodial activity of deprotected halogenated Fosmidomycin analogues 
 
Compound R FCR-3: IC50 (µM) SD (µM) 
FR900098 (1.45) -CH3 41.67 7.24 
2.1 -CH2Cl 64.07 2.87 
2.2 -CH2CH2Cl > 100 11.63 
2.38 -CH2CH3 > 100 14.16 
2.3 -CH2CH2CH2Cl > 100 12.99 
 
 
2.2.13 Synthesis and antiplasmodial activity of Boc-substituted halogenated 
FR900098 analogues 
In an effort to retain the lipophilic properties of 2.8 and determine if varying the protective 
group on hydroxamate group would affect the antiplasmodial activity of the FR900098 
analogues, a substitution of the protecting benzyl was sought. The N-oxime can be protected 
with different protecting groups however the Boc group was selected due to the ease with 
which it is removed and the high yield following the removal. Boc protected analogues 2.42 
and 2.43 were synthesized from 2.19 since it showed the best antiplasmodial activity. 
The Boc group was introduced to the chlorinated 2.19 by reacting with Boc anhydride 
yielding the Boc-protected chloroacetyl analogue 2.42. Finkelstein reaction of NaI and 2.42 
produced the iodinated derivative 2.43 (Scheme 2.15) 
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Scheme 2.15. Synthesis of Boc-protected halogenated derivatives of FR900098 
 
Compounds 2.42 and 2.43 were tested against CQR Gambian FCR-3 strain of P. falciparum. 
Both compounds exhibited good activity against the parasite with 2.42 having an IC50 of 
14.98 ± 0.31 µM and 2.43 an IC50 of 6.12 ± 0.59 µM. Their activity is comparable with those 
observed for 2.8 (IC509.09 ± 0.38 µM) and 2.15 (IC50 8.08 ± 0.91 µM) which are the chloride 
and iodide analogues respectively. The result clearly shows no significant difference in the 
antiplasmodial activity of the compounds when the benzyl protecting group is substituted 
with a Boc group. The choice of which protecting group is better might come down to the 
cytotoxicity profile of different analogues containing both protecting groups. 
 
2.3 SUMMARY OF ANTIPLASMODIAL ACTIVITY 
The fully protected halogenated acetyl analogues of FR900098 (2.8, 2.5 and 2.17) as well as 
the hydroxamic acid phosphonate esters 2.19 – 2.21 have demonstrated superior 
antiplasmodial activity to FR900098 (1.45) against CQR FCR-3 P. falciparum. This activity 
is attributed to the increased lipophilicity of compounds, as compared to FR900098 as well as 
the presence of halogens at the acetyl side chain. Extending the acyl side chain with 
halogenated and non-halogenated propyl or butyryl group results in loss of antiplasmodial 
activity. 
 
Substitution of the O-benzyl protecting group with Boc did not show any appreciable 
difference in antiplasmodial activity of the halogenated FR900098 derivatives. However, 
having a lipophilic protective group on the hydroxamate seem unnecessary since the free 
hydroxamic acid 2.19 – 2.21 maintained their antiplasmodial activity even without the benzyl 
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group. It is worth mentioning that based on the reactive nature of halogens the halogenated 
FR900098 analogues could exhibit non-specific interaction within a host cell. Cytotoxic 
property of these compounds would have to be determined in order to establish their 
selectivity for the malaria parasite.  
 
2.4 EXPERIMENTAL 
 
2.4.1 Antiplasmodial assay for chloroquine resistance Gambian FCR-3 strain of P. 
falciparum 
The antiplasmodial assay for the chloroquine resistant Gambian FCR-3 strain was carried out 
by Prof. van Zyl at the Department of Pharmacy and Pharmacology, University of 
Witwatersrand. 
 
Parasite cultivation 
The chloroquine-resistant Gambian FCR-3 strain of the malaria parasite Plasmodium 
falciparum was cultured in vitro in human erythrocytes according to the methods described 
by Jensen and Trager,138 and modified by van Zyl and Viljoen.139 In brief, parasitized 
erythrocytes were suspended at a 5% haematocrit in RPMI-1640, supplemented with 10 mM 
D-glucose, 0.32 mM hypoxanthine, 50 mg/L gentamicin, 10% (v/v) heat inactivated human 
plasma. The culture was buffered with 25 mM HEPES and 25 mM NaHCO3. Cultures were 
maintained daily and incubated at 37°C with a gas mixture of 5% CO2, 3% O2 and the 
balance with N2. For experimental purposes, cultures were synchronized with 5% D-sorbitol 
when the parasites were in the ring stage.142 The percentage parasitaemia and stages were 
assessed daily by microscopic examination of thin blood smears stained with Giemsa. 
 
Antiplasmodial screening 
The antimalarial activity of the various extracts was determined using the tritiated 
hypoxanthine incorporation assay.143 The parasite suspension, consisted predominately the 
ring stage and was adjusted to a 0.5% parasitaemia and 1% haematocrit. The suspension was 
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then exposed to the different compounds at 50µM concentration (plated in triplicate) for a 
single cycle of parasite growth. All assays were carried out using untreated parasites and 
uninfected red blood cells as controls. Labelled 3H-hypoxanthine (0.5 µCi/ well, Amersham) 
was added after 24 h and the parasitic DNA was harvested on a Wallac® GFB-filtermat with a 
Titertek® cell harvester. The filtermats were dried and counted in the Wallacbeta counter. 
The counts per minute (cpm) were generated and the parasite survival rate calculated. The 
IC50 value for each compound was determined from the log sigmoid dose response curve 
generated by the Enzfitterand Prism software. Chloroquine was used as the reference 
antimalarial agents. Each experiment was repeated, at least, in triplicate. 
 
2.4.2 Antiplasmodial assay for chloroquine sensitive D10 strain of P. falciparum 
Antiplasmodial assay was conducted by Prof. Peter J. Smith at the Division of Pharmacology, 
University of Cape Town. 
All the samples were tested in duplicates against the D10 strain of chloroquine sensitive P. 
falciparum. The continuous in vitro culture of the asexual erythrocytic stage used in the 
experiment was maintained using a modified method of Trager and Jensen.138 The result was 
quantitatively assessed to determine the in vitro antiplasmodial activity through the lactate 
dehydrogenase assay according to a modified method of Makler.144 
 
A 2mg/ml stock solution of the test samples were prepared in 10% methanol and sonicated to 
enhance solubility. Samples not completely dissolved were tested as suspension. Stock 
solutions were stored at -20ºC and further dilutions were prepared on the day of the 
experiment. A full dose-response was performed for all compounds to determine the IC50 
value. Chloroquine was used as the reference drug and was tested at concentrations of 30, 15 
and 7.5 ng/ml. The full dose response experiment of the test samples was started at a 
concentration of 100 µg/ml and was serially diluted 2-folds to give 10 concentrations with a 
minimum of 0.2 µg/ml. Chloroquine was tested at a starting concentration of 100 ng/ml. The 
highest concentration of solvent used did not have any measurable effect on the parasites. 
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2.4.3 General experimental, equipment, chemicals and reagents 
The following general procedures were used unless stated otherwise. All solvents used for 
column chromatography and HPLC were HPLC grade obtained from Sigma- Aldrich 
(EtOAc) and BDH laboratory supplies. Normal phase TLC was performed on TLC silica gel 
60 F254.The plates were viewed under UV light (254 nm) and developed in iodine vapour or 
phosphomolybdic acid solution. Purification by column chromatography was carried out 
using Merck Kieselgel 60 (0.040-0.063). 
 
HPLC was conducted on a Waters 1525 Binary HPLC pump equipped with Waters 2487 dual 
wavelength absorbance detector.  The UV absorbance was read at wavelengths of 254 and 
234 nm and a range of 2.0 in AUFs. Normal Phase chromatography was performed using 
Whatman Partisil 10 column with a 40 cm X 10 mm i.d.  
 
IR spectra were recorded on Perkin-Elmer Spectrum 100 FT-IR spectrometer with neat 
compounds placed on diamond window. UV was conducted on Lambda 25 Perkin Elmer 
UV-Vis spectrometer. 
 
Electrospray ionization mass spectrometry (ESI-MS) was obtained using Waters Synapt G2 
with direct injection (1 µl) into a stream of 50% acetonitrile, 0.1% formic acid using a Waters 
UPLC at flow rate of 0.2 ml/min. 
 
The NMR spectra were recorded on a Bruker Avance 400 or 600 NMR spectrometer using 
standard pulse sequences. Chemical shifts were recorded in parts per million (ppm). NMR 
solvents used included CDCl3, MeOD and D2O and were referenced to residual undeuterated 
solvent signals (CDCl3: δH = 7.25 ppm, δC = 77.0 ppm; MeOD: δH = 4.84 ppm; δC = 49.0 
ppm; D2O: δH = 4.84 ppm).  
 
All reactions requiring anhydrous conditions were conducted in flame-dried apparatus. Under 
N2, THF was dried over sodium wire and benzophenone as described in literature.145 
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2.4.4 Synthetic procedures and spectroscopic data 
Diethyl (3-bromopropyl)phosphonate (2.8) 
 
In a 50ml round bottom flask equipped with a stirrer bar and condenser, triethyl phosphate 
(P(OEt)3;1.5 ml; 8.74 mmol) was heated at 1500C with 1,3-dibromopropane (2.6, 1.33 ml; 
13.12 mmol). The reaction was monitored by TLC and stopped after one hour when all the 
P(OEt)3 had reacted. Column chromatography (Et2O/CH2Cl2, 1:1) of the crude product 
afforded the desired pure product as a colourless oil (1.21g; 54%). 1H NMR (400 MHz; 
CDCl3): δ = 4.02 (m, 4H, P-O-CH2-CH3); 3.40 (t, J = 6.5 Hz, 2H, P-CH2-CH2-CH2); 2.07 (m, 
2H, P-CH2CH2); 1.82 (m, 2H, P-CH2); 1.25 (t, J = 7.1 Hz, 6H, P-O-CH2-CH3) ppm. 13C 
NMR (100 MHz; CDCl3): δ = 61.5 (d, J = 6.5 Hz, 2 x CH2, P-O-CH2-CH3); 33.4 (d, J = 18.6 
Hz, P-CH2-CH2-CH2); 25.8 (d, J = 4.3 Hz, P-CH2-CH2); 24.2 (d, J = 142.6 Hz, P-CH2); 16.3 
(d, J = 6.0 Hz, 2 x CH3, P-O-CH2-CH3) ppm. 
 
Tert-butyl benzyloxy(3-(diethoxyphosphoryl)propyl)carbamate (2.7) 
 
Under dry conditions, tert-butyl benzyloxycarbamate (1.16 g; 5.2 mmol) was dissolved in 20 
ml freshly distilled THF at room temperature. NaH (0.25 g; 10.4 mmol) was added to the 
carbamate solution in portions over 15 minutes. After stirring the mixture for 30 minutes, 2.8 
(1.35 g; 5.2 mmol) was added dropwise and left to stir overnight. The cloudy white mixture 
was concentrated under reduced pressure and 10 ml of H2O was added. The resulting crude 
mixture was extracted with EtOAc (20ml x 3). The combined EtOAc extracts was washed 
with saturated brine solution (10 ml) and dried over anhydrous Na2SO4 before concentrating 
in vacuo to give the desired pure compound (2.08 g; 100%) as a colourless oil without further 
purification. 1H NMR (400 MHz; CDCl3): δ = 7.34 (m, 5H, N-O-CH2-Ph-H); 4.81 (s, 2H, N-
O-CH2-Ph); 4.05 (m, 4H, P-O-CH2-CH3); 3.45 (t, J = 6.8 Hz, 2H, P-CH2CH2CH2); 1.88(m, 
2H, P-CH2-CH2); 1.71(m, 2H, P-CH2); 1.48 (s, 9H, N-C(O)-O-C(CH3)3); 1.27 (t, J = 7.0 Hz, 
6H, P-O-CH2-CH3). 13C NMR (100 MHz; CDCl3): δ = 156.4 (s, N-C(O)-O-C(CH3)3); 135.4 
(s, N-O-CH2-C=CH-); 129.3 (s, 2 x CH,N-O-CH2-C=CH-CH=); 128.5 (s, N-O-CH2-C=CH-
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CH=CH);  128.4 (s, 2 xCH, N-O-CH2-C=CH-); 81.4 (s; N-C(O)-O-C(CH3)3); 77.0 (s, N-O-
CH2-Ph); 61.5 (d, J = 6.5 Hz,2 x CH2, P-O-CH2-CH3); 49.8 (d, J = 19.2 Hz, P-CH2-CH2-
CH2); 28.2 (s,3 x CH3,N-C(O)-O-C(CH3)3); 23.0 (d, J = 142.6 Hz, P-CH2); 20.4 (d, J= 4.7 
Hz, P-CH2CH2); 16.4 (d, J = 6.0 Hz, 2 x CH3, P-O-CH2-CH3). 
 
Diethyl 3-(benzyloxyamino)propylphosphonate (2.4)146 
 
 
Compound 2.7 (0.3 g; 0.75 mmol) was dissolved in CH2Cl2 (3 ml). TFA (3 ml) was added at 
room temperature and stirred overnight and the solvent was removed under reduced pressure. 
The resulting residue was washed with a saturated solution of NaHCO3 (10 ml) and extracted 
with EtOAc (3x 10 ml). The combined organic phase was washed with saturated brine, dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The concentrated product 
(0.21 g; 93%) was used in the next reaction without further purification.  
1H NMR (400 MHz; CDCl3): δ = 7.31 (m, 5H, N-O-CH2-Ph-H); 4.68 (s, 2H, N-O-CH2-Ph); 
4.04 (m, 4H, P-O-CH2-CH3); 2.96 (t, J = 6.3 Hz, 2H, P-CH2-CH2-CH2); 1.79 (m, 2H, P-CH2-
CH2); 1.73 (m, 2H, P-CH2) 1.29 (t, J = 7.0 Hz, 6H, P-O-CH2-CH3) ppm. 13C NMR (100 
MHz; CDCl3): δ = 137.7 (s,N-O-CH2-C=CH-); 128.4 (s, 2 x CH,N-O-CH2-C=CH-CH=); 
128.3 (s, 2 x CH,N-O-CH2-C=CH-);  127.8 (s, N-O-CH2-C=CH-CH=CH); 76.3 (s, N-O-CH2-
Ph); 61.5 (d, J = 6.5 Hz; 2 x CH2, P-O-CH2-CH3); 52.0 (d, J = 16.6 Hz, P-CH2-CH2-CH2); 
23.1 (d, J = 142.1 Hz, P-CH2); 20.5 (d, J = 4.9 Hz, P-CH2CH2); 16.4 (d, J = 6.0 Hz, 2 x 
CH3,P-O-CH2-CH3) ppm. 
 
General procedure for the synthesis of Diethyl 3-(N-(benzyloxy)-
chloroalkyl)propylphosphonate (2.8 – 2.12 and 2.17) 
 
A solution of 2.4 (0.25 g; 0.83 mmol) in CH2Cl2(20 ml) was treated with Et3N (0.14 ml; 1.05 
mmol) at room temperature. The mixture was stirred for 1.5 h, and the respective acyl 
chloride (1.05 mmol) was added dropwise and stirred for another 2.5 h (except for 2.11 which 
was stirred for 3.5 h). The mixture was diluted with CH2Cl2 (10 ml) and washed with water 
(20 ml), saturated NaHCO3 solution (20 ml), and finally with saturated brine solution (5 ml). 
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The organic layer was dried over anhydrous MgSO4. The concentrated product was purified 
by silica gel (10 g) column chromatography first eluting with EtOAc (50 ml), then 
MeOH/EtOAc (1:9, 50 ml) to give the pure products as clear, yellow oils. 
 
Diethyl 3-(N-(benzyloxy)-2-chloroacetamido)propylphosphonate (2.8) 
 
 
Yield: 0.25 g; 79%. See Tables 2.1 and 2.2 for 1H NMR (400 MHz, CDCl3) and 13C NMR 
(100 MHz, CDCl3) assignments. 
Mass (HRESI-MS): Calculated for C16H25ClNO5P [M + H]+: 378.1237, Found: 378.1226 
IR: νmax 3458, 2982, 1672 (C=O), 1238 (P=O), 1023; UV: λmax 209.07 nm  
 
Diethyl 3-(N-(benzyloxy)-3-chloropropanamido)propylphosphonate (2.9) 
 
 
Yield: 0.11 g; 33%. NMR (400 MHz, CDCl3) δ 7.37 (s, 5H, Ar-H); 4.82 (s, 2H,N-O-CH2-
Ar); 4.06 (m, 4H,P-O-CH2-CH3); 3.74 (overlapped t, J = 5.87 Hz, 4H, P-CH2CH2CH2 and 
CH2-Cl); 2.83 (t, J = 6.6 Hz, 2H, C(O)-CH2);1.94 (m, 2H,P-CH2CH2); 1.71 (m, 2H, P-CH2); 
1.29 (t, J = 7.0 Hz, 6H, P-O-CH2-CH3) ppm. 13C NMR (100 MHz, CDCl3) δ 171.9 (s, C=O); 
134. 1 (s, N-O-CH2-C=CH-); 129.3 (s, 2 x CH, N-O-CH2-C=CH-CH=); 129.1 (s, N-O-CH2-
C=CH-CH=CH); 128.8 (s, 2 x CH, N-O-CH2-C=CH-); 76.6 (s, N-O-CH2-Ph); 61.6 (d, J = 
6.5 Hz, 2 x CH2,P-O-CH2); 45.5 (s, P-CH2CH2CH2); 39.3 (s, CH2-Cl);35.4 (s, C(O)-CH2); 
23.0 (d, J = 142.7 Hz, P-CH2); 20.2 (d,J = 4.7 Hz,P-CH2-CH2); 16.4 (d, J = 5.9 Hz, 2 x CH3, 
P-O-CH2-CH3) ppm. 
Mass (HRESI-MS): Calculated for C17H27ClNO5P [M + H]+: 392.1394, Found: 392.1394 
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IR: νmax 3459, 2981, 1657 (C=O), 1238 (P=O), 1022; UV: λmax 206.23 nm 
 
Diethyl 3-(N-(benzyloxy)acrylamido)propylphosphonate (2.10)  
 
 
Yield: 0.03 g; 11%. NMR (400 MHz, CDCl3) δ 7.36 (s, 5H, Ar-H);6.71 (dd, J = 10.4 and 
17.1 Hz, 1H, C(O)-CH); 6.39 (d, J = 17.1 Hz, 1H, C(O)-CH-CH2A); 5.71 (d, J = 10.4 Hz, 1H, 
C(O)-CH-CH2B); 4.82 (s, 2H,N-O-CH2-Ph); 4.06(m, 4H,P-O-CH2-CH3); 3.76 (t, J = 6.9 Hz, 
2H, P-CH2CH2CH2); 1.96 (m, 2H,P-CH2CH2); 1.74 (m, 2H, P-CH2); 1.28 (t, J = 7.0 Hz, 6H, 
P-O-CH2-CH3) ppm. 13C NMR (100 MHz, CDCl3) δ 167.0 (s, C=O); 134. 1 (s, N-O-CH2-
C=CH-.); 129.3 (s, C(O)-CH-CH2); 129.2 (s, 2 x CH, N-O-CH2-C=CH-CH=); 129.0 (s, N-O-
CH2-C=CH-CH=CH); 128.7 (s, 2 x CH, N-O-CH2-C=CH-); 126.1 (s, C(O)-CH)77.1 (s, N-O-
CH2-Ph); 61.6 (d, J = 7.0 Hz, 2 x CH2, P-O-CH2); 45.7 (br s, P-CH2CH2CH2); 23.0 (d, J = 
142.0 Hz, P-CH2); 20.3 (d, J = 5.0 Hz, P-CH2-CH2); 16.4 (d, J = 6.0 Hz, 2 x CH3, P-O-CH2-
CH3) ppm. 
Mass (ESI-MS): Calculated for C17H26NO5P [M + H]+: 356.1627, Found: 356.1621 
IR: νmax 3461, 2982, 1655 (C=O), 1237 (P=O), 1020; UV: λmax 204.98 nm  
 
Diethyl 3-(N-(benzyloxy)-4-chlorobutanamido)propylphosphonate (2.11) 
 
 
Yield: 0.17 g; 53.4%. NMR (400 MHz, CDCl3) δ 7.35 (s, 5H, Ar-H); 4.80 (s, 2H,N-O-CH2-
Ar); 4.04(m, 4H,P-O-CH2-CH3); 3.68 (t, J = 6.5 Hz, 2H, P-CH2CH2CH2) 3.55 (t,J = 5.9 Hz, 
2H,CH2-Cl); 2.55(t, J = 6.8 Hz, 2H, C(O)-CH2);2.02 (m, 2H, C(O)-CH2-CH2);1.91 (m, 2H,P-
CH2CH2); 1.69 (m, 2H, P-CH2); 1.27 (t, J = 6.9 Hz, 6H, P-O-CH2-CH3) ppm. 13C NMR (100 
MHz, CDCl3) δ 173.6 (s, C=O); 134.2 (s, N-O-CH2-C=CH-.); 129.2 (s, 2 x CH, N-O-CH2-
  Chapter 2                   Design and synthesis of halogenated fosmidomycin analogues 
___________________________________________________________________________ 
 Page | 94 
 
C=CH-CH=); 128.9 (s, N-O-CH2-C=CH-CH=CH); 128.7 (s, 2 x CH, N-O-CH2-C=CH-); 
76.4 (s, N-O-CH2-Ph); 61.5 (d, J = 6.0 Hz, 2 x CH2, P-O-CH2); 45.8 (br s, P-CH2CH2CH2); 
44.5 (s, CH2-Cl); 29.2 (s, C(O)-CH2); 27.1 (s, C(O)-CH2-CH2); 23.0 (d, J = 142.0 Hz, P-
CH2); 20.2 (d, J = 5.0 Hz, P-CH2-CH2); 16.3 (d, J = 6.0 Hz, 2 x CH3, P-O-CH2-CH3) ppm. 
Mass (ESI-MS): Calculated for C18H29ClNO5P [M + H]+: 406.1550, Found: 406.1544 
IR: νmax 3462, 2981, 1659 (C=O), 1239 (P=O), 1025 UV: λmax 209.12nm  
 
Diethyl 3-(N-(benzyloxy)acetamido)propylphosphonate (2.12)108 
 
 
Yield: 0.25 g; 89%. NMR (400 MHz, CDCl3) δ 7.33 (s, 5H, Ar-H); 4.77 (s, 2H,N-O-CH2-
Ar); 4.03(m, 4H,P-O-CH2-CH3); 3.66 (t, J = 6.6 Hz, 2H, P-CH2CH2CH2); 2.04 (s, 3H,C(O)-
CH3); 1.91 (m, 2H,P-CH2CH2); 1.68 (m, 2H, P-CH2); 1.25 (t, J = 7.0 Hz, 6H, P-O-CH2-CH3) 
ppm. 13C NMR (100 MHz, CDCl3) δ 166.2 (s, C=O); 134.3 (s, N-O-CH2-C=CH-.); 129.0 (s, 
2 x CH, N-O-CH2-C=CH-CH=); 128.9 (s, N-O-CH2-C=CH-CH=CH); 128.6 (s, 2 x CH, N-O-
CH2-C=CH-); 76.3 (s, N-O-CH2-Ph); 61.4 (d, J = 6.5 Hz, 2 x CH2, P-O-CH2); 45.4 (s, P-
CH2CH2CH2); 22.9 (d, J = 142.7 Hz, P-CH2);20.3 (s, C(O)-CH3); 20.2 (d, J = 4.7 Hz, P-CH2-
CH2); 16.3 (d, J = 5.9 Hz, 2 x CH3, P-O-CH2-CH3) ppm. 
 
Diethyl 3-(N-(benzyloxy)-2-bromoacetamido)propylphosphonate (2.17) 
 
 
Yield: 0.30 g; 87%. See Tables 2.3 and 2.4 for 1H NMR (400 MHz, CDCl3) and 13C NMR 
(100 MHz, CDCl3) assignments. 
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Mass (ESI-MS): Calculated for C16H25BrNO5P [M]+: 422.0732, Found: 422.0735 
IR: νmax 3430, 2983, 1664 (C=O), 1210, 1018; UV: λmax 209.01 nm  
 
Diethyl 3-(N-(benzyloxy)-2-iodoacetamido)propylphosphonate (2.15).  
 
 
Compound 2.8 (0.26 g; 0.68 mmol) and NaI (0.31 g; 2.03 mmol) were dissolved in 10 ml 
acetone and stirred at room temperature overnight. The white precipitate was filtered off and 
the filtrate was concentrated under reduced pressure. The crude product was re-dissolved in 
20 ml CH2Cl2 and washed with 10 ml of water and then with 5 ml of brine. The organic layer 
was dried over MgSO4 and concentrated in-vacuo to yield the pure yellow oil (0.25 g; 
78.5%).  
See Tables 2.3 and 2.4 for 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) 
assignments. 
Mass (ESI-MS): Calculated for C16H25INO5P [M + H]+: 470.0593, Found: 470.0590 
IR: νmax 3453, 2981, 1654 (C=O), 1238 (P=O), 1020; UV: λmax 209.35 nm  
 
 
Diethyl 3-(N-(benzyloxy)-3-iodopropanamido)propylphosphonate (2.16) 
 
 
Compound 2.9 (0.14 g; 0.37 mmol) and NaI (0.17 g; 1.10 mmol) were dissolved in 10 ml 
acetone and stirred at room temperature for 24 h. The solution was then refluxed for 4 h and 
thereafter allowed to cool to room temperature and stirred another three days. The white 
precipitate was filtered off and the filtrate was concentrated under reduced pressure. The 
crude product was re-dissolved in CH2Cl2 and washed with water and brine. The organic 
  Chapter 2                   Design and synthesis of halogenated fosmidomycin analogues 
___________________________________________________________________________ 
 Page | 96 
 
layer was dried over MgSO4 and concentrated in vacuo. The crude product was purified with 
reverse phase HPLC using 20:80 H2O: MeOH to yield pure clear colourless oil (0.10 g; 
56%).  
1H NMR (400 MHz, CDCl3) δ 7.38 (s, 5H, Ar-H); 4.82 (s, 2H,N-O-CH2-Ar);  4.07 (m, 4H,P-
O-CH2-CH3); 3.72 (t, J = 6.7 Hz, 2H, P-CH2CH2CH2); 3.30 (t, J = 7.0 Hz, 2H, CH2-I); 3.00 
(t, J = 7.0 Hz, 2H, C(O)-CH2); 1.94 (m, 2H,P-CH2CH2); 1.72 (m, 2H, P-CH2); 1.29 (t, J = 7.0 
Hz, 6H, P-O-CH2-CH3) ppm. 13C NMR (100 MHz, CDCl3) δ 172.2 (s, C=O); 134.1 (s, N-O-
CH2-C=CH-.); 129.3 (s, 2 x CH, N-O-CH2-C=CH-CH=); 129.2 (s, N-O-CH2-C=CH-
CH=CH); 128.8 (s, 2 x CH, N-O-CH2-C=CH-); 76.6 (s, N-O-CH2-Ph); 61.6 (d, J = 6.5 Hz, 2 
x CH2, P-O-CH2); 45.8 (s, N-CH2); 36.6 (s, C(O)-CH2); 23.1 (d, J = 142.7 Hz, P-CH2); 20.2 
(br s, P-CH2-CH2); 16.4 (d, J = 5.9 Hz, 2 x CH3, P-O-CH2-CH3); -2.8 (s, CH2-I) ppm. 
Mass (ESI-MS): Calculated for C17H27INO5P [M + H]+: 484.0750, Found: 484.0748 
IR: νmax 3460, 2980, 1655 (C=O), 1237 (P=O), 1021; UV: λmax 217.01 nm  
 
General procedure for the preparation of diethyl 3-(N-
hydroxamido)propylphosphonate compounds 2.18, 2.19 and 2.22 – 2.24 
The O-protected hydroxamic acids 2.8 – 2.12 (0.20 g) were dissolved in 20 ml MeOH. 
Pd(OH)2/C (0.04 g) was added to the solution (except for 2.12 where Pd/C was used) and 
hydrogen gas was introduced to the mixture by means of an inflated a balloon to generate a 
positive pressure. The suspension was stirred for two hours at room temperature after which 
it was filtered through celite. The filtrate was concentrated under reduced pressure to give 
violet coloured oils 2.18, 2.19 and 2.22 – 2.24 respectively. 
Diethyl 3-(N-hydroxyacetamido)propylphosphonate (2.18)147 
 
 
Yield: 0.14 g; 93%. 1H NMR (400 MHz, MeOD) δ 4.13 (m, 4H, P(O)-CH2); 3.71 (t, J = 6.2 
Hz, 2H, P-CH2-CH2-CH2); 2.14 (s, 3H, C(O)-CH3); 1.89 (m, 4H; P-CH2-CH2); 1.36 (t, J = 
7.0 Hz, 6H, P(O)-CH2-CH3) ppm. 13C NMR (100 MHz, MeOD) δ173.9 (s, C=O); 63.3 (d, J 
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= 7.0 Hz, 2 x CH2, P(O)-CH2); 49.1 (d, J = 18.9 Hz,P-CH2-CH2-CH2); 23.2 (d, J = 141.0 Hz, 
P-CH2 ); 21.0 (d, J = 4.0 Hz, P-CH2-CH2); 20.2 (s, C(O)CH3); 16.7 (d, J = 6.0 Hz, 2 x CH3, 
P(O)-CH2-CH3) ppm. 
 
Diethyl 3-(2-chloro-N-hydroxyacetamido)propylphosphonate (2.19) 
 
 
Yield: 0.15 g; 100%.1H NMR (400 MHz, MeOD) δ 4.36 (s, 2H, CH2-Cl); 4.06 (br s, 4H, 
P(O)-CH2); 3.70 (br t, J = 6.1 Hz, 2H, P-CH2-CH2-CH2);  1.83 (m, 4H; P-CH2-CH2); 1.31 (t, 
J = 6.6 Hz, 6H, P(O)-CH2-CH3) ppm. 13C NMR (100 MHz, MeOD) δ169.4 (s, C=O); 63.32 
(d, J = 6.0 Hz, 2 x CH2, P(O)-CH2); 49.9 (d, J = 20.0 Hz,P-CH2-CH2-CH2); 42.0 (s, CH2-Cl); 
23.1 (d, J = 142.0 Hz, P-CH2 ); 20.8 (s, P-CH2-CH2 ); 16.7 (d, J = 6.0 Hz, 2 x CH3, P(O)-
CH2-CH3 ppm. 
Mass (ESI-MS): Calculated for C9H19ClNO5P [M + H]+: 288.0768, Found: 288.0768 
IR: νmax 3137, 2983, 2909, 1651 (C=O), 1018; UV: λmax 211.34 nm  
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Diethyl 3-(3-chloro-N-hydroxypropanamido)propylphosphonate (2.22) 
 
Yield: 0.12 g; 76%. 1H NMR (400 MHz, MeOD) δ 4.06 (m, 4H, P(O)-CH2); 3.75 (t, J = 6.4 
Hz, 2H, CH2-Cl); 3.66 (t, J = 6.3 Hz, 2H, P-CH2-CH2-CH2); 2.93 (t, J = 6.2 Hz, 2H, C(O)-
CH2); 1.81(m, 4H; P-CH2-CH2); 1.29 (t, J = 7.0 Hz, 6H, P(O)-CH2-CH3) ppm. 13C NMR 
(100 MHz, MeOD) δ172.6 (s, C=O); 63.3 (d, J = 6.4 Hz, 2 x CH2, P(O)-CH2); 49.9 (s,P-CH2-
CH2-CH2); 40.3 (s, CH2-Cl ); 36.4 (s, C(O)-CH2); 23.2 (d, J = 142.0 Hz, P-CH2); 20.9 (d, J = 
5.0 Hz, P-CH2-CH2); 16.7 (d, J = 6.0 Hz, 2 x CH3, P(O)-CH2-CH3) ppm. 
Mass (ESI-MS): Calculated for C10H21ClNO5P [M + Na]+: 324.0744, Found: 324.0745 
IR: νmax 3150, 2983, 2909,1647 (C=O), 1238 (P=O), 1025; UV: λmax 206.57 nm  
 
Diethyl 3-(N-hydroxyacrylamido)propylphosphonate (2.23)  
 
Yield: 0.15 g; 100%. 1H NMR (400 MHz, MeOD) δ 4.06 (m, 4H, P(O)-CH2); 3.63 (t, J = 6.3 
Hz, 2H, P-CH2-CH2-CH2); 2.45 (br d, J = 7.2 Hz, 2H, C(O)-CH2); 1.78 (m, 4H; P-CH2-CH2); 
1.29 (t, J = 7.0 Hz, 6H, P(O)-CH2-CH3); 1.06 (t, J = 7.5 Hz, 3H, C(O)-CH2-CH3) ppm. 13C 
NMR (100MHz, MeOD) δ177.2 (s, C=O); 63.3 (d, J = 6.0 Hz, 2 x CH2, P(O)-CH2); 49.9 
(s,P-CH2-CH2-CH2); 26.5 (s, C(O)-CH2); 23.2 (d, J = 141.0 Hz, P-CH2 ); 21.0 (br s, P-CH2-
CH2 ); 16.7 (d, J = 6.0 Hz, 2 x CH3, P(O)-CH2-CH3); 9.3 (s, C(O)-CH2-CH3) ppm. 
Mass (ESI-MS): Calculated for C10H22NO5P [M + H]+: 268.1314, Found: 268.1315 
IR: νmax 3160, 2981, 2937, 1627 (C=O), 1023; UV: λmax 205.66 nm  
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Diethyl 3-(4-chloro-N-hydroxybutanamido)propylphosphonate (2.24) 
 
Yield: 0.04 g; 23%.1H NMR (600 MHz, MeOD) δ 4.05 (m, 4H, P(O)-CH2); 3.60 (t, J = 6.5 
Hz, 2H, CH2-Cl); 3.76 (t, J = 5.6 Hz, 2H, P-CH2-CH2-CH2); 2.68 (t, J = 7.2 Hz, 2H, C(O)-
CH2); 2.08 (m, 2H, (CO)-CH2-CH2); 1.95 (m, 2H, P-CH2-CH2); 1.82 (m, 2H; P-CH2); 1.31(t, 
J = 7.0 Hz, 6H, P(O)CH2CH3) ppm. 13C NMR (150 MHz, MeOD) δ173.9 (s, C=O); 62.30 (d, 
J = 6.6 Hz, 2 x CH2, P(O)-CH2); 47.6 (s,P-CH2-CH2-CH2); 44.8 (s, CH2Cl); 29.6 (s, C(O)-
CH2); 27.5 (s, C(O)-CH2-CH2) 22.1 (d, J = 140.3 Hz, P-CH2); 18.7 (d, J = 5.1 Hz, P-CH2-
CH2); 16.3(d, J = 5.7 Hz, 2 x CH3, P(O)-CH2-CH3) ppm. 
Mass (ESI-MS): Calculated for C11H23ClNO5P [M + H]+: 316.1081, Found: 316.1082 
IR: νmax 3169, 2982, 2932, 1645 (C=O), 1213; UV: λmax 203.41 nm  
 
Diethyl 3-(2-bromo-N-hydroxyacetamido)propylphosphonate (2.20) 
 
Part 1: Compound 2.19 (0.11 g; 0.39 mmol) was dissolved in 15 ml acetone and LiBr (0.42 
g; 4.9 mmol) was added and stirred for 48 hours a room temperature. More LiBr (0.16 g; 1.84 
mmol) and acetone (5 ml) were added to the reaction mixture and refluxed for four hours 
before stirring at room temperature for another 24 hours. The cloudy solution was filtered and 
concentrated under reduced pressure. The crude product was re-dissolved in 30ml EtOAc and 
washed with brine (5ml). Part 2: The organic phase was concentrated in vacuo and re-
dissolved in 15 ml acetone with fresh LiBr (0.42g). The solution was stirred for 72 hours and 
worked up as before. Part 2 was repeated twice to obtain an orange crude product that was 
purified over 10 g silica gel column eluting with MeOH:EtOAc (1:9) to afford 2.20 (0.28 g; 
58%).  
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1H NMR (600 MHz, CDCl3) δ 4.12 (s, 2H, C(O)-CH2-Br); 4.05 (m, 4H, P-O-CH2); 3.74 (t, J 
= 6.07 Hz, 2H, P-CH2-CH2-CH2); 1.95 (m, 2H, P-CH2-CH2); 1.80 (m, 2H, P-CH2); 1.30 (t, J 
= 7.06 Hz, 6H, P-O-CH2-CH3) ppm.13C NMR (150 MHz, CDCl3) δ 167.9 (s, C=O); 62.34 (d, 
J = 6.72 Hz, 2 x CH2, P-O-CH2); 48.4 (d, J = 8.48 Hz, P-CH2-CH2CH2); 27.2 (s, CH2-Br), 
22.0 (d, J = 140.74 Hz, P-CH2); 19.0 (d, J = 5.18 Hz, P-CH2-CH2); 16.3 (d, J = 6.01 Hz, 2 x 
CH3, P-O-CH2-CH3) ppm. 
Mass (ESI-MS): Calculated for C9H19BrNO5P [M + H]+: 332.0262, Found: 332.0258 
 
Diethyl 3-(N-hydroxy-2-iodoacetamido)propylphosphonate (2.21) 
 
Compound 2.19 (0.11 g; 0.40 mmol) and NaI (0.18 g; 1.21 mmol) were dissolved in 10 ml 
acetone and stirred for two days at room temperature. The product was filtered and the filtrate 
was concentrated under reduced pressure. The crude product was dissolved in water (5 ml) 
and 1.5 g NaI was added. The solution was then extracted with 10 ml EtOAc. The solution 
was concentrated in vacuo to afford 0.09 g (59%) of pure yellow oil. 
1H NMR (400 MHz, D2O) δ 4.23 (m, 4H, P(O)-CH2); 4.05 (s, 2H, CH2-I); 3.79 (br s, 2H, P-
CH2-CH2-CH2);  2.03 (m, 4H; P-CH2-CH2); 1.41 (t, J = 7.0 Hz, 6H, P(O)-CH2-CH3) ppm. 
13C NMR (100 MHz, D2O) δ172.4 (s, C=O);64.0 (d, J = 6.0 Hz, 2 x CH2, P(O)-CH2); 49.0 
(d, J = 19.0 Hz,P-CH2-CH2-CH2); 21.6 (d, J = 139.0 Hz, PCH2 ); 19.3 (d, J = 5.0 Hz,P-CH2-
CH2); 16.2 (d, J = 6.0 Hz, 2 x CH3, P(O)-CH2-CH3); -5.2 (s, CH2-I ) ppm. 
Mass (ESI-MS): Calculated for C9H19INO5P [M + H]+: 380.0124, Found: 380.0124 
IR: νmax 3134, 2981, 2908, 1634 (C=O), 1204, 1017; UV: λmax 220.73 nm  
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Dibenzyl 3-bromopropylphosphonate (2.31) 
 
Dibenzyl phosphite (2.30, 1.50 ml; 6.79 mmol) was dissolved in 90 ml of anhydrous DMF 
under N2 gas. Cs2CO3 (6.64 g; 20.39 mmol) and tetramethylammonium iodide (CH3)4NI; 
4.10 g; 20.39 mmol) were added sequentially at room temperature and stirred for 1 h. 1,3-
Dibromopropane (2.08 ml; 20.39 mmol) was added and the suspension was stirred for 66 hrs. 
The suspension was poured into 110 ml of H2O and extracted three times with EtOAc. The 
combined organic layer was washed with water (100 ml) three times and then with brine (50 
ml). The organic solution was then dried over anhydrous Na2SO4 and concentrated in vaccuo. 
SiO2 gel column chromatography using gradient EtOAc:Hexane from 20% EtOAc to 50% 
EtOAc gave 1.76 g (67%) of pure product as a colourless oil.  
1H NMR (600 MHz, CDCl3) δ 7.34 (m, 10H, P-(O)CH2-Ph-H); 5.05 (dd, J = 9.00, 11.81 Hz, 
2H, P-(O)CH2-Ph-H); 4.96 (dd, J = 8.34, 11.83 Hz, 2H, P-(O)CH2-Ph-H); 3.37 (t, J = 6.49 
Hz, 2H, P-CH2-CH2-CH2); 2.08(m, 2H, P-CH2-CH2); 1.89 (m, 2H, P-CH2) ppm. 13C NMR 
(150 MHz, CDCl3) δ 136.3 (d, J = 5.91 Hz, 2 x C, P-O-CH2-C=CH-); 128.7 (s, 4 x CH, P-O-
CH2-C=CH-CH=); 128.6 (s, 2 x CH, P-O-CH2-C=CH-CH=CH-); 128.1 (s, 4 x CH, P-O-CH2-
C=CH-); 67.4 (d, J = 6.44 Hz, 2 x CH2, P(O)-CH2-Ph); 33.5 (d, J = 19.04 Hz, P-CH2-CH2-
CH2); 25.9 (d, J = 4.28 Hz, P-CH2-CH2); 24.9(d, J = 142.21 Hz,P-CH2) ppm. 
 
Tert-butyl benzyloxy(3-(bis(benzyloxy)phosphoryl)propyl)carbamate (2.32) 
 
Under dry conditions BocNHOBn (0.80 g; 3.58 mmol) was dissolved in 25 ml freshly dried 
THF. NaH (0.17 g; 7.09 mmol) was added in portions to the BocNHOBn solution at room 
temperature and stirred for 30 min. Compound 2.31 (1.38 g; 3.60 mmol) was added dropwise 
and the reaction mixture was stirred overnight. The suspension was concentrated under 
reduced pressure and re-suspended in H2O (30 ml).  The aqueous solution was extracted three 
times with EtOAc (25 ml) and the combined organic phase was washed with brine (20 ml). 
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The EtOAc solution was then dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. The crude product was purified over silica gel column chromatography eluting with 
20:80 EtOAc:Hexane (400ml) then 50:50 EtOAc:Hexane (600 ml) to give the pure 
compound 2.32 (0.71g; 56%) as a colourless oil in the later fraction. 
1H NMR (600 MHz, CDCl3) δ 7.32(m, 15H, P-O-CH2-Ph-H and N-O-CH2-Ph-H); 5.02 (m, 
2H,P-O-CH2-Ph-H)4.94 (dd, J = 8.26, 11.59 Hz, 2H, P-O-CH2-Ph-H); 4.77 (s, 2H, N-O-CH2-
Ph-H)); 3.42 (t, J = 6.75 Hz, 2H, P-CH2-CH2-CH2); 1.87 (m, 2H, P-CH2-CH2); 1.75 (m, 2H, 
P-CH2); 1.47 (s, 9H, N-C-(O)-O-C(CH3)) ppm. 13C NMR (150 MHz, CDCl3) δ 156.5 (s, N-
C-(O)-O-C(CH3); 136.4 (d, J = 5.96 Hz, 2 x C, P-O-CH2-C=); 135.4 (s, N-O-CH2-C=); 129.4 
(s, 2 x CH, N-O-CH2-C=CH-CH); 128.6 (s, 4 x CH, P-O-CH2-C=CH-CH=); 128.5 (s, N- O-
CH2-C=CH-CH=CH); 128.4 (s, 2 x CH, P-O-CH2-C=CH-CH=CH-); 128.3 (s, 2 x CH, N-O-
CH2-C=CH-); 127.9 (s, 4 x CH, P-O-CH2-C=CH-); 81.5 (s, N-C-(O)-O-C(CH3)); 77.0 (s, N-
O-CH2-Ph-H); 67.1 (d, J = 6.40 Hz, 2 x CH2, P-O-CH2-Ph-H); 49.9 (d, J = 19.60 Hz, P-CH2-
CH2-CH2); 28.3 (s, 3 x CH3, N-C-(O)-O-C(CH3)); 23.5 (d, J = 142.29 Hz, P-CH2); 20.4 (d, J 
= 4.77 Hz, P-CH2-CH2) ppm. 
 
Dibenzyl 3-(benzyloxyamino)propylphosphonate (2.33)115 
 
Compound 2.32 (0.38 g; 0.72 mmol) was dissolved in CH2Cl2 (10 ml) and cooled to 0OC. 
TFA (2.77 ml; 36.17) mmol) was added dropwise while the solution was stirred at 0OC for 45 
minutes. Volatile components were removed from the solution and the resulting product re-
dissolved in saturated solution of NaHCO3 (30 ml). The solution was extracted three times 
with EtOAc (25 ml) and the combined organic phase was washed with brine (20 ml) and 
dried over anhydrous Na2SO4. The product was concentrated to give 2.33 as pure clear 
yellow oil (0.30 g; 97 %). 
1H NMR (600 MHz, CDCl3) δ 7.31 (m, 15H, P-O-CH2-Ph-H and N-O-CH2-Ph-H); 5.04 (dd, 
J = 8.9, 11.7 Hz, 2H, P-O-CH2-Ph-H); 4.95 (dd, J = 8.1, 11.8 Hz, 2H, P-O-CH2-Ph-H); 4.63 
(s, 2H, N-O-CH2-Ph-H); 2.91 (t, J = 6.0 Hz, 2H, P-CH2-CH2-CH2); 1.82 (m, 2H, P-CH2-
CH2); 1.81 (m, 2H, P-CH2) ppm. 13C NMR (150 MHz, CDCl3) δ 137.8 (s, N-O-CH2-
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C=);136.4 (d, J = 6.0 Hz, 2 x C, P-O-CH2-C=); 128.6 (s, Ar-C), 128.4 (s, Ar-C ), 128.4 (s, 
Ar-C), 127.9 (s, Ar-C), 127.8 (s, Ar-C); 76.3 (s, N-O-CH2-Ph-H); 67.1 (d, J = 6.4Hz, 2 x 
CH2, P-O-CH2-Ph-H); 53.0 (d, J = 16.8 Hz, P-CH2-CH2-CH2); 23.6 (d, J = 141.6 Hz, P-CH2); 
20.5 (d, J = 4.9 Hz, P-CH2-CH2) ppm. 
 
Dibenzyl 3-(N-(benzyloxy)-2-chloroacetamido)propylphosphonate (2.34) 
 
A solution of 2.33 (0.20g; 0.47 mmol) and Et3N (0.08 ml; 0.56 mmol) in CH2Cl2 (30 ml) was 
stirred at room temperature for 1.5 hr. Chloroacetyl chloride (0.05 ml; 0.56 mmol) was added 
dropwise and the solution was stirred for a further 2.5 hr. CH2Cl2 (30 ml) was added and the 
solution was washed three times with H2O (50 ml), twice with a saturated solution of 
NaHCO3 (50 ml) and once with brine (20 ml). The combined organic phase was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified over SiO2 
gel column chromatography using a gradient solvent system of EtOAc:Hexane. The pure, 
transparent, light yellow oil of 2.34 was collected in the 10:0 EtOAc fraction (0.11 g; 46%).  
1H NMR (600 MHz, CDCl3) δ 7.34(m, 15H, P-O-CH2-Ph-H and N-O-CH2-Ph-H); 5.03 (dd, 
J = 9.1, 11.8 Hz, 2H, P-O-CH2-Ph-H); 4.94 (dd, J = 8.4, 11.8 Hz, 2H, P-O-CH2-Ph-H); 4.78 
(s, 2H, N-O-CH2-Ph-H)); 4.06 (s, 2H, CH2-Cl); 3.69 (t, J = 6.5 Hz, 2H, P-CH2-CH2-CH2); 
1.91 (m, 2H, P-CH2-CH2); 1.74 (m, 2H, P-CH2) ppm.13C NMR (150 MHz, CDCl3) δ 167.8 
(s, C=O); 136.2 (d, J = 5.7 Hz, 2 x C, P-O-CH2-C=); 133.6 (s, N-O-CH2-C=); 129.2 (s, 3 x N- 
O-CH2-C=CH-CH=CH); 128.8 (s, 2 x CH, P-O-CH2-C=CH-CH=CH-); 128.5 (s, 4 x CH, P-
O-CH2-C=CH-CH=); 128.4 (s, 2 x CH, N-O-CH2-C=CH-); 127.9 (s, 4 x CH, P-O-CH2-
C=CH-); 76.6 (s, N-O-CH2-Ph-H); 67.2 (d, J = 6.4 Hz, 2 x CH2, P-O-CH2-Ph-H); 45.8 (s, P-
CH2-CH2-CH2); 41.0 (s, CH2-Cl) 23.2 (d, J = 142.2 Hz, P-CH2); 19.9 (d, J = 4.5 Hz, P-CH2-
CH2) ppm. 
Mass (ESI-MS): Calculated for C26H29ClNO5P [M + H]+: 502.1550, Found: 502.1548 
IR: νmax 3463, 2949, 1669 (C=O), 1238 (P=O), 990; UV: λmax 208.52 nm  
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Dibenzyl 3-(N-(benzyloxy)-3-chloropropanamido)propylphosphonate (2.35) 
 
A solution of 2.33 (0.18g; 0.43 mmol) and Et3N (0.05 ml; 0.35 mmol) in CH2Cl2 (30 ml) was 
stirred at room temperature for 1.5 hr. Chloropropionyl chloride (0.05 ml; 0.51 mmol) was 
added dropwise and the solution was stirred for a further 2.5 hr. CH2Cl2 (30 ml) was added 
and the solution was washed three times with H2O (50 ml), twice with a saturated solution of 
NaHCO3 (50 ml) and once with brine (20 ml). The combined organic phase was dried over 
MgSO4 and concentrated under reduced pressure.  Flash column chromatography 
(EtOAc/CH2Cl2 1:3) of the crude product afforded pure yellow oil of 2.35 (0.05 g; 23%). 
1H NMR (600 MHz, CDCl3) δ 7.34 (m, 15H, P-O-CH2-Ph-H and N-O-CH2-Ph-H); 5.02 (dd, 
J = 8.9, 11.8 Hz, 2H, P-O-CH2-Ph-H); 4.94 (dd, J = 8.2, 11.8 Hz, 2H, P-O-CH2-Ph-H); 4.76 
(s, 2H, N-O-CH2-Ph-H)); 3.72 (t, J = 6.7 HZ, 2H, CH2-Cl); 3.67 (t, J = 6.0 Hz, 2H, P-CH2-
CH2-CH2); 2.79 (t, J = 6.5 Hz, 2H, C(O)-CH2); 1.90 (m, 2H, P-CH2-CH2); 1.75 (m, 2H, P-
CH2) ppm. 13C NMR (150 MHz, CDCl3) δ 171.3 (s, C=O); 136.3 (d, J = 5.9 Hz, 2 x C, P-O-
CH2-C=); 134.0 (s, N-O-CH2-C=); 129.2 (s, 2 x CH, N-O-CH2-C=CH-CH); 129.1 (s,N- O-
CH2-C=CH-CH=CH); 128.8 (s, 2 x CH, P-O-CH2-C=CH-CH=CH-); 128.6 (s, 4 x CH, P-O-
CH2-C=CH-CH=); 128.4 (s, 2 x CH, N-O-CH2-C=CH-); 127.9 (s, 4 x CH, P-O-CH2-C=CH-); 
76.5 (s, N-O-CH2-Ph-H); 67.2 (d, J = 6.5 Hz, 2 x CH2, P-O-CH2-Ph-H); 45.4 (s, P-CH2-CH2-
CH2); 39.2 (s, CH2-Cl); 35.4 (s, C(O)-CH2) 23.3 (d, J = 142.2 Hz, P-CH2); 20.1 (s, P-CH2-
CH2) ppm. 
Mass (ESI-MS): Calculated for C27H31ClNO5P [M + H]+: 516.1707, Found: 516.1713 
IR: νmax 3457, 2954, 1658 (C=O), 1242 (P=O), 991; UV: λmax 208.73 nm  
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Dibenzyl 3-(N-(benzyloxy)acrylamido)propylphosphonate (2.36) 
 
A solution of 2.33 (0.20 g; 0.47 mmol) and Et3N (0.08 ml; 0.56 mmol) in CH2Cl2 (30 ml) was 
stirred at room temperature for 1.5 hr. Chloropropionyl chloride (0.05 ml; 0.55 mmol) was 
added dropwise and the solution was stirred for a further 2.5 hr. CH2Cl2 (30 ml) was added 
and the solution was washed three times with H2O (50 ml), twice with a saturated solution of 
NaHCO3 (50 ml) and once with brine (20 ml). The combined organic phase was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified over SiO2 
gel column chromatography using a gradient solvent system of EtOAc:Hexane. The pure, 
transparent, colourless oil of 2.36 collected in the 10:0 EtOAc fraction (0.6 g; 27%). 
1H NMR (600 MHz, CDCl3) δ 7.37 – 7.27 (m, 15H, P-O-CH2-Ph-H and N-O-CH2-Ph-H); 
6.68 (dd, J = 10.4, 16.9 Hz, 1H, C(O)-CH); 6.38 (d, J = 17.0 Hz, 1H, C(O)-CH-CH2A); 5.71 
(d, J = 10.6 Hz, 1H, C(O)-CH-CH2B); 5.02 (dd, J = 9.0, 11.8 Hz, 2H, P-O-CH2-Ph-H); 4.94 
(dd, J = 8.2, 11.8 Hz, 2H, P-O-CH2-Ph-H); 4.76 (s, 2H, N-O-CH2-Ph-H); 3.71 (t, J = 6.8 HZ, 
2H, P-CH2-CH2-CH2); 1.94 (m, 2H, P-CH2-CH2); 1.76 (m, 2H, P-CH2) ppm. 13C NMR (150 
MHz, CDCl3) δ 166.6  (s, C=O); 136.3 (d, J = 5.9 Hz, 2 x C, P-O-CH2-C=); 134.0 (s, N-O-
CH2-C=); 129.2  (s, C(O)-CH-CH2); 129.1 (s, 2 x CH, N-O-CH2-C=CH-CH); 129.0 (s, N- O-
CH2-C=CH-CH=CH); 128.7 (s, 2 x CH, P-O-CH2-C=CH-CH=CH-); 128.5 (s, 4 x CH, P-O-
CH2-C=CH-CH=); 128.3 (s, 2 x CH, N-O-CH2-C=CH-); 127.9 (s, 4 x CH, P-O-CH2-C=CH-); 
126.1 (s, C(O)-CH); 77.1 (s, N-O-CH2-Ph-H); 67.1 (d, J = 6.4 Hz, 2 x CH2, P-O-CH2-Ph-H); 
45.7 (s, P-CH2-CH2-CH2); 23.3 (d, J = 142.1 Hz, P-CH2); 20.3 (d, J = 4.6 Hz, P-CH2-CH2) 
ppm. 
Mass (ESI-MS): Calculated for C27H30NO5P [M + H]+: 480.1940, Found: 480.1943 
IR: νmax 3477, 2947, 1653 (C=O), 1238 (P=O), 986; UV: λmax 208.35 nm  
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Dibenzyl 3-(N-(benzyloxy)-4-chlorobutanamido)propylphosphonate (2.37) 
 
A solution of 2.33 (0.20 g; 0.47 mmol) and Et3N (0.08 ml; 0.56 mmol) in CH2Cl2 (30 ml) was 
stirred at room temperature for 1.5 hr. Chlorobutryryl chloride (0.06 ml; 0.56 mmol) was 
added dropwise and the solution was stirred for a further 3.5 hr. CH2Cl2 (30 ml) was added 
and the solution was washed three times with H2O (50 ml), twice with a saturated solution of 
NaHCO3 (50 ml) and once with brine (20 ml). The combined organic phase was dried over 
MgSO4 and concentrated under reduced pressure. The crude product was purified over SiO2 
gel column chromatography eluting first with 100ml EtOAc/Hexane 2:8 then 5:5. The pure 
oil of 2.37 was collected in the later fraction (0.06 g; 24%). 
1H NMR (600 MHz, CDCl3) δ 7.33 (m, 15H, P-O-CH2-Ph-H and N-O-CH2-Ph-H); 5.02 (m, 
Hz, 2H, P-O-CH2-Ph-H); 4.94 (dd, J = 8.5, 11.5 Hz, 2H, P-O-CH2-Ph-H); 4.76 (s, 2H, N-O-
CH2-Ph-H); 3.65 ( br s, 2H, P-CH2-CH2-CH2); 3.56 (t, J = 6.1 Hz, 2H, CH2-Cl); 2.54 (t, J = 
6.3 Hz, 2H, C(O)-CH2); 2.03 (m, 2H, C(O)-CH2-CH2); 1.90 (m, 2H, P-CH2-CH2); 1.74 (m, 
2H, P-CH2) ppm. 13C NMR (150 MHz, CDCl3) δ 173.9 (s, C=O); 136.3 (d, J = 5.9 Hz, 2 x C, 
P-O-CH2-C=); 134.2 (s, N-O-CH2-C=); 129.2 (s, 2 x CH, N-O-CH2-C=CH-CH); 129.0 (s, N- 
O-CH2-C=CH-CH=CH); 128.7 (s, 2 x CH, P-O-CH2-C=CH-CH=CH-); 128.6 (s, 4 x CH, P-
O-CH2-C=CH-CH=); 128.4 (s, 2 x CH, N-O-CH2-C=CH-); 127.9 (s, 4 x CH, P-O-CH2-
C=CH-); 76.8 (s, N-O-CH2-Ph-H); 67.2 (d, J = 6.4 Hz, 2 x CH2, P-O-CH2-Ph-H); 45.5 (s, P-
CH2-CH2-CH2); 44.6 (s, CH2-Cl); 29.2 (s, C(O)-CH2); 27.1 (s, C(O)-CH2-CH2); 23.4 (d, J = 
142.1 Hz, P-CH2); 20.2 ( br s, P-CH2-CH2) ppm. 
Mass (ESI-MS): Calculated for C28H33ClNO5P [M + H]+: 530.1863, Found: 530.1865 
IR: νmax 3465, 2950, 1657 (C=O), 1238 (P=O), 990; UV: λmax 210.89 nm  
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General procedure for the preparation of 3-(N-hydroxyamido)propylphosphonic acids 
2.1 – 2.3 and 2.38 
The benzyl-protected hydroxamic acids 2.34 – 2.37 (0.10 g) were dissolved in 20 ml MeOH. 
Pd(OH)2/C (0.02 g) was added to the solution and hydrogen gas was introduced to the 
mixture by means of a balloon to generate a positive pressure. The suspension was stirred for 
1hr 45 minutes at room temperature then filtered over celite. The filtrate was concentrated 
under reduced pressure to give violet coloured oils 2.1 – 2.3 and 2.38. 
 
3-(2-chloro-N-hydroxyacetamido)propylphosphonic acid (2.1) 
 
Yield: 0.046 g; 100%. 1H NMR (600 MHz; D2O): δ 4.46 (s, 2H, CH2-Cl); 3.73 (br s, 2H, P-
CH2CH2CH2); 1.90 (br s, P-CH2-CH2); 1.77 (br s, 2H, P-CH2). 13C NMR (150 MHz; D2O): δ 
169.3 (s, C=O); 49.3 (br s, P-CH2-CH2-CH2); 41.6 (s, CH2-Cl); 23.8 (d, J = 140.9 Hz, P-
CH2); 19.8 (s,P-CH2CH2) ppm. 
Mass (ESI-MS): Calculated for C5H11ClNO5P [M + H]+: 232.0142, Found: 232.0139 
IR: νmax 3146, 2868, 1619 (C=O), 1220 (P=O), 1128; UV: λmax 211.38 nm  
 
3-(3-chloro-N-hydroxypropanamido)propylphosphonic acid (2.2) 
 
Yield: 0.046 g; 96%. 1H NMR (600 MHz, D2O) δ 3.90 (t, J = 5.9 HZ, 2H, CH2-Cl); 3.79 (t, J 
= 6.4 Hz, 2H, P-CH2-CH2-CH2); 3.11 (t, J = 6.0 Hz, 2H, C(O)-CH2); 1.95 (m, 2H, P-CH2-
CH2); 1.73 (m, 2H, P-CH2) ppm. 13C NMR (150 MHz, D2O) δ 172.7 (s, C=O); 48.8 (s, P-
CH2-CH2-CH2); 39.7 (s, CH2-Cl); 34.8 (s, C(O)-CH2) 24.5 (d, J = 136.6 Hz, P-CH2); 20.3 (s, 
P-CH2-CH2) ppm. 
Mass (ESI-MS): Calculated for C6H13ClNO5P [M + H]+: 246.0298, Found: 246.0300 
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IR: νmax 3153, 2924, 1615 (C=O), 1054; UV: λmax 208.29 nm  
 
3-(N-hydroxypropionamido)propylphosphonic acid (2.38) 
 
Yield: 0.044 g; 100%. 1H NMR (600 MHz, D2O) δ 3.77 (s, 2H, P-CH2-CH2-CH2); 2.59 (br s, 
2H, CH2--CH3); 1.95 (br s, 2H, P-CH2-CH2); 1.80 (br s, 2H, P-CH2); 1.15 (br s, 3H, 
CH2CH3) ppm.13C NMR (150 MHz, D2O) δ 177.6 (s, C=O); 48.6 (s, P-CH2-CH2-CH2); 25.4 
(s, CH2-CH3); 23.6 (s, P-CH2); 20.1 (s, P-CH2-CH2); 8.6 (s, CH2-CH3). 
Mass (ESI-MS): Calculated for C6H14NO5P [M + H]+: 212.0688, Found: 212.0694 
IR: νmax3164, 2876, 1598, 1217, 925; UV: λmax 207.89 nm  
 
3-(4-chloro-N-hydroxybutanamido)propylphosphonic acid (2.3) 
 
Yield: 0.015 g; 30%. 1H NMR (600 MHz, D2O) δ  3.70 (t, J = 6.4 Hz, 2H, CH2-Cl); 3.66 (t, J 
= 6.5 Hz, 2H, P-CH2-CH2-CH2);  2.49 (t, J = 7.5 Hz, 2H, C(O)-CH2); 2.11 (m, 2H, C(O)-CH-
2-CH2); 2.06 (m, 2H, P-CH2-CH2); 1.86 (m, 2H, P-CH2) ppm. 13C NMR: Could not be 
obtained due to fast degradation. 
Mass (ESI-MS): Was not obtained as product was mixed 
IR: νmax 3135, 2873, 1616 (C=O), 1240 (P=O); UV: λmax 206.88 nm  
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Dibenzyl 3-(N-(benzyloxy)-2-iodoacetamido)propylphosphonate (2.39) 
 
Compound 2.34 (0.16 g; 0.32 mmol) and NaI (0.15 g; 0.97 mmol) were dissolved in 20 ml 
acetone at room temperature and stirred overnight. The resulting suspension was filtered and 
the filtrate was concentrated under reduced pressure. The crude product was re-dissolved in 
20 ml EtOAc and washed with 10 ml of water and then with 5 ml of brine. The organic layer 
was dried over Na2SO4 and concentrated in vacuo to yield 2.39 as a yellow oil (0.18 g; 97%). 
 
1H NMR (600 MHz, CDCl3) δ 7.33 (m, 15H, P-O-CH2-Ph-H and N-O-CH2-Ph-H); 5.03 (dd, 
J = 9.1, 11.6 Hz, 2H, P-O-CH2-Ph-H); 4.94 (dd, J = 8.2, 11.8 Hz, 2H, P-O-CH2-Ph-H); 4.85 
(s, 2H, N-O-CH2-Ph-H)); 3.70 (s, 2H, CH2-I); 3.69 (br s, 2H, P-CH2-CH2-CH2); 1.93 (m, 2H, 
P-CH2-CH2); 1.79 (m, 2H, P-CH2) ppm.13C NMR (150 MHz, CDCl3) δ 169.7 (s, C=O); 
136.3 (d, J = 5.7 Hz, 2 x C, P-O-CH2-C=); 133.8 (s, N-O-CH2-C=); 129.19 (s, 2 x CH, N-O-
CH2-C=CH-CH); 129.16 (s, N- O-CH2-C=CH-CH=CH); 128.8 (s, 2 x CH, P-O-CH2-C=CH-
CH=CH-); 128.6 (s, 4 x CH, P-O-CH2-C=CH-CH=); 128.4 (s, 2 x CH, N-O-CH2-C=CH-); 
127.9 (s, 4 x CH, P-O-CH2-C=CH-); 76.3 (s, N-O-CH2-Ph-H); 67.2 (d, J = 6.4 Hz, 2 x CH2, 
P-O-CH2-Ph-H); 45.4 (s, P-CH2-CH2-CH2); 23.2 (d, J = 141.8 Hz, P-CH2); 19.6 (s, P-CH2-
CH2);-5.1 (s, CH2-I) ppm. 
 
Diethyl 3-(N-(tert-butyloxycarbonyl)-2-chloroacetamido)propylphosphonate (2.42) 
 
Et3N (0.08 ml; 0.54 mmol) was added to a solution of compound 2.19 (0.16 g; 0.54 mmol) in 
15 ml dry THF, was added at room temperature and the mixture was stirred for 10 minutes. 
Di-tert-butyl dicarbonate (Boc2O; 0.12 g; 0.54 mmol) was pre-dissolved in 5 ml THF and 
added dropwise at room temperature to the solution of 2.19. The reaction was stirred 
overnight then concentrated under reduced pressure. The crude product was re-dissolved in 
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20 ml CH2Cl2 and washed consecutively with 10 ml saturated solution of NaHCO3, H2O and 
brine. The organic phase was dried over anhydrous MgSO4 and concentrated in vacuo. The 
concentrated organic fraction was purified over SiO2 gel chromatography eluting with 50 ml 
consecutively with 100% CH2Cl2, 50:50 CH2Cl2: EtOAc, 100% EtOAc and 100% MeOH. 
The pure 2.42 was obtained from the 100% EtOAc fraction as a clear colourless oil (0.08g, 
38%).  
1H NMR (400 MHz; CDCl3): δ 4.06 (s, 2H, CH2-Cl); 4.04 (m, 4H, P-O-CH2-CH3); 3.78 (t, J 
= 6.5 Hz, 2H, P-CH2CH2CH2); 1.89 (m, 2H, P-CH2-CH2); 1.73 (m, 2H, P-CH2); 1.50 (s, 9H, 
N-O-C(O)-O-C(CH3)3); 1.27 (t, J = 7.0 Hz, 6H, P-O-CH2-CH3). 13C NMR (100 MHz; 
CDCl3): δ 166.7 (s, C=O); 151.4 (s, N-O-C(O)-O-C(CH3)3); 86.9 (s; N-C(O)-O-C(CH3)3); 
61.6 (d, J = 6.5 Hz, 2 x CH2, P-O-CH2-CH3); 49.0 (s, P-CH2-CH2-CH2); 40.6 (s, CH2-Cl); 
27.4 (s, 3 x CH3, N-C(O)-O-C(CH3)3); 22.7 (d, J = 143.2 Hz, P-CH2); 20.0 (d, J= 4.0 Hz, P-
CH2CH2); 16.3 (d, J = 6.0 Hz,  2 x CH3, P-O-CH2-CH3). 
Mass (ESI-MS): Calculated for C14H27ClNO7P [M + H]+: 388.1290, Found: 388.1289 
IR: νmax3154, 2983, 1663 (C=O), 1259 (P=O), 1027 
 
Diethyl 3-(N-(tert-butoxycarbonyloxy)-2-iodoacetamido)propylphosphonate (2.43) 
 
Compound 2.42 (0.08 g; 0.20 mmol) and NaI (0.92 g; 0.62 mmol) were dissolved in 15 ml 
acetone at room temperature and stirred overnight. The resulting suspension was filtered and 
filtrate was concentrated under reduced pressure. The crude product was re-dissolved in 20 
ml EtOAc and washed with 10 ml of water and then with 5 ml of brine. The organic layer 
was dried over Na2SO4 and concentrated in vacuo to yield 2.43 as yellow oil (0.07 g; 67%). 
1H NMR (400 MHz; CDCl3): δ 4.07 (m, 4H, P-O-CH2-CH3); 3.78 (t, J = 6.6 Hz, 2H, P-
CH2CH2CH2); 3.72 (s, 2H, CH2-I); 1.91 (m, 2H, P-CH2-CH2); 1.77 (m, 2H, P-CH2); 1.53 (s, 
9H, N-O-C(O)-O-C(CH3)3); 1.29 (t, J = 6.4 Hz, 6H, P-O-CH2-CH3). 13C NMR (100 MHz; 
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CDCl3): δ 171.1 (s, C=O); 151.3 (s, N-O-C(O)-O-C(CH3)3); 86.8 (s; N-C(O)-O-C(CH3)3); 
61.6 (d, J = 6.5 Hz, 2 x CH2, P-O-CH2-CH3); 48.4 (s, P-CH2-CH2-CH2); 27.5 (s, 3 x CH3, N-
C(O)-O-C(CH3)3); 22.7 (d, J = 143.9 Hz, P-CH2); 19.9 (br s, P-CH2CH2); 16.4 (d, J = 6.0 Hz,  
2 x CH3, P-O-CH2-CH3); -6.3(s, CH2-I). 
Mass (ESI-MS): Calculated for C14H27INO7P [M + H]+: 480.0650, Found: 480.0657 
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3. SYNTHESIS OF CHLOROQUINE-FOSMIDOMYCIN HYBRIDS 
 
3.1 INTRODUCTION 
Hybridization of drugs has been employed as an effective strategy to overcome drug 
resistance in different areas of medicinal chemistry. Drug hybridization involves linking two 
or more individual drugs or pharmacophores by a covalent bond to make one drug 
compound.148 It has become common practice to use a combination of drugs to treat 
infectious diseases in order to prevent emergence of resistance to the individual drugs and 
improve efficacy due to synergistic effects of the individual drugs. Hybrid drugs while 
sharing the advantages of drug combinations also offer a simpler way of delivering the drugs. 
Other advantages of hybrid drugs may include better patient compliance and more predictable 
pharmacokinetic-pharmacodynamic relationship as compared to two separately dosed drugs. 
 
There has been an increased interest in development of hybrid drugs for the treatment of 
malaria in recent years. Many of these hybrids involve hybridization of two known 
antimalarial drugs e.g. artemisinin-quinine hybrid (Figure 3.1, 1.35)50 or two known drugs 
with different biological activity such as chloroquine-imipramine hybrid (Figure 3.1, 3.1).149 
The artemisinin-quinine hybrid (1.35) combines the fast-acting property of artemisinin with 
the slower and longer acting quinine such that the hybrid has the advantage of a longer half-
life than artemisinin and has a quick onset of action when compared to quinine alone. The 
chloroquine-imipramine hybrid (3.1) was designed to reverse chloroquine resistance even 
though imipramine is not a known antimalarial agent. Since the discovery that chloroquine 
resistance can be reversed, several diverse molecules, termed reversal agents, have been 
identified to reverse chloroquine resistance. Some of the reversal agents have been studied to 
have two aromatic rings usually with an aliphatic nitrogen a few atoms away from the 
aromatic rings. They are postulated to bind and prevent the chloroquine transporter protein 
PfCRT from actively removing chloroquine from the digestive vacuole of the parasite 
(section 1.3.1).58 Examples of identified reversal agents include the calcium channel blocker 
verapamil,150 antipsychotics such as imipramine151 and antihistamines such as 
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chlorpheniramine.152 In this study we investigated hybridized chloroquinoline compound with 
fosmidomycin derivatives. 
 
O
O
H3C
CH3
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O
O O
O
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O
N
HHO
H
NNHN
NCl
1.35
3.1
 
Figure 3.1. Antimalarial hybrids 
 
Fosmidomycin (1.46) and its acetyl analogue FR900098 (1.45) as discussed in chapter 1 are 
inhibitors of DXR in organisms such as E. coli, P. falciparum, and M. tuberculosis. Many 
organisms possessing this enzyme require an active uptake of fosmidomycin and FR900098 
in order to inhibit the enzyme because the compounds are highly hydrophilic and cannot pass 
through membranes unaided. It thus follows that provided these compound could be absorbed 
into the bacteria or plasmodium species, there is a chance that they could inhibit DXR and 
hence the growth of the parasites. Increasing their lipophilic property through ester prodrugs 
has been shown to increase their oral absorption as well as absorption into the parasite. We 
postulated that increasing the lipophilicity of the DXR inhibitors through hybridization with a 
known antimalarial compound would not only increase the absorption of the compounds into 
the parasite but could also provide a dual mode of action for such a hybrid. This is true 
especially if both drugs have different targets within the plasmodium parasite, which is a 
desired property for malaria chemotherapy.  
 
Chloroquine (1.10) was considered for hybridization with fosmidomycin due to its low side 
effect profile, affordability as well as the history of its antiplasmodial success when 
hybridized with other compounds such as shown in Figure 3.1. Chloroquine (CQ) resistance 
(section 1.3.1) is due to mutations in the chloroquine resistance transporter (PfCRT) protein 
and not the ability of the drug to inhibit its target. Hybridizing a CQ-like molecule with 
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fosmidomycin analogues to form a single compound could help overcome the limitations of 
individual compounds.  Of particular interest to us was whether we could produce a hybrid 
compound containing an active fosmidomycin component with improved pharmacokinetic 
profile.  Although we focus on using chloroquine as hybrid component, in this study, it may 
be possible to use other antimalarial drugs in a similar way.  A chloroquine-fosmidomycin 
hybrid may accumulate in the digestive vacuole which would mean that it’s likely not going 
to reach sufficient concentrations in the apicoplast.  In this case it will act as a chloroquine 
analogue targeting haem detoxification.  However, of it is actively transported out of the 
digestive vacuole it will then likely reach the required concentrations to target the apicoplast.  
Furthermore, the most important aspect of this study is to explore the feasibility of extending 
the acyl chain in fosmidomycin into the NADPH binding pocket to give rise to a completely 
novel series of DXR inhibitors. 
 
The hybrid of CQ and fosmidomycin was designed such that chloroquine and fosmidomycin 
retain their functional groups which are necessary for antiplasmodial activity. This meant that 
the CQ moiety would consist of its chloroquinoline core for activity as well as two basic 
nitrogen atoms for concentration within the acidic digestive vacuole of the parasite. The 
fosmidomycin moiety would also retain the phosphonate group and the retrohydroxamate 
group which is necessary for metal chelation at the active site of the DXR enzyme where it 
exhibit its inhibitory property.   
 
3.1.1 Approach to the design and synthesis of chloroquine-fosmidomycin hybrids 
It has been established that the binding pocket at the active site of DXR into which 
fosmidomycin binds requires a free phosphonic acid in order to bind and inhibit the 
enzyme.88 Hybridization of fosmidomycin to chloroquine derivative was considered at the 
phosphonate end, the hydroxamate end and at the α-position to the phosphorus. Due to the 
fact that the enzyme is flexible, it has been suggested that the phosphonate binding pocket 
within the DXR active site might also be able to accommodate a very small functional group 
but not a group as big as a chloroquinoline derivative. This left the options of hybridizing the 
fosmidomycin analogue with the quinoline derivative on the carbon at α-position to the 
phosphorus atom or at the hydroxamate side chain. This resulted in the two proposed hybrid 
Chapter 3            Synthesis of chloroquine-fosmidomycin hybrid 
___________________________________________________________________________ 
 Page | 116 
 
structures 3.2 and 33 respectively (Figure 3.2). While substitution of fosmidomycin (1.46) 
and FR900098 (1.45) at these two sites often show reduced inhibitory activity of the 
compounds, some successes have been reported such as the α-substituted compound 1.80 
(section 1.7.5) and the extended side chain analogue 1.70 (section 1.6.4) discussed in Chapter 
1. Recent research in DXR inhibitor design has focused on exploring the binding pocket 
alpha to the phosphonate.104, 107, 121, 130 Relatively little attention has been paid to the 
possibility of exploring the NADPH binding pocket of DXR. Support for this idea was 
obtained from docking studies of the fosmidomycin-chloroquine hybrids 3.3 and 3.4 (Figure 
3.2) on DXR in the absence of NADPH, which gave promising inhibition results on E. coli 
DXR (Chapter 4). 
R N
OH
O
P
HN
O
OH
OH
NH
NCl
N P
OH
OH
N
H
O
H
N
N
Cl
O
OH
3.2
3.3 n = 1
3.4 n = 2
n
n
 
Figure 3.2. Proposed structures of chloroquine-fosmidomycin hybrids 
 
Our synthetic strategy employed a convergent synthesis of the hybrid by first constructing the 
fosmidomycin and the chloroquine moieties separately (Scheme 3.1). While the 
aminoquinoline moiety can be easily synthesized by reactions of appropriate diaminoalkane 
with 4,7-dichloroquinoline (2.6), the synthesis of the fosmidomycin component is somewhat 
more complicated as described in Chapter 2. A retrosynthetic method for the synthesis of 
chloroquine-fosmidomycin hybrids 3.3 and 3.4 was developed (Scheme 3.4). Implementing 
the synthetic method then gave rise to some of the halogenated fosmidomycin which was 
explored in the previous chapter. Aminoquinoline (3.5) is easily synthesised from the reaction 
of 4,7-dichloroquinoline (3.6) and diaminoethane (3.7). Reaction of the quinoline with the 
halogenated analogues was expected to result in chloroquine-fosmidomycin hybrids.  
 
The antiplasmodial results of the halogenated fosmidomycin analogues had shown the 
derivatives with acetyl side chain to be the most potent and to a lesser extent the propyl 
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analogues. It was unknown if the length of the side chain, which was to be a linker between 
the hybridized compounds, would have any effect on the antiplasmodial activity of the 
hybrids. Thus the effect of varying the length of the carbon chain between the fosmidomycin 
and the aminoquinoline group was investigated by synthesizing hybrids with acetyl and 
propyl linkers (3.3 and 3.4 respectively). 
 
 
Scheme 3.1. Retrosynthetic analysis of the chloroquine-fosmidomycin hybrids 
 
3.2 RESULTS AND DISCUSSION 
 
3.2.1 Synthesis of chloroquine-fosmidomycin hybrids 
A detailed discussion of the synthesis of a number of halogenated FR900098 analogues is 
presented in Chapter 2.  The synthesis of the chloroquine part of the hybrid involve the 
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reaction of 4,7-dichloroquinoline (3.6) with 1,2-diaminoethane (3.7) by heating at 110oC for 
six hours to obtain 3.5.153 Compound 3.5 possesses the chloroquinoline core and two basic 
nitrogen atoms required for the compound to be active against plasmodium species.  The 
fosmidomycin components of the hybrid included the iodoacetyl derivative 2.15 and the 
iodopropionyl derivatives 2.16. In two separate reactions 2.15 and 2.16 were stirred with 3.5 
at room temperature overnight to obtain 3.8 and 3.9 respectively (Scheme 3.2). The primary 
amine of 3.5 was able to displace iodine from the fosmidomycin components to covalently 
link the two parts of the hybrids, giving 3.8 in 48% yield and 3.9 in 79% yield. 
 
 
Scheme 3.2. Synthesis of chloroquine-fosmidomycin hybrids 3.8 and 3.9 
 
3.2.2 Structure analysis of chloroquine-fosmidomycin hybrids 
High resolution mass spectroscopy of 3.9 showed a molecular ion peak at m/z 577.2339. This 
is consistent with the molecular formula C28H38ClN4O5P expected for the hybrid. Due to the 
fact that the hybrid was synthesized by combining the completely synthesized quinoline and 
fosmidomycin analogue segments it was not surprising to see that the NMR spectra of the 
hybrid was similar in part to the NMR spectra of the individual components with 
characteristic phosphonate splitting as described in Chapter 2. 
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Figure 3.3. 1H NMR spectrum (CDCl3, 400 MHz) of 3.9 
 
Two dimensional and one dimensional NMR analysis of the hybrids were conducted to 
ensure that the two segments making up the hybrids were linked and were not present as 
individual components of a mixture.  The 1H NMR spectrum of 3.9 showed eight methylene 
protons (Figure 3.3 and Table 3.1) with characteristic overlapping of the phosphorus coupled 
signals. The methylene at δ 4.04 was coupled to the methyl triplet at δ 1.26, confirming the 
ethyl ester group of the compound. The methylene shift at δ 1.93 (H-2) showed 1H-1H COSY 
correlations to δ1.73 (H-1) and 3.37 (H-3), which is the same pattern observed for H-1, H-2 
and H-3 for compound 2.16. The more deshielded signals at δ 2.60 (H-5) and 2.90 (H-6) 
showed COSY correlations to each other and an HMBC correlations to the carbonyl carbon at 
δ 173.97 (C-4). The most important relationship was the HMBC correlations of the 
methylene protons at δ 2.90 (H-6) and 2.97 (H-7) to the carbons at δ 46.99 (C-7) and 43.93 
(C-6) respectively (Table 3.1). This confirmed that the two components i.e. the quinoline and 
the fosmidomycin analogue components making up the hybrid were linked. The structure of 
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3.8 was similarly elucidated and all other spectroscopic data obtained for 3.8 and 3.9 
confirmed the structures of the hybrids.  
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Table 3.1. 1Dand 2D NMR (400 MHz) data of 3.9 in CDCl3 
 
 
PositionII δ 1H (#; mult; JHZ) 13C (#; mult; JHZ) 1H-1H COSY 1H-13C HMBC 
2’
 
1.26 (6H; t; 7.0) 16.39 (2 x CH3; d; 5.9)  H-1’ C-1’ 
1’
 
4.11 – 3.96 (4H; m) 61.61 (2 x CH2; d; 6.5) H-2’ C-2’ 
1
 
1,79 – 1.66 (2H; m) 22.97 (CH2; d; 142.7) H-2 C-2 
2
 
2.01 – 1.85 (2H; m) 20.20 (CH2; br s) H-1; H-3 C-1 
3
 
3.72 (2H; t; 6.2) 45.37 (CH2; s) H-2 C-2 
4  173.97 (C=O; s)   
5 2.60 (2H; t; 5.6) 32.41 (CH2; s) H-6 C-4; C-6 
6 2.90 (2H; t; 5.7) 43.93 (CH2; s) H-5 C-4; C-7; C-8 
8 2.97 (2H; t; 5.4) 46.99 (CH2; s) H-9 C-6 
9 3.32 (2H; s) 41.93 (CH2; s) H-8; H-10  
10 6.13 (1H; br s)  H-9  
11  150.08 (C; s)   
12 6.34 (1H; d; 5.4) 98.97 (CH; s) H-13 C-13 
13 8.48 (1H; d; 5.3)  151.90 (CH; s) H-12 C-11 
15  140.03 (C; s)   
16 7.91 (1H; s) 128.43 (CH; s)  C-18 
17  134.72 (C; s)   
18 7.37 – 7.26 (1H; m)* 125.00 (CH; s) H-19 C-20 
19 7.86 (1H; d; 8.9) 121.88 (CH; s) H-18 C-11 
20  117. 47 (C; s)   
1” 4.79 (2H; s) 76.38 (CH2; s)   
2” – 7” 7.37 – 7.26 (5H; m)*    
2”  134. 10 (CH; s)   
4” and 6”  129.13 (2 x CH; s)   
5”  129.06 (CH; s)   
3” and 7”  128.73 (2 x CH; s)   
*overlapping chemical shifts 
                                                 
IIAtoms are numbered for easier comparison and are not the standard numbering system 
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3.2.3 Attempted Deprotection of the Chloroquine-fosmidomycin hybrids 
Deprotection of the hybrid was desired to compare the effect of the free phosphonic acid on 
absorption and antiplasmodial activity of the compounds. This was attempted in stages i.e. 
debenzylation of the hybrids followed by ester hydrolysis. Initial attempts to remove the 
benzyl protecting group of 3.8 by hydrogenation using Pd/C resulted in degradation of the 
sample. The catalyst was then changed to Pd(OH)2/C, also to no avail. It was suspected that 
the presence of the aliphatic amines was hindering hydrogenolysis of the hybrid as they have 
been known to cause problems during debenzylation.154 To investigate this hypothesis 1,2-
diaminoethane (3.7) was reacted with the alkene analogue 2.10 of 2.16 to produce 3.10 and 
thereafter hydrogenolysis of the product was conducted with Pd/C. The reaction was 
successful and the benzyl protecting group was hydrolysed from the N-oxime to afford 3.11 
(Scheme 3.3). This disproved the hypothesis that the aliphatic amines were responsible for 
the prevention of hydrolysis of the benzyl group from the hybrid. Unfortunately no reaction 
was observed between 4,7-dichloroquinoline (3.6) and 3.11 when stirred together overnight 
to try and obtain the desired benzyl deprotected hybrid 3.12.  
 
Scheme 3.3. Attempted preparation of deprotected hybrid 3.12 
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The hydrogenolysis method was modified to attempt debenzylating 3.9. The reaction was 
carried out under inert atmosphere, which involved degassing a hot mixture of 3.9 with Pd/C 
in MeOH and introducing N2 gas. Cyclohexene was added to the system as the hydrogen 
donor and stirred overnight at room temperature. The crude product after workup did not 
show the desired semi-deprotected hybrid 3.12.  
 
After all attempts to use a mild hydrogenation method failed, a harsher method of 
debenzylation using BCl3 was employed. Due to the small amount of hybrid available, the 
method was carried out on the fully protected fosmidomycin backbone 2.7 in order to 
determine if the method will be successful in the production of 3.13 before applying it to the 
hybrids. A 1 M solution of BCl3 in CH2Cl2 was introduced into the reaction vessel containing 
2.7 in dry CH2Cl2 at -78oC. The temperature was kept at -60oC for three hours and thereafter 
allowed to heat up to room temperature and stirred overnight (Scheme 3.4). 1H NMR of the 
crude product after work up did not indicate presence of the Boc group and an attempt to 
purify this crude product mixture did not yield the desired compound.  
 
 
Scheme 3.4. Attempted debenzylation of fosmidomycin backbone 2.7 
 
In a last attempt to deprotect the hybrid, the ethyl group of the phosphate ester of 3.9 was 
substituted with benzyl group. The benzyl protected hybrid 3.14 was synthesized by reacting 
3.5 with 2.363, a benzyl protected analogue of 2.10. The hybrid was then hydrogenated at 
atmospheric pressure using Pearlman’s catalyst and AcOH (Scheme 2.5). Analysis of the 1H 
NMR of the product showed broad peaks that were inconclusive in determining the presence 
of starting material or product. However, the benzyl group still appeared in the spectrum 
indicating that the reaction had again been ineffective at yielding the desired unprotected 
hybrid 3.4.  
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Scheme 3.5. Attempted synthesis of deprotected hybrid 3.4 
 
Having unsuccessfully attempted various methods of benzyl deprotection to synthesize the 
free hybrid, it was decide that the protected hybrid alone would be tested for antiplasmodial 
activity. Whilst it would have been useful to compare the effectiveness of the protected 
hybrid versus the unprotected hybrid, the antiplasmodial activity of the protected hybrid was 
expected to be higher against the Plasmodium parasite. This is because the protective groups 
would increase the lipophilicity of the compounds. This in turn would increase the absorption 
of the compound into the parasite where in vivo deprotection might occur to release the free 
hybrid for activity.  
 
3.2.1 Antiplasmodial activity of fosmidomycin hybrids 
Antiplasmodial activity of the hybrids and their intermediates were determined against CQR 
Gambian FCR-3 strain of P. falciparum. The chloroquinoline group of compounds showed 
the best antiplasmodial activity against the parasite even when compared with the active 
halogenated fosmidomycin analogues  (Table 3.2), exhibiting IC50 < 5µM. 
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Table 3.2 Antiplasmodial activity of Chloroquine-fosmidomycin and their intermediates 
against CQS D10 and CQR FCR-3 strains of P. falciparum 
  % parasite survival (CQS D10) CQR FCR-3 
Comp  20 
(µg/ml) 
10 
(µg/ml) 
5 
(µg/ml) 
*IC50 
(µM) 
IC50 
(µM) 
SD 
3.5 
 
6.5 3.3 8.7 15.2 0.02 0.01 
2.15 
 
0.02 2.4 2.0 6.0 8.08 0.91 
2.16 
N
O
OBn
P
OEt
O
OEt
I
 
26.6 59.7 75.0 26.9 ND ND 
2.4 
 
100 98 95 2133.9 ND ND 
3.8 
 
ND ND ND ND 0.18 0.05 
3.9 
 
10.6 9.0 10.3 6.7 0.82 0.12 
2.10 
N
O
P
OBn
OEt
O
OEt
 
12.8 28.7 66.7 25.9 ND ND 
3.10 
 
36.1 72.2 66.0 36.7 ND ND 
3.11 
 
73.7 73.2 73.4 115.0 ND ND 
2.7 
 
14 21 66 21.9 ND ND 
1.10 
 
Chloroquine 
0.03 0.052 0.089 0.062 0.07 0.01 
ND =Not determined; * = Estimated IC50 values 
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The CQR FCR-3 P. falciparum showed borderline resistance to chloroquine (1.10) at 0.07 
µM (70 nM) seeing that the threshold defining resistance to this strain is 70 – 120 nM. The 
antiplasmodial test of the chloroquine-fosmidomycin hybrids as well as the fosmidomycin 
analogue intermediates provided promising antiplasmodial results. Not surprisingly 
chloroaminoquinoline 3.5 showed the most potent activity against CQR FCR-3 strain of P. 
falciparum with an IC50 of 0.02 µM (Table 3.2). This is even more potent than the literature 
reported IC50 values of 231.1155 and 92 nM27 against CQS D10 P. falciparum.  
 
The acetyl linked chloroquine-fosmidomycin hybrid 3.8 with an IC50 value of 0.18 µM 
against FCR-3 showed four times more antiplasmodial activity than the propyl linked hybrid 
3.9 with an IC50 value of 0.82 µM. This indicates that the length of the linker between the 
hybrid components is important for the antiplasmodial activity of the hybrids. For the reason 
that these hybrids are fully protected and are unlikely to fit into the DXR active site, coupled 
with the fact that the chloroaminoquinoline 3.5 showed better antiplasmodial activity than 
these hybrids, it is most likely that the mechanism of action of the hybrids is related to the 
mechanism of action of aminoquinolines. In order to get a better understanding of the 
relationship between the compounds and the DXR enzyme in silico studies of the hybrids 
docked into the active site of DXR was conducted. The study, explored in chapter 4, was also 
expected to provide more information on the role of the different chain linker between the 
two moieties making up the hybrids.  
 
3.2.2 Synthesis of pyrazinoic acid-FR90098 hybrid (3.15) 
Having observed high antiplasmodial activity for the chloroquine-fosmidomycin hybrids 3.8 
and 3.9, the motivation to hybridize fosmidomycin with another class of drug developed. The 
new hybrid was designed such that only the fosmidomycin component would possess 
antimalarial property. This was expected to shed more light on whether both components of 
hybrids 3.8 and 3.9 were responsible for the activity of the compounds or only one of the two 
moieties was responsible. 
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Figure 3.4. Pyrazinoic acid-FR90098 hybrid 
 
Pyrazinoic acid (Scheme 3.6, POA, 3.16), the active metabolite of pyrazinamide used in the 
treatment of tuberculosis was selected for hybridization with fosmidomycin analogues. POA 
(3.16) was selected on the basis that it has a simple structure which is bulky enough and 
could fit into the DXR active site of fosmidomycin and NADPH as predicted for the 
chloroquine-fosmidomycin hybrid. The compound was also favoured because its hybrid with 
fosmidomycin could provide a drug that is not only active against malaria but also against 
tuberculosis which is another major cause of death by infectious diseases in Africa. At the 
very least if inactive against P. falciparum, the hybrid could create a lead compound from 
which other antimycobacterial agents can be developed since Mycobacterium tuberculosis, 
the causative agent of tuberculosis, also requires DXR for survival.156 Pyrazinamide 
resistance by M. tuberculosis has been reported and is attributed to mutation in the 
pyrazinamidase gene which codes for the pyrazinamidase enzyme that hydrolyse 
pyrazinamide to POA.157 It is therefore envisaged that a hybrid of this drug with 
fosmidomycin might provide reversal for its resistance in the mycobacterium while 
promoting the uptake of fosmidomycin component by the bacterium although this was not the 
focus of this study. 
 
POA-FR900098 hybrid 3.15 emerged from the esterification reaction of POA (3.16) with the 
protected bromine analogue of FR900098, 2.17 (Scheme 3.6). The two components were 
refluxed for six hours to afford hybrid 3.15 at a very good yield of 97%. Attempt to 
debenzylate 3.15 did not yield the desired hydroxamic acid 3.17. 
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Scheme 3.6. Synthesis of Pyrazinoic acid-fosmidomycin hybrid 
 
The structure of the POA-FR900098 was confirmed with 1D and 2D NMR, UV, IR and mass 
spectroscopy. The proton spectrum of the hybrid (Figure 3.5) showed similar spin systems as 
observed for the fosmidomycin moiety of the chloroquine-fosmidomycin hybrids. Signals for 
the ethyl ester were be observed at δ 1.29 (t; 7.0 Hz; 6H; H-2’) and 4.05 (m; 4H; H-1’) while 
the methylene protons of the propyl backbone resonated δ 1.72 (m, 2H; H-1), 1.95 (m, 2H; H-
2) and 3.74 (t; 6.8 Hz; 2H; H-3). The methylene linking the POA to the FR900098 derivative 
was observed as a singlet at δ 5.01. While the benzyl protons could be observed at 7.39, the 
POA aromatic protons were more deshieled at δ 9.32 (s; H-9), 8.75 (s; H-11) and 8.71 (s, H-
12). The carbon data showed the ester and amide carbonyl carbons at δ 167.6 and 163.5 
respectively (Table 3.3). An HMBC correlation between δ 5.01 and 167.6 confirmed the ester 
linkage between the POA component and the FR900098 derivative.   
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Figure 3.5. 1H NMR spectrum (CDCl3; 400 MHz) of POA-fosmidomycin hybrid 3.15  
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Table 3.3 1D and 2D NMR (400 MHz) data of 3.15 in CDCl3 
 
 
PositionIII δ 1H (#; mult; JHZ) 13C (#; mult; JHZ) 1H-1H COSY 1H-13C HMBC 
1’
 
1.29 (6H; t; 7.0) 16.4 (2 x CH3; d; 6.0)  H-2’ C-2’ 
2’
 
4.05 (4H; m) 61.6 (2 x CH2; d; 6.5) H-1’ C-1’ 
1
 
1,72 (2H; m) 22.8 (CH2; d; 142.7) H-2 C-2 
2
 
1.95 (2H; m) 20.0 (CH2; d; 4.7) H-1; H-3 C-1; C-3 
3
 
3.74 (2H; t; 6.8) 46.0 (CH2; d; 19.1) H-2 C-1; C-2 
4  163.5 (C=O; s)   
5 5.01 (2H; s) 62.6 (CH2; s)  C-4; C-6 
7  167.6 (C=O; s)   
8  142.8 (C; s)   
9 9.32 (1H; s) 146.5 (CH; s)  C-11; C-8 
11 8.75 (1H; s) 147.9  (CH; s)  C-9; C-12 
12 8.71 (1H; s)  144.4 (CH; s)   C-8; C-11; 
1” 4.90 (2H; s) 76.38 (CH2; s) 2”  
3” – 7” 7.39 (5H; m)    
2”  133.7 (CH; s)   
4” and 6”  129.4 (2 x CH; s)   
5”  129.4 (CH; s)   
3” and 7”  128.9 (2 x CH; s)   
 
As was the case with the chloroquine-fosmidomycin hybrids 3.8 and 3.9, attempts to 
deprotect the POA-fosmidomycin hybrid 3.15 through hydrogenation using Pd/C as catalyst 
or by treatment with BCl3 were ineffective. At this point it was suspected that the aromatic 
nitrogens might be responsible for the resistance of the hybrids to debenzylation. To 
investigate this, benzoyl chloride (Scheme 3.7, 3.18) was reacted with the fosmidomycin 
backbone 2.4 to afford the protected benzyl fosmidomycin derivative 3.19 (Scheme 3.7). The 
benzyl group of compound 3.19 was easily hydrolysed through hydrogenation with Pd/C to 
give 3.20. This further reiterate that the presence of aromatic nitrogen is responsible for the 
                                                 
IIIAtoms are numbered for easier comparison and are not the standard numbering system 
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resistance to debenzylation observed for both the chloroquine-fosmidomycin hybrids 3.8 and 
3.9 as well as the POA -fosmidomycin hybrid 3.15. While it was desirable to have the free 
hydroxamic acids for comparison with fosmidomycin (1.46) and FR900098 (1.45), it was 
expected that the presence of the protective groups on the hybrids would increase the 
lipophilicity of the compounds and thus render them more absorbable through the parasite 
membrane than the free acid derivatives. 
 
Scheme 3.7. Synthesis and debenzylation of benzyl substituted fosmidomycin analogue 
 
3.2.3 Antiplasmodial activity of pyrazinoic acid-FR90098 hybrid (3.15) and benzyl 
substituted fosmidomycin analogue 
The antiplasmodial activity of the POA-fosmidomycin hybrid 3.15 as well the benzyl 
substituted fosmidomycin analogues 3.19 and 3.20 were tested against CQS P. falciparum 
D10 strain. The brominated fosmidomycin intermediate 2.17 was also tested for comparison.  
 
The POA-FR900098 hybrid 3.15 and the benzyl fosmidomycin analogues 3.19 and 3.20 had 
no significant activity on the plasmodium parasite (Table 3.4). This also promotes the fact 
that the antiplasmodial activity observed for chloroquine-fosmidomycin hybrids was most 
probably due to the aminoquinoline moiety of the compounds. 
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Table 3.4. Antiplasmodial activity of POA-FR900098 hybrid and fosmidomycin derivatives 
  D10: % parasite survival   
Comp Structure 20 µg/ml 10 µg/ml 5 µg/ml Cal. IC50 
(µM) 
cLogP 
3.15 
 
78.7 91.7 87.4 110.4 1.524 
2.17 
 
0.00 3.04 26.1 11.1 2.271 
3.19 
 
62.7 71.2 73.7 62.2 3.246 
3.20 
 
88.4 87.5 79.8 412.3 1.327 
 
 
In conclusion the fosmidomycin derivatives were successfully hybridized with a quinoline 
derivative, POA and benzoyl chloride. Only the hybrid with quinoline derivatives were 
however active against P. falciparum indicating that the activity is most probably due to the 
quinoline moiety than the fosmidomycin constituent. It would be useful to obtain the free or 
deprotected form of the hybrid in order to determine if the lack of apparent fosmidomycin 
activity is as a result of the protection or if the size of the molecule is perhaps preventing the 
binding of the hybrid to the DXR enzyme  
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3.3 EXPERIMENTAL 
 
3.3.1 Antiplasmodial assays 
The Antiplasmodial assays were carried out as described in sections 2. 4.1 and 2.4.2. 
 
3.3.2 General experimental, equipment, chemicals and reagents 
The details of the general experimental, equipment, chemicals and reagent used were as 
described in section 2.4.3 
 
3.3.3 Synthetic procedures and spectroscopic data 
N1-(7-chloroquinolin-4-yl)ethane-1,2-diamine (3.5) 
 
1,2-Diaminoethane (3.7, 1.7 ml; 25.43 mmol) was stirred with 4,7-dichloroquinoline (3.6, 
1.03 g; 5.18 mmol) at 1100C for 6 hours under N2 gas. The reaction mixture was cooled to 
room temperature and 25 ml 1.0 M NaOH solution was added and the mixture extracted three 
times with CH2Cl2. The combined organic layers was washed with water and brine and dried 
over anhydrous Na2SO4. CH2Cl2 was removed under reduced pressure to obtain pure pale 
yellow crystals (0.89 g; 77%).  
1H NMR (400 MHz, CDCl3) δ 8.50 (d, J = 5.3 Hz, 1H, -N-C=CH-CH=); 7.93 (br s,1H, =N-
C=CH-C-Cl); 7.71 (d, J = 8.9 Hz, 1H, Cl-C=CH-CH=); 7.33 (br d, J = 8.9 Hz, 1H, Cl-C=CH-
CH=); 6.38 (d, J = 5.35 Hz, 1H, -N-C=CH-CH=); 5.27 (s, 2H, NH2), 3.31 (m, 2H, -NH-CH2), 
3.10 (m, 2H, CH2-NH2) ppm.13C NMR (101 MHz, CDCl3) δ 152.1(s, -NH-C=CH-CH=); 
149.9 (s, -NH-C=); 149.2 (s, =N-C=C-); 134.81 (s, Cl-C=C-); 128.8(s, =N-C=CH-C-Cl); 
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125.2 (s, Cl-C=CH-CH); 121.2 (s, Cl-C=CH-CH=); 117.4 (s, Cl-C=CH-CH=C-); 99.2 (s, -
NH-C=CH-CH=); 44.8 (s, -NH-CH2-); 40.2 (s, CH2-NH2) ppm. mp 43-45 oC.158 
 
Diethyl 3-(N-(benzyloxy)-2-(2-(7-chloroquinolin-4-
ylamino)ethylamino)acetamido)propylphosphonate (3.8) 
 
In 10 ml MeOH, 0.27 g (0.58 mmol) of 2.15 and 0.28 g (1.27 mmol) of 3.5 were dissolved 
and stirred at room temperature overnight. The yellow solution was concentrated and 
redissolved in H2O (20 ml). The dissolved solution was extracted three times with EtOAc 
(10ml) and the combined fraction washed with brine (5ml). The organic phase was dried over 
Na2SO4 and concentrated under vacuum. The crude product was purified over a sephadex 
column (10 g) eluting with MeOH and the obtained fraction was further purified over 10 g of 
silica gel column chromatography eluting with MeOH to afford 3.8 (0.15g; 48%).  
1H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 5.30 Hz, 1H, -N-C=CH-CH=); 7.87 (s, 1H, =N-
C=CH-C-Cl); 7.85 (s, 1C, Cl-C=CH-CH=); 7.30 (m, 6H, Cl-C=CH-CH= and Ar-H); 6.34 (s, 
1H, Quinoline-NH-); 6.27 (d, J = 5.36 Hz, 1H, -N-C=CH-CH=); 4.75 (s, 2H, N-O-CH2-Ph); 
4.04 (m, 4H, P(O)-CH2); 3.74 (t, J = 6.15 Hz, 2H, P-CH2-CH2-CH2);3.44 (s, 2H, C(O)-CH2); 
3.21 (t, J = 4.86 Hz, 2H, -NH-CH2-CH2-N-quinoline); 2.84 (t, J = 4.86 Hz, 2H, -NH-CH2-
CH2-NH-quinoline); 1.95 (m, 2H, P-CH2-CH2); 1.71 (m, 2H, P-CH2); 1.26 (t, J = 7.01 Hz, 
6H, P(O)-CH2-CH3) ppm. 13C NMR (100 MHz, CDCl3) δ 173.6 (s, C=O); 151.8 (s, -NH-
C=CH-CH=); 150.0 (s, -NH-C=); 148.9 (s, =N-C=C-); 134.6 (s, Cl-C=C-); 133.7 (s, N-O-
CH2-C=CH); 129.3 (s, 2 x CH, N-O-CH2-C=CH-CH=); 129.2 (s, N-O-CH2-C=CH-CH=CH); 
128.7 (s, 2 x CH, N-O-CH2-C=CH-); 128.2 (s, =N-C=CH-C-Cl);125.0 (s, Cl-C=CH-CH); 
121.9 (s, Cl-C=CH-CH=); 117.3 (s, Cl-C=CH-CH=C-); 98.7 (s, -NH-C=CH-CH=); 76.2 (s, 
N-O-CH2-Ph); 61.6 (d, J = 6.55 Hz, 2 x CH2, P(O)-CH2); 49.2 (s, C(O)CH2); 47.4 (s, -NH-
CH2-CH2-NH-quinoline); 45.8 (s, P-CH2-CH2-CH2); 42.3 (s, -NH-CH2-CH2-NH-quinoline); 
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22.9(d, J = 142.75 Hz, P-CH2);20.1 (s, P-CH2CH2);16.3 (d, J = 5.95 Hz, 2 x CH3, P(O)-CH2-
CH3) ppm. 
Mass (ESI-MS): Calculated for C27H36ClN4O5P [M]+: 563.2190, Found: 563.2186 
IR: νmax 3316, 2981, 1658 (C=O), 1234 (P=O), 960; UV: λmax 216.83 nm  
 
Diethyl 3-(N-(benzyloxy)-3-(2-(7-chloroquinolin-4-
ylamino)ethylamino)propanamido)propylphosphonate (3.9) 
 
In 10 ml MeOH, 0.11 g (0.23 mmol) of 2.16 and 0.10 g (0.46 mmol) of 3.5 were dissolved 
and stirred at room temperature overnight. The crude product was concentrated under 
reduced pressure then re-suspended in CHCl3 and 0.2 ml of MeOH was added. The solution 
was placed on ice for 10 minutes and the supernatant was separated from the precipitated 
excess 3.5. Reverse phase HPLC with 20:80 H2O: MeOH afforded pure, clear, light yellow 
3.9 (0.10 g; 79%).  
 
See Table 2.1 for 1H NMR (400 MHz, CDCl3) and 13C NMR (100 MHz, CDCl3) 
assignments. 
Mass (ESI-MS): Calculated for C28H38ClN4O5P [M]+: 577.2347, Found: 577.2339 
IR: νmax 3321, 2981, 1650 (C=O), 1235 (P=O), 1023; UV: λmax216.23 nm 
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2-(Benzyloxy(3-(diethoxyphosphoryl)propyl)amino)-2-oxoethyl pyrazine-2-carboxylate 
(3.15) 
 
In a flame dried round bottom flask, pyrazinoic acid (3.16, 0.06 g; 0.48 mmol) was dissolved 
in 10 ml acetonitrile. Et3N (0.07 ml; 0.48 mmol) was added to the mixture and temperature 
was allowed to rise to reflux. Compound 2.17 (0.20 g; 0.48 mmol) was introduced into the 
solution and refluxed for six hours. The solution was cooled to room temperature and then 
concentrated under reduced pressure. The crude product was re-dissolved in 30 ml CHCl3 and 
washed twice with 10 ml 5% NaHCO3 solution and once with 10 ml H2O and brine. The 
organic phase was dried over anhydrous MgSO4 and concentrated in vacuo to give pure 0.21 
g 3.15 (79%). 
1H NMR (400 MHz, CDCl3) δ 9.32 (s, 1H, N-CH-C(C=O)); 8.75 (br s, 1H, N-CH-C(C=O)-
N-CH-CH); 8.71 (s, 1H, N-CH-C(C=O)-N-CH); 7.39 (s, 5H, N-O-CH2-Ph-H); 5.01 (s, 2H, 
N-C(O)-CH2-O-C(O-); 4.90 (s, 2H, N-O-CH2-Ph); 4.05 (m, 4H, P(O)-CH2; 3.74 (t, J = 6.8 Hz, 
2H, P-CH2-CH2-CH2);  1.95 (m, 4H; P-CH2-CH2); 1.72(m, 2H, P-CH2); 1.29 (t, J = 7.0 Hz, 
6H, P(O)-CH2-CH3) ppm. 13C NMR (100 MHz, CDCl3) δ 167.6 (s, N-C(O)-CH2-O-C(O)-); 
163.5 (s, N-C(O)-CH2-O-C(O)-); 147.9 (s, N-CH-C(C=O)-N-CH); 146.5 (s, N-CH-C(C=O)-
N-CH-CH); 144.4 (s, N-CH-C(C=O)); 133.7 (s, N-O-CH2-C=CH-); 129.4 (s, 2 x CH, N-O-
CH2-C=CH-CH= and N-O-CH2-C=CH-CH=CH); 128.9 (s, 2 x CH, N-O-CH2-C=CH-); 76.7 
(s, N-O-CH2-Ph); 62.6 (s, N-C(O)-CH2-O-C(O-); 61.6 (d, J = 6.5 Hz, 2 x CH2, P(O)-CH2); 
46.0 (d, J = 19.1 Hz, P-CH2-CH2-CH2); 22.8 (d, J = 142.7 Hz, PCH2 ); 20.0 (d, J = 4.7 Hz,P-
CH2-CH2); 16.39 (d, J = 6.0 Hz, 2 x CH3, P(O)-CH2-CH3) ppm. 
Mass (ESI-MS): Calculated for C21H28N3O7P [M]+: 466.1743, Found: 466.1736 
IR: νmax 3451, 2982, 1679 (C=O), 1237 (P=O); UV: λmax 209.00 nm  
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Diethyl 3-(N-(benzyloxy)benzamido)propylphosphonate (3.19) 
N P
OEt
OBn
O
O
OEt
 
A solution of 2.4 (0.20 g; 0.66 mmol) in CH2Cl2(20 ml) was treated with Et3N (0.11 ml; 0.79 
mmol) at room temperature. The mixture was stirred for 1.5 h, and benzoyl chloride (0.1 ml; 
0.79 mmol) was added dropwise and stirred for another 2.5 h. The mixture was diluted with 
CH2Cl2 (10 ml) and washed with water (20 ml), saturated NaHCO3 solution (20 ml), and 
finally with saturated brine solution (5 ml). The organic layer was separated and dried over 
anhydrous MgSO4. The concentrated product was purified by silica gel (10 g) column 
chromatography first eluting with EtOAc (50 ml), then MeOH/EtOAc (1:9, 50 ml) to give 
0.22 g (81%) pure 3.19 as oil. 
1H NMR (600 MHz, CDCl3) δ 7.64 (d, J = 7.3 Hz, 2H, 2 x NC(O)-C-CH), 7.47 (m, 1H, N-
C(O)-C-CH-CH-CH), 7.40 (m, 2H, 2 x N-C(O)-C-CH-CH), 7.29 (m, 3H, N-O-CH2-Ph-H), 
7.06 (brs, 2H, N-O-CH2-Ph-H)), 4.64 (s, 2H, N-O-CH2-Ph), 4.08 (m, 4H, P(O)-CH2), 3.74 (t, 
J = 6.8 Hz, 2H, P-CH2-CH2-CH2), 2.05 (m, 2H; P-CH2-CH2), 1.81 (m, 2H, P-CH2), 1.30 (t, J 
= 7.1 Hz, 6H, P(O)-CH2-CH3). 13C NMR (151 MHz, CDCl3) δ 170.0 (s, C=O), 134.2 (s, N-
O-CH2-C=CH-), 133.8 (s, N-C(O)-C-CH), 130.4 (s, Ar-C), 129.3 (s, 2 x Ar-C), 128.7 (s, Ar-
C), 128.3 (s, 2 x Ar-C), 128.1 (s, Ar-C), 127.9 (s, Ar-C), 76.3 (s, N-O-CH2-Ph), 61.5 (d, J = 
6.5 Hz 2 x CH2, P(O)-CH2), 46.9 (s, P-CH2-CH2-CH2), 22.8 (d, J = 142.8 Hz, PCH2), 20.4 (d, 
J = 4.6 Hz, P-CH2-CH2), 16.3 (d, J = 6.0 Hz, 2 x CH3, P(O)-CH2-CH3). 
Mass (ESI-MS): Calculated for C21H28NO5P [M]+: 406.1774, Found: 406.1783 
IR: νmax 3454, 2981, 1638 (C=O), 1239 (P=O); UV: λmax 204.80 nm  
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Diethyl 3-(N-hydroxybenzamido)propylphosphonate (3.20) 
 
 
Compound 3.19 (0.12 g) was dissolved in 20 ml MeOH. Pd/C (0.03 g) was added to the 
solution and hydrogen gas was introduced to the mixture by means of a balloon to generate a 
positive pressure. The suspension was stirred for two hours at room temperature after which 
it was filtered through celite. The filtrate was concentrated under reduced pressure to give 
violet coloured oil  3.20 (0.09 g; 98%). 
1H NMR (400 MHz, CDCl3) δ 7.54 (br s, 2H, N-O-CH2-Ph-H), 7.31 (m, 3H, N-O-CH2-Ph-
H), 3.97 (m, 4H, 4H, P(O)-CH2), 3.71 (br s, 2H, P-CH2-CH2-CH2), 1.92 (m, P-CH2-CH2), 
1.73 (m, 2H, P-CH2), 1.21 (t, J = 7.0 Hz, 6H, P(O)-CH2-CH3). 
Mass (ESI-MS): Calculated for C14H22NO5P [M]+: 316.1317, Found: 316.1314 
IR: νmax 3141, 2982, 1614 (C=O), 1280 (P=O), 1016; UV: λmax 201.15 nm 
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4. IN SILICO AND IN VITRO ASSESSMENT OF HALOGENATED FR900098 
ANALOGUES AS DXR INHIBITORS 
 
4.1 INTRODUCTION 
1-Deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) plays a major role in the 
mevalonate independent biosynthesis of isoprenoid units isopentenyl pyrophosphate (IPP) 
and dimethylallyl pyrophosphate (DMAPP) of some bacteria, higher plants and P. falciparum 
as discussed in chapter 1. DXR catalyzes the first committed step of the pathway. Due to the 
absence of the pathway in humans and its necessity for survival of the plasmodium parasite, 
the enzymes involved are good targets for antiplasmodial drug development. We were unable 
to confirm if the antiplasmodial activity of the halogenated fosmidomycin analogues reported 
in chapter 2 was due to DXR inhibition. This part of the study thus explores the direct effect 
of these halogenated FR900098 analogues on DXR in an enzyme inhibition assay. Here we 
also report the affinity of the compounds to DXR through in silico studies. The study 
examined the possibility of the phosphonic acid chloroquine-fosmidomycin hybrids 3.3 and 
3.4 binding to the DXR enzyme in the absence of NADPH. 
 
There has been an increased interest in the development of inhibitors of DXR since the 
discovery of the mevalonate-independent pathway and its inhibition by fosmidomycin in P. 
falciparum.73 Characterization of DXR from different organisms has been successful and has 
led to development of other active inhibitors from the lead compounds fosmidomycin and 
FR900098. 
 
The ability to over-express recombinant proteins, isolate and purify them for inhibition 
studies is essential in drug development. Often the target recombinant protein is expressed in 
a host such as E.coli. E. coli is favoured mostly because of its rapid growth rate, simple 
genetics, ease of handling and low cost as it gives high yield per unit biomass. Recombinant 
DXR from various organisms have been successfully over expressed in E. coli to study the 
kinetics of the enzyme as well as perform inhibition test for inhibitor lead compounds.  While 
it would have been ideal to conduct the inhibition test discussed in chapter 4 on PfDXR, the 
test was carried out on EcDXR. Although some research groups have been able to over 
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express and purify of PfDXR in E. coli,73, 88 this proved difficult during the course of this 
study. It has been reported that plasmodium genes exhibit long clusters of codons which are 
rare in E. coli and consequently lead to problems in protein translation which prevent 
successful expression of plasmodial recombinant protein in E. coli.159 It has been reported 
that the catalytic domain of EcDXR and PfDXR are 36% identical (145 amino acid residues) 
and 54% similar (216 amino acid residues). This represents the vast majority of the residues 
involved in substrate/inhibitor, NADPH binding and divalent metal ion coordination.160 As a 
result either one of the homologues can be used as a model for the inhibition studies to 
discover lead compounds that are active against the enzyme. 
 
Solving the crystal structures of DXR has improved the understanding of the catalytic site of 
the enzyme and has made it possible to conduct in silico studies of potential inhibitors which 
in turn have improved the rate at which active inhibitors are discovered. In silico studies 
provide a means of screening thousands of compounds in a short space of time by 
computationally simulating binding of ligands to the crystal structure of a target receptor or 
protein. Apart from being quick, in silico studies helps to minimize waste of resources 
required in expensive lab work or high-throughput screening and clinical trials to test each 
compound which usually results in less than a 1% hit rate. The docking studies is also used to 
understand the binding or the structure activity relationship between ligands and receptors. 
This study employ the use of molecular modeling to better understand the interaction 
between the halogenated fosmidomycin analogues and the DXR enzyme as well as the 
chloroquine-fosmidomycin hybrid with the enzyme.   
 
 
4.1.1 Short review of crystallographic and modeling studies of DXR 
The PfDXR is essentially very similar in structure to the EcDXR discussed in section 1.6.3. 
In its active form PfDXR is a homodimer which consists of amino acid residues from Lys75 
to Ser488. Each monomer has a molecular weight of approximately 47kDa. The monomer 
consists of the N-terminal domain, which binds NADPH in a similar mode to EcDXR and is 
comprised of residues 77 to 230 forming the biggest of the three domains. The catalytic 
domain comprises of residues 231 to 369 and the small C-terminal domain extends over 
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residues 396 to 486. The lid which closes upon substrate/inhibition binding spans the length 
of amino acid residues 291 to 299.88 
 
The second step in the mevalonate independent pathway of isoprenoid synthesis involved the 
intramolecular rearrangement and reduction of the substrate 1-deoxy-D-xylulose 5-phosphate 
(DOXP) to 2-C-methyl –D-erythritol 4-phosphate (MEP) by DXR. The reaction is dependent 
on the presence of divalent metal ion Mn2+, Co2+ or Mg2+ and NADPH cofactors. Each of the 
three divalent metal ions have been shown to activate DXR and although initial studies have 
shown Mn2+ to be the most effective161, Koppisch and co-worker found all three to be equally 
effective in E. coli.162 Based on the fact that Mg2+ is more abundant in cells as it has been 
found in Synechocystis sp. PCC6803,163M. tuberculosis,164and E. coli,162 it is suggested to be 
the more relevant cofactor for DXR activity in vivo. 
 
Over the past decade, a number of crystal structures of DXR has been solved and reported 
from E. coli,89-94 M. tuberculosis,165, 166 Zymomonas mobilis,167 Thermotogamaritime,168 and 
very recently the first report on P. falciparum.88 The crystal structures were solved to provide 
a better understanding of the catalytic activity of the enzyme in order to be able to rationally 
design inhibitors as potential antimalarial drugs. The structures were reported as apo enzymes 
and in complexes.  The apo form of EcDXR was first reported by Reuter and co-worker (pdb 
code: 1K5H).90 Since then many complexes of the enzyme have been reported by various 
groups. These include EcDXR with sulphate ion and NADPH (1JVS),92 with Mn2+ and 
fosmidomycin (1ONP),91 with sulphate and bisphosphonate ions (1T1R and 1T1S),93 with 
DOXP and NADPH(1Q0Q) and with NADPH and fosmidomycin (1Q0L).89 Yajima et al.94 
reported the complexed structure of EcDXR with NADPH, Mg2+ and fosmidomycin (2EGH), 
the only study that has reported the full cofactors for EcDXR. These quaternary structures of 
EcDXR while overall very similar, showed slight differences to each other particularly in the 
flexible loop, which is completely disordered in the apo enzyme but ordered and in contact 
with fosmidomycin in the complex structure that includes the NADPH, Mg2+ and the 
inhibitor. Slight differences in the orientation of the catalytic centre was also observed when 
1Q0L, 1ONP and 2EGH were compared, which reflects the structural flexibility of the DXR 
conformation.94 Umeda and co-workers88 solved the crystal structure of PfDXR and reported 
the enzyme in complex with fosmidomycin, Mg2+ and NADPH (3AU9) and also in complex 
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with Mg2+, NADPH and FR900098 (3AUA). This was the first time DXR has been reported 
in complex with FR900098 which is more potent against PfDXR than fosmidomycin.   
 
4.1.2 Approach and specific objectives of the DXR inhibition assay 
Many of the halogenated fosmidomycin derivatives synthesized and reported in chapter 2 
exhibited good antiplasmodial activity against CQS and CQR strains of P. falciparum. One of 
the observations made however was that while the protected halogenated compounds 2.4, 
2.15, 2.17 and 2.19 – 2.21 were even more active than FR900098, the protected non-
halogenated FR900098 analogues 2.12 and 2.18 were inactive against the parasite. This was 
intriguing as the conditions under which the assay was carried indicated hydrolysis of ester 
protected compounds110 possibly by non-specific esterases. No report was found on whether 
P. falciparum possess debenzylating enzymes and as a result cannot be confirmed that the 
protected compounds had been hydrolysed to hydroxamic acid which is necessary for 
chelation of the metal at DXR active site. While this could explain why 2.12 was inactive, it 
does not explain why 2.18 was inactive as it is not protected at the hydroxamate end.  It was 
considered that the halogens are either solely responsible for the activity of the halogenated 
analogues at the enzyme’s active site or they have alternative targets in the parasite. In order 
to investigate this theory, the direct effects of the compounds including the de-protected 
analogues 2.1 – 2.3 and 2.38 were tested in a preliminary E. coli DXR inhibition assay. 
EcDXR was used for the assay due to the ease with which recombinant EcDXR is over 
expressed and purified while purification of PfDXR is proved to be more difficult. However 
due to the similarities between the homologues, EcDXR is expected to be a good model of 
PfDXR and the result of the inhibition would be useful in making a informed conclusions 
about the binding of the compounds to the plasmodium DXR.  
 
While many in silico studies are geared towards discovering lead compounds that can be 
synthesized and then tested for activity, in this project the in silico study served to explain the 
binding affinity of the active halogenated fosmidomycin analogues to DXR. The docking 
studies further helped to compare the affinity of the compounds for EcDXR and PfDXR and 
consolidate the result obtained from the inhibition assay. The halogenated fosmidomycin 
analogues as well as fosmidomycin (1.46) and FR900098 (1.45) were docked into the crystal 
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structure of EcDXR (pdb code: 2EGH) and Pf DXR (pdb code: 3AUA) obtained from the 
Protein Data Bank. 
 
The aim of these studies were thus to determine the effect of the halogenated fosmidomycin 
analogues on EcDXR in an enzyme inhibition assay and to determine the binding energies of 
the active compounds to both the plasmodium and the bacterium DXR enzyme in an in silico 
study. As such the specific objectives of these studies included:  
1. Conducting inhibition studies of halogenated FR900098 analogues and  
2. Conducting in silico studies of the halogenated FR900098 derivatives on both PfDXR 
and EcDXR.  
 
4.2 RESULTS AND DISCUSSION 
 
4.2.1 EcDXR assay of halogenated fosmidomycin analogues 
DXR inhibition assay was developed by Kuzuyama et al. (1998)169 and had been widely used 
in screening potential inhibitors. The assay has been used successfully for testing of inhibitors 
on both recombinant EcDXR and PfDXR.  For the purpose of this study, recombinant E. coli 
DXR was over expressed, produced in competent E. coli cells and purified. Inhibition of the 
enzyme was assessed based on the consumption of NADPH which is necessary for reduction 
step in the conversion of DOXP to MEP. The depletion of NADPH was monitored by 
spectrophotometric measurement of the optical density of the reaction solution over 10 
minutes at 340nm. The enzyme was initially pre-incubated with the inhibitor for five minutes 
at 37oC. The reaction was initiated by addition of the pre-incubated enzyme-inhibitor solution 
to a similarly incubated solution of MnCl2, Tris-HCl, NADPH, DOXP and ddH2O in 1 well 
of a 96-well UV microtitre plate. Pre-incubation was carried out because fosmidomycin, the 
known inhibitor of this enzyme is a slow, tight-binding inhibitor and the halogenated 
FR900098 analogues were expected to bind the same way. Pre-incubation of DXR with 
fosmidomycin for five minutes was found to be long enough to establish full binding of the 
enzyme to fosmidomycin without saturating it.162 
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A preliminary inhibition test of compounds 2.1 – 2.3, 2.8, 2.9, 2.11, 2.12, 2.18 – 2.24 and 
2.38 against EcDXR at 5µM concentration was conducted with FR900098 (1.45) as a 
positive control. Five other controls were employed in the experiment. This included the 
assay in the absence of NADPH, MnCl2, substrate, inhibitor and the DXR enzyme. The assay 
was blanked against the control lacking the DXR enzyme. The rate of activity of the enzyme 
in the presence of the FR900098 analogues was determined as the slope of the initial linear 
stage of the reaction and expressed as a percentage of the rate of activity of the enzyme in the 
absence of an inhibitor (Equation 4.1; Table 4.1) 
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Table 4.1. Relative percentage inhibition of FR900098 analogues on EcDXR at 5 µM 
concentration 
 
Compound  R1 R2 R3 Relative rate (%)a 
2.15 Et Bn -CH2I 88.7 
2.16 Et Bn -CH2CH2I 103.4 
2.17 Et Bn -CH2Br 111.3 
2.1 H H -CH2Cl 38.5 
2.2 H H -CH2CH2Cl 28.5 
2.3 H H -CH2CH2CH2Cl 92.3 
2.8 Et Bn -CH2Cl 101.7 
2.9 Et Bn -CH2CH2Cl 90.6 
2.11 Et Bn -CH2CH2CH2Cl 102.3 
2.12 Et Bn -CH3 83.8 
2.18 Et H -CH3 103.4 
2.19 Et H -CH2Cl 88.7 
2.20 Et H -CH2Br 87.0 
2.21 Et H -CH2I 99.1 
2.22 Et H -CH2CH2Cl 100 
2.23 Et H -CH2CH3 105.7 
2.24 Et H -CH2CH2CH2Cl 100.4 
2.38 H H -CH2CH3 77.2 
FR900098 (1.45) H H -CH3 24.7 
aRelative to uninhibited reaction (i.e. no inhibitor = 100%) 
 
As shown in Table 4.1, FR900098 (1.45) clearly showed the best inhibition of EcDXR 
activity to 24.7% at 5 µM concentration. This was followed closely by phosphonic acids 2.2 
(28.5%) and 2.1 (38.5%). This shows the need for a free phosphonic acid in order for the 
compound to bind and inhibit the enzyme. In contrast, some of the bulky protected analogues 
such as 2.15 and 2.12 showed a small reduction in the activity of the enzyme to 88.7 and 
83.8% respectively. This could be an indication of possible displacement of NADPH from 
the active site but due to the protected hydroxamate group it was unable to chelate metals or 
bind strongly enough to significantly inhibit the enzyme.  
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Interestingly, the propyl phosphonic acid 2.2 showed a stronger inhibition of EcDXR than the 
acetyl phosphonic acid 2.1. This is contrary to the antiplasmodial result which showed the 
shorter chained 21 to be more active. The result observed for the enzyme inhibition could 
possibly be due to competitive displacement of the smaller compound 2.1 from the active site 
of the enzyme by the substrate. The chlorobutyryl phosphonic acid 2.3 as expected did not 
show any appreciable inhibition of the enzyme reducing the activity to 92.3%. This is likely 
because the chlorobutyryl side chain is long and unable to fit into the hydroxamic acid 
binding pocket of the enzyme.  
 
The chlorinated phosphonic acid 2.2 showed superior inhibition of EcDXR over its 
unchlorinated analogue 2.38 (77.2%) indicating that the presence of the chlorine atom 
contributes to its DXR inhibition activity. Conversely, the effect of chlorine appears to be 
secondary to the effect of lengthening the acyl side chain. This is observed with the 
chlorinated phosphonic acid 2.3 only reducing the activity of DXR to 92.3% while the 
unchlorinated propyl phosphonic acid reduced the activity to 77.2%. The observation is 
further supported by the fact that FR900098 (1.45) showed the highest inhibition despite not 
having any chlorine atom in its structure. Although the result indicate the acetyl chain to be 
the optimum acyl side chain of the FR900098 analogues, it does not preclude the possibility 
that the enzyme might be able to accommodate larger groups in the absence of NADPH from 
the site of action. 
 
Phosphonic acids 2.1 and 2.2 showed higher enzyme inhibition but lower antiplasmodial 
activity than their protected analogues 2.8 and 2.9 respectively. This signifies the possibility 
that the protected analogues might have been better absorbed by the Plasmodium and then 
hydrolyzed to the respective phosphonic acids. It is quite possible the unprotected compounds 
2.8 and 2.9 could have other targets once absorbed into the parasite especially since they 
carry a possibly reactive chlorine atom. 
 
The enzyme inhibition assay showed DXR activity increase when some of the halogenated 
fosmidomycin analogues such as 2.17 was tested. It is not impossible that these compounds 
potentiate or induce the enzyme activity. However, this will contradict the antiplasmodial 
result especially for 2.17 which showed potent activity against the parasite. Alternatively, if 
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these compounds induce DXR their antiplasmodial activity would then be attributed to 
targeting of other proteins or enzyme in the parasite. This will most probably possibly  be due 
to the presence of non-selective reactive halogens that they carry.  
  
This preliminary experimental result shows a high potential for the halogenated phosphonic 
acid analogues of FR900098 especially the chloroacetyl and chloropropyl analogues to 
inhibit EcDXR. Further investigations on the compounds to determine their IC50, cytotoxicity 
and particularly their effect on PfDXR are thus recommended. 
 
4.2.1 In silico studies of halogenated FR900098 analogues 
In silico studies of the halogenated FR900098 analogues were conducted for two reasons: 1) 
To be able to relate the antiplasmodial result to the DXR assay conducted on E. coli DXR and 
2) to investigate the binding affinity of these compounds to both E. coli (pdb code: 2EGH) 
and P. falciparum DXR (pdb code: 3AUA) enzymes. The docking was carried out on both 
DXR enzymes of P. falciparum and E. coli obtained from the protein data bank. The docking 
was carried out on the two enzymes in order to reconcile the result of the antiplasmodial 
activity with the inhibition assay conducted on EcDXR. Although DXR from the two 
organisms are similar, studies have shown that some compounds bind better to one than the 
other, an example been FR900098 which inhibits PfDXR better than EcDXR while 
fosmidomycin exhibit better inhibition towards EcDXR than PfDXR. 
 
E. coli DXR in complex with Mg2+, Fosmidomycin and NADPH (pdb code: 2EGH)  and P. 
falciparum DXR (pdb code: 3AUA) in complex with Mg2+, FR900098 and NADPH were 
obtained from the protein data bank. The enzymes were obtained as dimers and one subunit 
(subunit A) was removed from the enzymes using Discovery Studio Visualizer 3.0170 to allow 
for easier docking and analysis of the docking result. The inhibitors were also removed from 
the respective crystal structures to leave the catalytic site open for the halogenated analogues 
to bind to the enzymes. The docking was conducted on AutoDock 4.2.171 Preparation of the 
enzymes for docking involved removal of water molecules from the enzyme, addition of 
Gastieger charges and spreading non-integral charges across the entire surface of the enzyme. 
A check for missing atoms was conducted and all the missing atoms were replaced. All 
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hydrogen atoms were added and non-polar hydrogens were merged and all possible torsions 
allowed. Residues of the catalytic centres and those that complexed with the hydroxamic acid 
group were made flexible for the binding.  
 
In a living system, DXR exhibit flexibility that allows it to change conformation as required 
especially after binding the substrate or inhibitor. In order to emulate the system in a living 
organism, some residues of the DXR enzymes were made flexible for the docking. Residues 
Ser185, Ser221, Lys227, Asp149, Glu151 and Glu230 were selected as flexible residues for 
the EcDXR docking as these residues were reported to be necessary for the binding of 
fosmidomycin to the enzyme.94 The more residues made flexible, the closer the experiment to 
a biological system. However the drawback to having many flexible residues is that it makes 
it more difficult to reproduce the same docking result when repeated. The residues that bind 
the inhibitor in PfDXR include Ser270, Asn311, His293, Asp231 and Glu315, which were 
made flexible for the docking of 3AUA to the halogenated FR900098 analogues.88  
 
The divalent metal (Mg2+) was assigned a charge of +2.0 as AutoDock automatically assigns 
a charge of 0.0 to the metal. Although many reports involving the docking of DXR to 
inhibitors have paid little attention to the metal ion, Bodil and colleagues highlighted the 
importance of having the charged divalent metal ion present in the docking crystal.118 The 
absence of the metal ion in inhibition assays of DXR has also shown no activity of the 
enzyme indicating its necessity for inhibition. The fact that DXR is inactive in the absence of 
a divalent metal ion also signifies the necessity of the metal being incorporated in the 
experiment.  
 
After selecting the flexible residues, a grid box was created around the active site of the 
remaining rigid structure of DXR. Grid dimensions of 62, 52, 56 along the x, z, y axis 
respectively were used for 2EGH while 58, 60 and 58 were used along the same dimensions 
for the PfDXR 3AUA. All possible atoms in the ligand including Cl, Br and I were mapped 
for docking using AutoDock 4.2.  
 
Preparation of the ligands 2.1 – 2.3, 2.8 – 2.12, 2.15 – 2.24 and 2.38 prior to docking into the 
enzymes involved sketching the compounds using ChemBioDraw Ultra 11.0.1.172 A random 
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rotor search for a global minimum conformation was conducted for each ligand and the best 
conformer was geometrically optimized using Avogadro (version 1.0.3).173 Gasteiger charges 
were added with AutoDock tools, and all non-integral charges were spread over the entire 
molecule. Docking of the compounds was conducted on AutoDock 4.2 which makes use of 
genetic algorithm to search for possible orientation and conformation of the ligands at the 
defined active site of the enzyme. All active and rotatable bonds in the ligands were made 
rotatable except for the amide bonds which were made non-rotatable according to the defaults 
of AutoDock. 
 
The dockings were carried out using the Lamarckian algorithm to create a population of 150 
individuals with 2500000 maximum number of evaluations in 100 GA runs. Although some 
researchers have generated 10 conformations to investigate binding of ligands to proteins, 
generating 100 conformations increases the chance of obtaining conformations closer to the 
conformation that the compound would adopt in a biological system.   
 
The docking conformations which were typically docked at 2.0 Å rmsd were arranged in 
clusters from lowest to highest energy. FR900098 (1.45) and fosmidomycin (1.46) were also 
docked into the active sites of both the 2EGH and the 3AUA crystal structures to validate the 
docking position of the compound and ensure that the parameters set for the docking of the 
FR900098 derivatives were appropriate for the docking. Initial docking of FR900098 (1.45) 
into the modified 3AUA gave complexes that had FR900098 orientated in the reverse 
direction to the original crystal structure-complex obtained from the protein data bank (Figure 
4.1). That is, the phosphonate region was orientated towards the divalent metal ion. While it 
is not impossible for the phosphonate moiety to chelate metals, several complexes of DXR 
with inhibitors have consistently shown that the hydroxamic acid present in the inhibitors is 
responsible for metal chelation and that the phosphonate has its own binding pocket at the 
active site of the enzyme. The change in orientation of the FR900098 was deemed to have 
occurred based on the higher negative charge of the phosphonate moiety as compared to the 
hydroxamic acid moiety which attracts the positive charge on the metal ion. Decreasing the 
charge on the Mg2+ ion did not re-orientate the compounds. Consequently Mg2+ was re-
assigned a charge of +2.00 and the hydroxamic acid moieties as well as the phosphonate 
moiety were each assigned a charge of -1.00 on the ligand (FR900098). This gave docking 
  Chapter 4         In silico and in vitro assessment of halogenated FR900098 analogues as DXR inhibitors 
____________________________________________________________________________________________________ 
 
 Page | 151 
 
results in which clusters of docked confirmations showed hydroxamic acid component 
orientated towards the Mg2+ ion as opposed to the phosphonate. These charges were thus 
used for the docking of all the free phosphonic acid ligands i.e. 2.1 – 2.3 and 2.38, 
fosmidomycin (1.46) and FR90098 (1.47). The best docked conformation was selected based 
on the docking energy, visual examination of how close in orientation it is to the FR900098 
that came with the crystal structure, size of the cluster and the hydrogen bond network around 
the ligand. 
 
 
Figure 4.1. Crystal FR900098 and the reverse docked conformation of FR900098 at the 
PfDXR active site (3AUA) 
Initial docking of FR900098 prior to assigning the phosphonate and hydroxamate group a charge of -1.00 each. 
The figure shows reverse binding of the ligand in the active site pocket of the enzyme. The surface at 1.4 Å is 
coloured by interpolated charges. Docked fosmidomycin  is shown as ball and stick coloured by element,crystal 
fosmidomycin as stick coloured by elements, NADPH as stick coloured in light blue and Mg2+as pink sphere.  
 
Fosmidomycin was docked into 2EGH for validation. The best conformation selected had a 
binding energy of -12.26 Kcal/mol to DXR (2EGH). Although this was not the lowest energy 
conformation (-15.57 kcal/mol) in the cluster, it showed the best orientation to fosmidomycin 
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and had similar hydrogen bond networks with the active site residues of the enzyme as the 
original fosmidomycin to which it was complexed. It was also part of the largest cluster of 
docked conformations which had 45 conformations as opposed to the lowest energy cluster 
which only contained 5 conformations, an indication that this group of conformation is 
favoured. The fact that the lowest energy cluster (cluster 1) has fewer conformers than some 
of the other clusters indicates that although the binding energy is low, the conformations are 
not the most favourable. The original complexed fosmidomycin showed hydrogen bonding to 
residues Ser185, Asn226, Lys227 with the phosphonate component, and to residues Asn226, 
Glu151, Glu230 with the hydroxamic moiety. This was mimicked by the docked 
fosmidomycin which showed hydrogen bonding of the phosphonate oxygens to Lys227 and 
Asn226 and the hydroxamate oxygen to Lys214, Ser150, Asp149 and Glu230 (Figure 4.2). 
This validates and confirms that the in silico study is able to mimic the binding of the 
inhibitor to DXR under the conditions and parameters used on the AutoDock. Based on this, 
the docked conformations of the halogenated FR900098 analogues were also analyzed.  
 
 
Figure 4.2. Crystal and Docked fosmidomycin at the active site of EcDXR (2EGH) 
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Showing docked fosmidomycin correctly orientated with crystal fosmidomycin and binding to the same active 
site residues. Docked fosmidomycin is represented as ball and stick and coloured by element, crystal 
fosmidomycin as stick coloured by elements, NADPH as stick coloured in light blue and Mg2+as pink sphere. 
 
All the free phosphonic acid FR900098 analogues that were docked in this study were 
assigned a charge of -1.00 at the phosphonate and hydroxamate ends while the Mg2+ ion in 
the enzymes were assigned a charge +2.00. Gastieger charges were assigned to the protected 
phosphonates with AutoDock tools and all non-integral charged were spread over the 
molecules. The negative charges on the phosphonate moiety of the protected derivatives were 
expected to be much less than that of the free phosphonic acids and thus the attraction 
between the phosphonate and the divalent metal ion would be reduced such that the 
hydroxamic acid would have greater attraction for the ion. As such AutoDock was allowed to 
assign charges on the atoms of the protected analogues. Compounds 2.1 – 2.3, 2.8 – 2.12, 
2.15 – 2.24 and 2.38 were docked into both EcDXR and PfDXR. Table 4.2 shows the binding 
energy of the best conformations of each compound after visual assessment at the active site 
and orientation relative to the original crystal inhibitor, the clusters according to the binding 
energy and the hydrogen bond network of the inhibitors with the enzyme. Binding energy is 
the difference between the ligand-receptor complex energy and the sum of the individual 
energies of the receptor and the ligand. This is automatically calculated on AutoDock 4.2. 
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Table 4.2. Binding energies and H-bonds of docked FR900098 analogues 
 
 2EGH 3AUA  EcDXR 
assay 
Comp R1 R2 R3 BE 
(kcal/mol) 
#  
H-bond 
BE 
(kcal/mol) 
#  
H-bond 
Relative 
rate  
(%) 
 
2.15 Et Bn -CH2I -3.59 3 -3.25 3 88.7 
2.16 Et Bn -CH2CH2I -6.11 1 -3.14 3 103.4 
2.10 Et Bn -CH=CH2 -6.49 3 -2.75 2 
 
2.17 Et Bn -CH2Br -5.92 2 -3.36 3 111.3 
2.1 H H -CH2Cl -13.68 8 -14.65 5 38.5 
2.2 H H -CH2CH2Cl -11.90 4 -11.33 1 28.5 
2.3 H H -CH2CH2CH2Cl -11.80 4 -7.65 4 92.3 
2.8 Et Bn -CH2Cl -3.62 1 -3.00 2 101.7 
2.9 Et Bn -CH2CH2Cl -7.04 1 -3.63 3 90.6 
2.11 Et Bn -CH2CH2CH2Cl NDb - -2.94 3 102.3 
2.12 Et Bn -CH3 -3.86 6 -3.28 3 83.8 
2.18 Et H -CH3 -3.94 3 -1.79 5 103.4 
2.19 Et H -CH2Cl -11.72 5 -3.59 3 88.7 
2.20 Et H -CH2Br -13.09 7 -3.33 4 87.0 
2.21 Et H -CH2I -12.02 10 -3.24 4 99.1 
2.22 Et H -CH2CH2Cl -12.11 5 -10.93 7 100 
2.23 Et H -CH2CH3 -11.75 6 -3.56 4 105.7 
2.24 Et H -CH2CH2CH2Cl -11.15 5 -2.03 4 100.4 
2.38 H H -CH2CH3 -10.75 9 -12.08 7 77.2 
FR900098 
(1.45) 
H H -CH3 -12.36 5 -14.62 5 24.7 
Fosmidom
ycin(1.46) 
H H H -12.26 6 -14.47 6  
bNo docking occurred 
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From Table 4.2, it is clear that the unprotected phosphonic acids (2.1 – 2.3 and 2.38) as well 
as FR90098 (1.45) and fosmidomycin (1.46) binds with less energy than the protected 
analogues to both EcDXR and PfDXR. Interestingly, compounds 2.18 – 2.24 showed similar 
binding affinity for EcDXR as the phosphonic acid where it was reasoned that the absence of 
a free phosphonic acid will diminish binding. These results suggest that perhaps the EcDXR 
harbors enough space to fit the phosphonate ethyl esters of the halogenated FR90098 
analogues. 
 
The docking result also showed that the binding affinity of FR900098 derivatives to DXR 
decreases with increasing length of the side chain, which is consistent with the result of the 
antiplasmodial test. From the phosphonic acid series 2.1 – 2.3 and 2.38 the derivative with 
chloroacetyl side chain (2.1) had the lowest binding energy of -14.65 kcal/mol while the 
chlorobutyryl side chain derivative had the highest binding energy of -7.65 kcal/mol (Table 
4.2) when docked into PfDXR (3AUA) active site. This trend was however not clear with the 
ester protected analogues as they did not dock into the active site of the enzyme, which is 
attributed to their bulky sizes.  Compound 2.1 exhibited the best inhibition of both 3AUA and 
2EGH even when compared with fosmidomycin and FR900098. Where fosmidomycin and 
FR900098 had six H-bonds and five H-bonds respectively to the active site residues in 
2EGH, 2.1 had eight H-bonds. Its phosphonate oxygen atoms were bound to Ser185, Asn210, 
Trp211 and Ser 253 while its hydroxamate moiety had H-bond interaction with Glu151, 
Asn226 and Glu230 (Figure 4.3) all of which with the exception of Asn210 and Ser253 are 
active site residues of EcDXR.94At the PfDXR active site, the phosphonate group of 2.1 had 
H-bond interaction with Gly271 and the active site residue Asn311 while its hydroxamate 
oxygens formed a H-bond network with residues Glu315 and Glu233. These H-bond 
interactions and the low binding energy of compound 2.1 to both DXR enzymes confirm the 
inhibition superiority of the compound to fosmidomycin and FR900098. This is supported by 
the antiplasmodial test which showed its protected and partially protected analogues 2.8 and 
2.19 respectively (envisaged to hydrolyze to 2.1) to have higher antiplasmodial activity than 
FR900098 and its protected and partially protected analogues 2.12 and 2.18 respectively. In 
light of this observation the possibility exists that the lower assay inhibition of EcDXR by 2.1 
as compared to FR900098 (Table 4.1) occurred over time and could be greater than that of 
FR900098, but is displaced from DXR more quickly. This reiterates the importance of 
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evaluating the enzyme inhibition from the moment the react
modeling being a static state, cannot explain how long the inhibitor would remain bound to 
the enzyme or if it will be displaced by another inhibitor or substrate of the enzyme but it 
does suggest that that 2.1 binds more st
Figure 4.3. 2D visualization of the docked conformation of 
Docked conformation of 2.1 showing residues involved in H
(Green circle). Dashed blue arrows represent H
represent H-bond interaction with main chain amino acid and pink double headed arrow represent charge 
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With the exception of one conformation of the 100 docks of 
protected derivatives of FR900098 did not bind at the active site where FR900098 was 
originally removed from 3AUA. Conversely, a significant number of
from each of the phosphonic acids formed a cluster and were docked and orientated at the 
active site as the original FR900098. Since the same grid and parameter were used to dock 
the ligands, the result supports the knowledge that bu
 and in vitro assessment of halogenated FR900098 analogues as 
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analogues might be unable to fit into the active site pocket of the enzyme. The inhibition 
assay (Table 4.1) also supports this result as the protected compound showed no significant 
activity on the DXR enzyme. An example of the cluster of FR900098 and protected 
FR900098 (2.12) docked into 3AUA is shown in Figure 4.4 A and B respectively. This 
clearly shows the docked conformations of 2.12 outside the active site of the enzyme and 
although FR900098 also showed some clusters outside the active site pocket, several of the 
conformations were bound at the active site pocket.  
 
 
A 
Active site with clustered 
FR900098 (1.45) 
Clustered of FR900098 
(1.45) outside active site 
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B 
Figure 4.4. Docked conformation clusters of FR900098 (1.45, A) and 2.12 (B) 
Clusters are shown in sticks coloured by atoms, protein residues as wireframe coloured by atom, NADPH as 
sticks coloured in light blue, Mg2+ as a pink sphere and original crystal FR900098 coloured in yellow. 
 
Hydrogen bonding between the inhibitors and the enzyme, particularly at the active site plays 
a role in indicating the level of inhibition exhibited by an inhibitor. This is proved by the 
number of hydrogen bonds observed for the different categories of the FR900098 derivatives 
tested. The protected compounds 2.8 – 2.12, 2.15 and 2.17 showed the least number of 
hydrogen bonds with the enzymes. This is not surprising since the protective groups on the 
compounds rendered the active sites unavailable for interaction. The protective groups also 
render the compounds more bulky and unable to fit into the active site pocket where they 
could interact with the active site residues. Figure 4.5 and 4.6 representing the partially 
protected and fully chloroacetyl analogues 2.8 and 2.9 respectively, showed less H-bond 
when compared to the free phosphonic acid compound 2.1 (Figure 4.3). The number of H-
bonds  clearly decreased with increased protection of the pharmacophores in the compounds.   
 
Active site with no 2.12 
conformer 
Clustered of 2.12 outside 
active site 
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Figure 4.6. 2D visualization of the docked conformation of 
Docked conformation of 2.9 showing residues involved in H
(Green circle), and the Mg2+ ion (Grey circle)
side chain, pink double headed arrow represent charge i
between the amino acid and the ligand
 
One very interesting observation was the high binding affinity of the protected chloropropyl 
analogues as compared to the protected chloroacetyl analogues. This is
observed in the antiplasmodial activity and the unprotected analogues of the compounds 
where there is reduced activity with the longer side chain. Of the series of protected 
compounds, 2.22 and 2.9 showed less binding energy 
than 2.19 and 2.8. Combined with the fact that 
when compared with the other FR900098 analogues (Table 4.1), there appears to be a high 
level of inhibition with the chloropropyl analogu
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compound (2.38) did not show the same activity. Unfortunately the protected and unprotected 
analogues 2.9, 2.22 and 2.2 did not show any significant antiplasmodial activity. This is 
suspected to be a delivery problem where the compound is unable to reach its site of action 
i.e. the DXR active site. Compound 2.2 would therefore make a good lead compound for 
investigation to determine how to ensure that the drug gets to the site of action where it can 
bind to DXR. 
 
The in silico studies did not reveal any significant difference in the binding of compounds 
carrying different halogens. No major difference was observed between the binding energies 
of compounds 2.19, 2.20 and 2.21 and between compounds 2.8, 2.15 and 2.17. This further 
confirms the observation made from the antiplasmodial test where compounds with different 
halogens did not show any significant difference in their antiplasmodial activity (Table 2.5). 
This can be interpreted to mean that the type of halogen present in compound have no effect 
on the binding of the compounds to DXR although the presence of a halogen promotes the 
inhibition property of the compounds. The effect of the presence of chlorine is observed with 
the chloropropyl analogue 2.2 and the chloroacetyl analogue 2.1 which showed better binding 
affinity for both EcDXR and PfDXR than the unchlorinated propyl (2.38) and acetyl 
(FR900098 (1.45)) analogues respectively. 
 
The phosphonic acids 2.1 – 2.3 and 2.38 as well as FR900098 (1.45) and fosmidomycin 
(1.46) showed slightly higher affinity for PfDXR than EcDXR. However, apart from the 
partially deprotected compounds which showed significantly higher preference for 2EGH 
than 3AUA, binding of the analogues to the two enzymes showed similar trends and are thus 
comparable i.e. no significant difference was observed in the binding of the compounds to 
both enzymes. Thus the enzyme assay inhibition result can be expected to be similar to what 
would be obtained had PfDXR been used for the assay. 
 
From the series of compounds docked, compound 2.1 showed the best (strongest) binding to 
both EcDXR and PfDXR even when compared with fosmidomycin and FR90098. However 
while this compound showed good antiplasmodial and DXR inhibition property, it was not as 
active as fosmidomycin and FR900098 in the enzyme inhibition assays. Its ester-protected 
analogue 2.19, though cannot inhibit the enzyme or bind to the enzyme as indicated by the 
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docking, has antiplasmodial activity superior to FR900098 (1.45) which indicates that if 
absorbed appropriately the chlorinated FR900098 derivative has the potential to highly 
inhibit DXR once the protective groups have been removed after absorption into the parasite. 
 
4.2.2 In silico studies of chloroquine-fosmidomycin hybrids 3.3 and 3.4 
Many studies focused on developing inhibitors against DXR rightly take into consideration 
the small pocket into which such inhibitors must fit in order to inhibit the enzyme. We 
postulated that bulky inhibitors could fit into this pocket if NADPH is removed or displaced. 
The chloroquine-fosmidomycin hybrids 3.3 and 3.4 designed and discussed in chapter 3 were 
considered good candidates to displace NADPH from binding to DXR. To test this 
hypothesis, the hybrids 3.3 and 3.4 were prepared and docked into the active sites of PfDXR 
(PDB code: 3AUA) and EcDXR (PDB code: 2EGH) after removing NADPH and inhibitors 
from the sites.  
 
The experiment was conducted on AutoDock 4.2 using the Lamarckian algorithm to create a 
population of 150 individuals with 2500000 maximum number of evaluations in 10 GA runs. 
As this was an experiment to determine the feasibility of the hybrids binding to DXR, 10 GA 
runs were considered sufficient. The docked conformations were assessed based on their 
binding energy and the number of hydrogen bonds formed with the enzyme amino acid 
residues. 
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Table 4.3. Binding energies and H-bonds of docked chloroquine-fosmidomycin hybrids 3.3 
and 3.4 
 
  2EGH 3AUA 
Compound n BE (Kcal/mol) # H-bonds BE (Kcal/mol) # H-bonds 
3.3 1 -10.72 4 -3.75 3 
3.4 2 -3.72 3 -3.23 5 
NADPH  ND 6 ND 10 
 
Analysis of the docking result of hybrids 3.3 and 3.4 showed that both hybrids required less 
energy to bind to EcDXR than PfDXR i.e. the hybrids have more affinity for the EcDXR. 
The acetyl linked hybrid 3.3 binds with the least energy (-10.72 Kcal/mol) to EcDXR as 
compared to the propyl linked hybrid 3.4. This supports the antiplasmodial activity of their 
protected derivatives which showed the acetyl linked hybrid 3.8 to be more active than the 
propyl linked hybrid 3.9 (Chapter 3, Table 3.2) indicating the important role of the linker. 
Hybrid 3.3 showed four hydrogen bonds to the active site residues Lys124, Asn226, Asp149 
and Glu230 of the EcDXR (Figure 4.7). Although this is less than the number of hydrogen 
bond interaction of NADPH with the same enzyme (6 H-bonds), it shows that there is a 
possibility for the compound to bind to EcDXR. Hybrid 3.3 orientate such that it spans the 
space between the fosmidomycin (1.46) and NADPH binding site with its hydroxamate end 
towards the Mg2+ metal ion and overlapping towards the NADPH binding site. This indicates 
a potential of the hybrid to displace or prevent the optimum binding of NADPH to the 
enzyme.   
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Figure 4.7. Docked conformation of protected chloroquine-fosmidomycin hybrid 3.3 in 
2EGH 
Showing hybrid 3.3 docked between fosmidomycin (1.46) and NADPH binding sites and overlapping into the 
NADPH binding site. Hybrid 3.3 is represented as stick coloured by element, fosmidomycin as stick coloured in 
yellow, NADPH as stick coloured in light blue,Mg2+as pink sphere and hydrogen bonds as broken green lines. 
 
Unfortunately both hybrids 3.3 and 3.4 showed considerably less hydrogen bonds to the 
enzyme residues as compared to NADPH and coupled with the generally high binding energy 
for PfDXR they might not exhibit good inhibition of the DXR enzymes. It should be noted 
however, that the crystal structures 3AUA and 2EGH were obtained with NADPH and 
inhibitors already docked into the active sites. This means that the enzyme had already 
rearranged into a particular conformation upon binding of the inhibitors. Since there is 
limited flexibility during docking it is possible that the compounds could not conform to the 
more rigid structure and hence could not attain optimum binding or interaction with the 
enzyme. In a biological system, the enzymes would be more flexible and might be able to 
adjust their conformation to better fit the hybrids.  
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4.3 EXPERIMENTAL 
 
4.3.1 Expression and purification of E. coli DXR 
The expression and purification of E. coli was carried out by Nicodemus Mautsa at the 
Rhodes University Centre for Chemico- and Biomedicinal Research using an established 
method developed by Kuzuyama et al. (1998).169 In summary, competent E. coli XL1 Blue 
cells were transformed with E. coli DXR plasmid construct. The transformed cells were 
incubated in 2xYT broth until the mid-logarithmic growth was reached after which isopropyl 
β-D-1-thiogalactopyranoside (IPTG) was added to the culture to induce over expression of the 
DXR gene and hence over production of the enzyme. The cells were harvested and treated 
with lysozyme. Sonication of the cells allowed the release of DXR from the bacterial cells 
and removal of the cell debris was achieved by centrifugation. Purification of DXR was 
achieved by agitation of the lysate with nickel charged resins to adsorb the protein unto the 
resins. Pure DXR was obtained by displacement of the enzyme from the resins by washing 
with native elution buffer which was made up of 20mM Tris-HCl, 300mM NaCl and 1M 
imidazole at pH 8.0. 
 
4.3.2 In vitro EcDXR inhibition assay 
The inhibition assay was conducted by Nicodemus Maustsa at the Centre for Chemico- and 
Biomedicinal Research, Rhodes University. The assay was conducted in 96-well UV 
microtitre plates. The reaction mixture was made up of 100mM Tris-HCl, 1mM MnCl2, 0.3 
mM NADPH and 0.3mM DOXP to a volume of 100 µl in ddH2O. Negative controls or 
blanks which included mixture lacking 1) DOXP, 2) MnCl2, 3) DXR and 4) NADPH were 
prepared and tested to determine activity of the enzyme. The enzyme was pre-incubated with 
equal volumes of inhibitor and in case of the blanks with ddH2O for five minutes at 37oC 
before initiating the reaction. The reactions were initiated by introduction of 100 µl of the 
pre-incubated enzyme-inhibitor solution into the reaction mixture to make a total of 200 µl 
and 5 µM concentration of inhibitor in each case. The reaction which involved the 
consumption of NADPH to give NADP at 37oC was monitored on a PowerWave 
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spectrophotometer by measuring the UV absorbance of the reaction mixture at 340nm over 
10 minutes.  
 
4.3.3 In silico EcDXR inhibition assay 
Preparation of Ligands for docking 
Structures of ligands 2.1 – 2.3, 2.8 – 2.12, 2.15 – 2.24, 3.3 and 3.4 were sketched in 
chemDraw Ultra 11.0.1 with the phosphonic acids deprotonated. A random rotor search was 
conducted on Avogadro 1.0.3 to obtain the in vacuo global minimum conformer for each 
ligand. The lowest energy conformer of the 100 conformations generated for each lignad was 
further optimized geometrically and saved as pdb files.  
 
Flexible docking of FR900098 analogues to EcDXR and PfDXR 
The X-ray crystal structures of EcDXR (PDB code: 2EGH) and PfDXR (PDB code: 3AUA) 
were obtained from the Protein Data Bank. On AutoDock 4.2, missing atoms from the 
proteins were repaired and water molecules were removed from the proteins. Gastieger 
charges were added, all non-polar hydrogens were merged and residual charges were spread 
over the protein. Active site residues Ser185, Ser221, Lys227, Asp149, Glu151 and Glu230 
from 2EGH and Ser270, Asn311, His293, Asp231 and Glu315 from 3AUA were defined as 
flexible residues. In the remaining rigid protein structure Mg2+ was manually assigned a 
charge of +2.00. The prepared geometry optimized ligands were imported into AutoDock 4.2 
where the Gastiger charges were added and non-polar hydrogens were merged. All possible 
torsions were allowed and the amide bonds were by default made non-rotatable. Maps of all 
possible atoms involved in the ligand-receptor interaction were created and a grid box was 
placed at the active site to localize the site to which the ligands would dock. A grid box of 62, 
52, 56 units dimension along the x, z, y axis respectively and a grid point of 0.375 Å were 
used for 2EGH. The box was offset from center by -1.694, 0.944 and 1.472 at the x, y and z 
axis respectively.  On 3AUA, the grid box had dimensions of 58, 60 and 58units along the x, 
y and z axis and were offset from the centre by 4.333, -1.083 and 2.500 Å respectively. A 
grid point spacing of 0.375 Å was maintained. A Lamarckian genetic algorithm was 
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employed for the docking simulation in AutoDock 4.2. The default genetic algorithm 
parameters on AutoDock 4.2 was used except the number of GA runs which was increased to 
100. That is, a population size of 150 allowing for a maximum of 2 500 000 energy 
evaluations and 27 000 generation was used for the docking. The 100 conformers generated 
for each ligand after the docking were clustered at 2.0 rmsd.  
 
The docked conformations were visualized on Discovery Studio Visualizer 3.0. The docked 
conformers were assessed based on the numbers in the clusters, the binding energy, the 
number of hydrogen bonds with the protein residues and visual assessment of the orientation 
of the conformers at the active site of the enzyme. 
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5. SUMMARY AND CONCLUSIONS 
 
The aim of the study was to design and synthesize FR900098 analogues with improved 
antiplasmodial and lipophilic properties. This was to be achieved through the synthesis of 
halogenated fosmidomycin analogs and hybrid compounds.. Although both sets of 
compounds were successfully synthesised, synthetic challenges prevented the full exploration 
of the synthetic molecules. 
  
The series of synthesized halogenated FR900098 analogues investigated the effect of varying 
acyl side chain length, different halogens and effect of protection groups on the 
pharmacophore of the compounds. The phosphonate esters of the halogenated FR900098 
analogues showed higher antiplasmodial activity than their free phosphonic acid analogues. 
The antiplasmodial activity decreased with increasing length of the acyl side chain with the 
halogenated acetyl analogues 2.8, 2.15, 2.17 and 2.19 – 2.21 showing the best activity. No 
significant difference was observed in the antiplasmodial activity when the compound was 
substituted with different halogens.  However, the presence of the halogens increased their 
potency when compared with their non-halogenated analogues.   
 
Two protected chloroquinoline-fosmidomycin hybrids 3.8 and 3.9 were successfully 
synthesized, differentiated by the length of the linker between the quinoline and the 
fosmidomycin components. The two components of the hybrids were covalently linked 
through their side chains having synthesized each component separately. The study revealed 
the chloroquinoline-fosmidomycin hybrids as potent antiplasmodial agents against both the 
D10 and FCR-3 strains of P. falciparum. The acetyl linked hybrid 3.8 was four times more 
potent than the propionyl linked hybrid 3.9 on the Gambian FCR-3P. falciparum strain. It is 
however suspected that the activity of the hybrids was due more to the quinoline moiety than 
the fosmidomycin moiety since other hybrids of fosmidomycin such as the pyrazinoic acid-
fosmidomycin hybrid showed no antiplasmodial activity. 
 
Preliminary enzyme inhibition studies of the halogenated FR900098 analogues were 
conducted on recombinant E. coli DXR. The phosphonic acids as opposed to the phosphonate 
esters showed the best inhibition of the enzyme. Here the chloropropionyl analogue 2.2 
  Chapter 5                Summary and Conclusions 
____________________________________________________________________________________________________ 
 
 Page | 170 
 
demonstrated the best inhibition of DXR followed by the chloroacetyl derivative 2.1, 
reducing the activity of the enzyme to 28.5% and 38.5% respectively. FR900098 however 
showed better inhibition of EcDXR than derivatives 2.1 and 2.2. However both 2.1 and 2.2 
are provide good lead compounds for further modifications and development as 
antiplasmodial agents. 
 
Molecular modelling of the halogenated fosmidomycin analogues into crystal structures of E. 
coli and P. falciparum DXR was conducted to investigate the binding potential and 
interaction of the compounds with the enzymes. The phosphonic acids 2.1 – 2.3 and 2.38 
exhibited the lowest binding energies comparable to fosmidomycin and FR900098. The 
phosphonate esters showed minimal to moderate binding probably due to their bulky 
structure which prevented optimum fitting into DXR active site. This corroborates the result 
of the enzyme inhibition assay and confirms the need for free phosphonic acids to bind at 
DXR active site. 
 
Phosphonic acid hybrids 3.3 and 3.4 were docked into EcDXR and PfDXR lacking NADPH, 
to explore their potential to fit into the active site and possibly displace NADPH. The acetyl 
linked hybrid 3.3 showed more promising interactions to both enzymes indicating that the 
linker between the quinoline and fosmidomycin moieties is important for efficient binding. 
Although the binding energy of the hybrids were much higher than FR900098 or the 
halogenated FR900098 derivatives, the hybrids bind such that it aligns itself in the space 
between FR900098 and the NADPH binding site. The possibility therefore exist that the 
hybrids might be able to compete with NADPH for binding to DXR.   
 
Overall the halogenated acetyl FR900098 analogues and the acetyl linked hybrid are a very 
promising group of compounds that could be valuable for further development as antimalarial 
drugs. Based on the enzyme inhibition assay and the in silico study result, the 
chloropropionyl phosphonic acid 2.3, which also exhibited intriguing inhibition and binding 
to DXR will be worth investigating further as a lead compound for antiplasmodial drug 
development. 
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5.1 RECOMMENDATIONS 
The scope of the present study was centered on the synthesis of the halogenated 
fosmidomycin derivatives and the chloroquinoline-fosmidomycin hybrids. As such the 
biological activity of the synthesized compounds has not been fully explored. Further 
assessment of their enzyme inhibition and the nature of inhibition especially on PfDXR is 
recommended.  
 
The reactive nature of halogens potentiates the halogenated FR90098 analogues to undergo 
non-specific reactions. For this reason it is imperative and recommended that future studies 
on the group of compounds include full cytotoxicity studies to determine their selectivity for 
the malaria parasite.  
 
Further studies into developing synthetic methods for the preparation of fully deprotected 
hybrids are important in confirming both the binding to DXR and haematin detoxification. 
The molecular docking studies of the hybrids support the idea of designing new DXR 
inhibitors by exploring the NADPH binding pocket. 
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